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Background: With a higher proportion of older people in the UK population, new approaches are needed
to reduce emergency hospital admissions, thereby shifting care delivery out of hospital when possible
and safe.
Study aim: To evaluate the introduction of predictive risk stratification in primary care.
Objectives: To (1) measure the effects on service usage, particularly emergency admissions to hospital;
(2) assess the effects of the Predictive RIsk Stratification Model (PRISM) on quality of life and satisfaction;
(3) assess the technical performance of PRISM; (4) estimate the costs of PRISM implementation and its
effects; and (5) describe the processes of change associated with PRISM.
Design: Randomised stepped-wedge trial with economic and qualitative components.
Setting: Abertawe Bro Morgannwg University Health Board, south Wales.
Participants: Patients registered with 32 participating general practices.
Intervention: PRISM software, which stratifies patients into four (emergency admission) risk groups;
practice-based training; and clinical support.
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Main outcome measures: Primary outcome – emergency hospital admissions. Secondary outcomes –
emergency department (ED) and outpatient attendances, general practitioner (GP) activity, time in hospital,
quality of life, satisfaction and costs.
Data sources: Routine anonymised linked health service use data, self-completed questionnaires and staff
focus groups and interviews.
Results: Across 230,099 participants, PRISM implementation led to increased emergency admissions to
hospital [ΔL = 0.011, 95% confidence interval (CI) 0.010 to 0.013], ED attendances (ΔL = 0.030, 95% CI
0.028 to 0.032), GP event-days (ΔL = 0.011, 95% CI 0.007 to 0.014), outpatient visits (ΔL = 0.055, 95% CI
0.051 to 0.058) and time spent in hospital (ΔL = 0.029, 95% CI 0.026 to 0.031). Quality-of-life scores
related to mental health were similar between phases (Δ = –0.720, 95% CI –1.469 to 0.030); physical
health scores improved in the intervention phase (Δ = 1.465, 95% CI 0.774 to 2.157); and satisfaction
levels were lower (Δ = –0.074, 95% CI – 0.133 to –0.015). PRISM implementation cost £0.12 per patient
per year and costs of health-care use per patient were higher in the intervention phase (Δ = £76, 95% CI
£46 to £106). There was no evidence of any significant difference in deaths between phases (9.58 per
1000 patients per year in the control phase and 9.25 per 1000 patients per year in the intervention phase).
PRISM showed good general technical performance, comparable with existing risk prediction tools (c-statistic
of 0.749). Qualitative data showed low use by GPs and practice staff, although they all reported using
PRISM to generate lists of patients to target for prioritised care to meet Quality and Outcomes Framework
(QOF) targets.
Limitations: In Wales during the study period, QOF targets were introduced into general practice to
encourage targeting care to those at highest risk of emergency admission to hospital. Within this dynamic
context, we therefore evaluated the combined effects of PRISM and this contemporaneous policy initiative.
Conclusions: Introduction of PRISM increased emergency episodes, hospitalisation and costs across, and
within, risk levels without clear evidence of benefits to patients.
Future research: (1) Evaluation of targeting of different services to different levels of risk; (2) investigation
of effects on vulnerable populations and health inequalities; (3) secondary analysis of the Predictive Risk
Stratification: A Trial in Chronic Conditions Management data set by health condition type; and
(4) acceptability of predictive risk stratification to patients and practitioners.
Trial and study registration: Current Controlled Trials ISRCTN55538212 and PROSPERO
CRD42015016874.
Funding: The National Institute for Health Research Health Services Delivery and Research programme.
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Plain English summary
As the population ages, there are more people with chronic conditions. It is best for patients and theNHS to avoid emergency admissions to hospital, and to care for these patients at home when possible.
To help identify people at high risk of emergency admission to hospital, a computer program called the
Predictive RIsk Stratification Model (PRISM) has been developed. General practitioners (GPs) and their staff
can use PRISM to identify these patients, and provide extra care to keep them safely at home.
We evaluated the effects of introducing PRISM into 32 general practices in south Wales, including effects
on use of services, quality of life and satisfaction. We worked closely with patients to study how GPs and
health-care managers introduced and understood PRISM.
We included 230,000 patients in the study, and received completed questionnaires from 1400 patients.
To our surprise we found that, after the introduction of PRISM, there were more emergency admissions to
hospital, more attendances at accident and emergency, and more outpatient appointments. So, health-care
costs rose without clear evidence of benefits to patients. However, patients reported that their physical
health had improved. General practice staff reported that a new incentive payment introduced at the same
time as PRISM had encouraged them to use PRISM.
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Scientific summary
Background
With a higher proportion of older people in the UK population, demand on health and social care is
increasing. New approaches are needed to shift care delivery out of hospital wherever possible, and to
safely reduce emergency admissions to hospital. A predictive risk stratification tool (the Predictive RIsk
Stratification Model; PRISM) has been developed for general practice to estimate risk of an emergency
hospital admission in the following year for each registered patient. Practices can use the resulting risk
scores to target primary- and community-based services at patients at the highest level of risk. The
introduction of PRISM coincided with a new payment under the Quality and Outcomes Framework (QOF)
in the contract for general practitioners (GPs) in Wales to identify and manage the care of people at high
risk of emergency hospital admission.
Study aim
To evaluate the introduction of PRISM in primary care.
Objectives
To:
1. measure the effects on service usage, particularly emergency admissions to hospital
2. assess the effects of PRISM on quality of life and satisfaction
3. assess the technical performance of PRISM
4. estimate the costs of PRISM implementation and its effects
5. describe the processes of change associated with PRISM.
Setting
The trial site was in south Wales, and included all 32 general practices, grouped in 11 clusters, who agreed
to take part within the Abertawe Bro Morgannwg University Health Board.
Methods
We undertook a systematic review; randomised stepped-wedge trial with control and intervention phases
specific to each cluster, and participant-specific anonymised linked outcomes; and complementary
investigation using qualitative methods evaluation. We implemented the intervention first in the practices
of two GP champions and then at random in practice clusters over a 1-year period from March 2013.
We included routine linked data outcomes on all registered patients from 1 February 2013 to
30 September 2014, and assessed quality of life and satisfaction by self-completed postal questionnaire
for a sample of patients at 6 and 18 months.
In our analyses we considered covariates and factors of gender, age, deprivation score, PRISM score,
seasonality, trend and days at risk, with adjustment when appropriate.
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Primary outcome
l Emergency hospital admissions.
Secondary outcomes
l Attendances at emergency departments (EDs).
l Primary care events.
l Outpatient attendances.
l Emergency admission bed-days.
l Health-related quality of life (Short Form questionnaire-12 items; SF-12).
l Patient satisfaction.
l NHS implementation costs.
l NHS recurrent costs.
We also compared deaths between control and intervention phases to monitor unexpected effects.
We worked closely with service users throughout the study.
Results
Systematic review
We included 13 papers from 11 studies, from 6632 papers initially identified. These studies were largely
observational and heterogeneous in both intervention and population. Predictive risk stratification was
generally used as a tool for identifying patients suitable for further intervention e.g. virtual ward, rather
than as a formal part of that intervention. No studies reported comparative data about processes or
outcomes related to predictive risk stratification. When predictive risk stratification was used as part of an
RCT, risk tools were used to identify patients eligible for the trial – and were therefore used in the same
way in both trial arms. Meta-analysis was not possible, as there were no comparative data available to
examine the effects of predictive risk stratification on processes or ouctomes of care.
Randomised stepped-wedge trial
Numbers included
We included routine outcomes for 230,099 participants, with questionnaire responses from 1403 of these
participants. Participants were assigned by initial predicted risk between four ranked risk groups, from
1 (lowest, constituting 80% of participants), through 2 and 3 (constituting, respectively, 15% and 4.5% of
participants) to 4 (highest, constituting 0.5% of participants).
Clinical effectiveness: primary outcome
Across risk groups, people were admitted to hospital as emergencies, on average, 0.161 times per year
in the control phase and 0.167 times per year in the intervention phase; these unadjusted rates varied
between 0.063 in risk group 1 and 3.481 in risk group 4 in the control phase and between 0.066 in risk
group 1 and 3.300 in risk group 4 in the intervention phase. Distribution of admissions was highly skewed,
with most people not admitted to hospital at all and others admitted on multiple occasions.
The rate of emergency admissions was higher in the intervention phase than in the control phase [adjusted
difference in number of emergency admissions per participant per year at risk ΔL = 0.011, 95% confidence
interval (CI) 0.010 to 0.013]. This increase was found at all levels of risk.
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Clinical effectiveness: secondary outcomes
Emergency department attendances
People attended ED, on average, 0.359 times per year in the control phase and 0.361 times per year in the
intervention phase, rising with risk group from 0.266 in the control phase and 0.271 times per year in the
intervention phase in risk group 1 to 3.235 times per year in the control phase and 3.037 times per year in
the intervention phase in risk group 4 (all unadjusted rates). Again, the distribution of attendances was
highly skewed.
The average rate of ED attendances was higher in the intervention phase than in the control phase (adjusted
difference in emergency attendances per participant per year at risk ΔL = 0.030, 95% CI 0.028 to 0.032).
General practitioner activity
General practitioner events were much more common, an average of 14.10 per patient per year in the control
phase and 14.08 per patient per year in the intervention phase, rising from 9.32 per patient per year in the
control phase and 9.42 per patient per year in the intervention phase at the lowest level of risk to 78.72 per
patient per year and 67.3 per patient per year at the highest level of risk (all unadjusted rates), respectively.
There was an increase in the average number of days with recorded events per participant per year at risk
(adjusted ΔL = 0.011,95% CI 0.007 to 0.014). This effect was reversed in the two groups at highest risk.
Outpatient visits
Across all risk revels, patients made, on average, 1.704 outpatient attendances per year in the control
phase and 1.717 in the intervention phase, rising from 1.022 outpatient attendances per year in the
control phase and 1.086 outpatient attendances per year in the intervention phase in risk group 1 to
13.833 outpatient attendances per year in the control phase and 13.503 outpatient attendances per year
in the intervention phase in risk group 4 (unadjusted), respectively.
Outpatient attendances per patient per year were slightly higher in the intervention phase (ΔL = 0.055,
95% CI 0.051 to 0.058); this was consistent across risk groups, except at the highest level, at which no
significant difference was seen between phases.
Time spent in hospital
People spent an average of 0.792 days per year in hospital in the control phase, compared with 0.728 days
in the intervention phase, rising from 0.276 days per year in the control phase and 0.263 days per year in
the intervention phase in risk group 1 to 15.15 days per year in the control phase and 13.38 days per year
in the intervention phase in risk group 4. The distribution of data was highly skewed, with most people
spending no time in hospital and a small number spending long periods of time in hospital.
Once figures were adjusted, on average, participants spent more days in hospital per year during the
intervention phase than during the control phase (ΔL = 0.029, 95% CI 0.026 to 0.031), an effect that was
consistent across risk groups, rising from 0.015 in risk group 1 to 0.197 in risk group 4.
Mortality
There was no evidence of any difference in death rates between phases: 9.58 per 1000 patients per year
in the control phase and 9.25 per 1000 patients per year in the intervention phase.
Self-reported outcomes
There was no significant effect on SF-12 Mental Health Component scores between phases (adjusted
Δ = –0.720, 95% CI –1.469 to 0.030). SF-12 Physical Health Component scores were significantly higher
in the intervention phase (adjusted Δ = 1.465, 95% CI 0.774 to 2.157), with a trend towards greater
improvements at the higher levels of risk (adjusted Δ = –4.385 in risk group 1, but 4.103 in risk group 4).
These differences were not reflected in adjusted Short Form questionnaire-6 Dimensions scores.
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Satisfaction scores were slightly, but significantly, lower in the intervention phase (adjusted Δ = –0.074,
95% CI –0.133 to –0.015), but not consistently across risk levels.
Economic evaluation
Intervention costs
We estimated that use of PRISM software cost £822 per general practice in year 1 (including activation and
training), and projected that it would cost £474 per practice in every subsequent year. With 32 practices
with 230,000 registered patients included in the analysis, we estimated that PRISM implementation cost is
£0.12 per patient per year.
Resource costs
Total costs of admissions to hospital, ED attendances, GP activity and outpatient visits per patient per year
were higher in the intervention phase than in the control phase (adjusted Δ = £76, 95% CI £46 to £106),
an effect that generally increased with risk level.
Processes of change: qualitative findings
At baseline, GPs and practice staff expressed a willingness to adopt PRISM, but raised concerns about
whether or not it would identify patients not yet known, and about whether or not there were sufficient
community-based services to deliver care to patients identified as at high risk, in order to prevent
hospital admission.
All practices reported that they used PRISM to fulfil their QOF targets, and generally limited their use of PRISM to
the small number at highest risk. After the QOF reporting period ended, only two practices reported continuing
to regularly use PRISM. Reasons given for not using it included lack of time to work prospectively, inadequate
support, limited internet access, and data being out of date and not well integrated with practice records.
General practitioners were unsure if using PRISM had any effect on emergency admissions and ED
attendances. They felt that PRISM had changed their awareness of patients and focused them on targeting
the patients at highest risk, although they were not sure that proactive management could make any
difference to emergency admissions in this group. Among health service managers and community health
staff, awareness and understanding of PRISM was high, though they expressed similar concerns as practice
staff about the availability of services to which practices could refer.
Technical performance
Using data from 51,600 patients with both an early PRISM score and a sufficient control phase, PRISM
showed good technical performance, comparable to existing risk prediction tools (c-statistic of 0.749).
However, it generally underpredicted risk at higher risk levels and overpredicted risk at the lowest risk level.
Conclusions: implications for health care – research recommendations
Summary of key findings
l Our systematic review found that previous research evidence, limited in scope and quality, showed
minimal effects of predictive risk stratification tools on emergency admissions.
l Primary outcome: emergency admissions increased slightly in the intervention phase of the trial.
Secondary outcomes: attendances at EDs, GP events and outpatient visits were also slightly higher in
the intervention phase; and patients spent more time in hospital in the intervention phase. Mental
health quality-of-life scores were not dissimilar between phases. Physical health scores were higher in
the intervention phase. Satisfaction scores were lower in the intervention phase.
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxiv
l Costs: set-up and running costs of PRISM were low, at £0.12 per patient per year; resource costs were
£76 per patient per year higher in the intervention phase than in the control phase.
l Processes of change associated with PRISM: a change to the GP contract for 12 months encouraged
use of PRISM, but, after this period ended, use was reported as minimal. All users reported some
change in practice resulting from PRISM.
l Technical performance of PRISM: the extent to which PRISM accurately predicted risk of emergency
admission to hospital was consistent with similar models.
Strengths and weaknesses of the research
Our stepped-wedge study design randomised clusters of general practices to receive PRISM tool at intervals
over 1 year. Together with linked routine outcome data, this enabled us to conduct a rigorous evaluation
of this population-level intervention by monitoring outcomes for nearly 250,000 people. We anonymously
linked self-completed questionnaires from a sample stratified to favour higher levels of risk to our routine
data outcomes, thus describing effects on quality of life and satisfaction as well as on health service use.
Response rates were no higher than expected in this general population and need non-response analysis.
This was the first evaluation of the effects of the introduction of a PRISM in normal practice, even though
the tools have since been widely introduced across the UK as part of a comprehensive policy for the care
of people with chronic conditions.
Conclusions
Use of anonymised data linkage has enabled us to conduct an experimental study with a randomised
design at the population level, and include almost all primary and secondary routine outcomes, as well as
self-reported outcomes from a sample of patients.
Introduction of PRISM in primary care in a large urban area in Wales was followed by increased emergency
admissions, both overall and at each level of risk. We also found increases in each secondary measure of
resource use following PRISM implementation. There was evidence of improved quality of life, but
satisfaction scores were slightly lower.
Despite low reported use of PRISM, we found clinically and operationally important effects of the
introduction of the new risk stratification tool alongside contractual incentives (QOF) to target those at the
highest risk of emergency admission to hospital. Unexpectedly, most effects were in the opposite direction
to those intended. Although we cannot disentangle the effects of introducing PRISM from those of
introducing the QOF targets, this has the merit of reflecting practice across the UK, where predictive risk
stratification tools for emergency admissions operate alongside incentives to focus on patients at risk.
Hence, we believe that our findings from a large population in south-west Wales, mixing urban and
semi-urban, are generalisable.
In brief, the introduction of PRISM increased emergency episodes, hospital admissions and costs across the
population and at each risk level without clear evidence of benefits to patients.
Recommendations for research
1. Evaluate the alternative approach of delivering different services to different levels of risk, rather than
the current focus on the very highest level of risk.
2. Investigate the effects of emergency admission risk stratification tools on vulnerable populations and
health inequalities.
3. Conduct a secondary analysis of the Predictive Risk Stratification: A Trial in Chronic Conditions
Management data set by condition type.
4. Explore the acceptability of predictive risk stratification and communication of risk scores to patients
and practitioners.
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Trial and study registration
The trial is registered as ISRCTN55538212 and the study is registered as PROSPERO CRD42015016874.
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Funding for this study was provided by the Health Services and Delivery Research programme of the
National Institute for Health Research.
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Chapter 1 Introduction
Background
An increasingly older population and rising incidence of chronic conditions places a significant and
unprecedented demand on health-care services.1,2 In 2012–13, in England alone, there were 5.3 million
emergency admissions to hospitals, costing approximately £12.5B.3 Around half of these admissions can be
attributed to just 5% of the population – typically older people with comorbidities.4,5 Patients with chronic
conditions are more likely to experience emergency hospital admissions for potentially avoidable causes,
resulting in a ‘triple fail event’ of suboptimal health outcomes, significant health costs and poor patient
experience.6 An emergency admission to hospital is disruptive and unsettling, exposing patients to clinical
and psychological risks and increasing their dependency.7
Primary- and community-based care offers the opportunity to deliver efficient, co-ordinated and
individualised care that can prevent emergency admissions, improve care quality and reduce costs.8,9
A recent Health Foundation and Nuffield Trust report estimates that up to one in five emergency admissions
are avoidable,10 especially where they relate to ambulatory care-sensitive conditions – conditions amenable
to community prevention.11 These include instances in which problems develop over longer periods and the
risk of a crisis leading to emergency hospital admission can be reduced by timely and effective self-care,
primary and community care or outpatient care.12 Admissions related to common chronic conditions such
as asthma, chronic obstructive pulmonary disease (COPD), diabetes mellitus and hypertension are included in
most ambulatory care-sensitive condition lists. Recent analysis in England suggests that better management
of ambulatory care could achieve yearly savings of > £1.4B,13 as well as improving patient health and service
quality. In England and Wales, > 16 million people have a long-term (or chronic) condition – and their care
accounts for 70% of expenditure on health and social care.4
Recognising such challenges and opportunities, England in 2005,5 and Wales in 2007,14 developed
‘evidence-based’ frameworks for the care of patients with long-term conditions. They shared key features
of early identification and response to patient needs, joined-up care, and holistic support centred on the
person rather than on specific conditions.
Both models championed risk profiling as a means of identifying patients at risk (case finding) who may
benefit from proactive management. The English model included systematic risk profiling as one of three
primary drivers for the model, alongside integrated locality teams and systematised support for patients to
manage themselves.5
The underlying theoretical model for introduction of emergency admission predictive risk models is that
they are expected to improve patient outcomes and experience and provide better value for money by
identifying those at high risk of admission and enabling the targeting of proactive management to prevent
health deteriorations requiring emergency care.15,16 This proactive targeting of services at people at defined
risk has retained prominence in UK Government policy ever since, notably within efforts to introduce
integrated care.17
Given the challenges of rising emergency admissions, their association with long-term conditions, and the
financial and political impetus, there has been considerable international investment in the systematic risk
profiling of emergency admissions. The approach is based on proactive targeting and support for those
at risk, with the aim of preventing health deterioration and emergency admissions to hospital. To be
cost-effective, however, preventative interventions must use case-finding techniques that target those
at risk.3,15,18
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Identifying those at risk
A number of approaches to identifying patients at risk have been explored. One approach is to ask clinicians
to select at-risk patients based on their knowledge and experience, but a study by Allaudeen et al.19 found
that the predictions made by junior doctors, senior doctors, nurses and case managers were statistically
no different from chance. An alternative is to use a criteria-based approach, whereby individuals meeting
certain conditions are selected for intervention. For example, in the UK Evercare pilots, in nine English primary
care trusts (PCTs), patients aged ≥ 65 years with two or more emergency admissions in the previous year
were eligible for case management by community matrons. The intervention did not show an effect, however,
with the accuracy of the approach to identifying patients at risk criticised.20 Such criteria-based approaches
systematically exclude those who may be at high risk, but who do not meet what are typically a narrow set of
criteria (such as younger people and those who have not had a recent emergency admission).21 Furthermore,
such an approach is susceptible to the statistical phenomenon of regression to the mean.16 Offering hospital
avoidance interventions to patients identified merely from history of emergency admissions can therefore
be inefficient.22
An alternative approach to identifying patients at risk that has gained widespread support is the use of a
range of demographic and clinical data (such as age, gender, body mass index and medical history to
calculate disease risk), or to predict an undesirable outcome (such as an emergency admission). The resulting
clinical prediction models are intended to help clinicians make better decisions by providing more objective
estimates of probability as a supplement to other clinical information.23,24 Building on the successful
implementation of risk models predicting diabetes mellitus (e.g. QDiabetes®) and cardiovascular disease
(Framingham Risk Score25), emergency admission risk prediction (EARP) models have been widely developed –
Table 1 provides examples. In calculating individualised risk for a given population, the models use data from
up to three sources: self-reported data from patients; routinely collected administrative data; and data from
the clinical record or other primary data source.26
A 2014 systematic review of the technical performance of EARP models identified 27 tools, 18 using
routine or primary data, with nine using self-reported data.26 The majority of models (18 of 27) were
developed to predict emergency hospital admission at 12-month follow-up. Those models that performed
best (in terms of predictive accuracy, as measured by c-statistics of > 0.8), featured ‘prior health care
utilization variables, multimorbidity or polypharmacy measures, and named medical diagnoses or named
TABLE 1 Example EARP models
Model Developer Outcome
PRISM (Predictive RIsk
Stratification Model)
Informing Healthcare and Health Dialog for
NHS Wales
Risk of emergency admission in 1 year
Combined model The King’s Fund for the Department of Health Risk of emergency admission in 1 year
QAdmissions ClinRisk Ltd, UK Risk of emergency admission in 1 and
2 years
PEONY (Predicting Emergency
Admissions Over the Next Year)
NHS Tayside, UK Risk of emergency admission in 1 year
PARR (Patients At Risk of
Re-hospitalisation)
The King’s Fund for Department of Health Risk of hospital re-admission
ACGs Johns Hopkins University, Baltimore, MD,
USA
Range of outcomes, including risk of
hospitalisation (planned and unplanned)
HARP (Hospital Admission Risk
Programme)
Health Quality Ontario, Toronto, ON, Canada
and the Canadian Institute for Health
Information, Canada
Risk of emergency admission in 30 days
and 15 months
ACG, Adjusted Clinical Group.
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prescribed medications variables’. These better-performing models all used routinely collected clinical
patient data rather than self-reported patient data, and it is recognised that models reliant on self-reported
(questionnaire) data are limited by response rates, recall issues and respondent burden.27
Implementing risk prediction models
Although the EARP models are widely advocated in international policy and practice, notably in the UK,
Europe and the USA,5,14,28,29 evidence regarding their implementation and effects is limited. A 2015 NHS
England paper on the Next Steps for Risk Stratification in the NHS recognised the need for robust evidence,
and a pressing need for further research and evaluation, using high-quality study designs.15 We present a
systematic review of the existing published evidence in Chapter 2. The review confirms that the most
common intervention used in emergency admission avoidance are various forms of case management.
Although definitions of case management vary, Hutt et al. described it as ‘the process of planning,
co-ordinating and reviewing the care of an individual’ (as cited in Ross et al.22). Case management often
covers a range of activities, but it is recognised that these can vary widely between programmes.22
Evidence for case management is mixed. A 2013 review found good evidence that many common aspects
of case management are effective, including continuity of care with a general practitioner (GP), structured
discharge planning and advanced care planning (as cited in Lewis15). However, a recent systematic review
by Stokes et al. concludes that there is little evidence that case management is effective in reducing
secondary care use or costs, but does show a positive impact on patient satisfaction.30 Of the 36 studies
included, only four used routine data risk prediction tools to identify patients for intervention, with most
relying on referral criteria or identification by clinicians unaided by a risk model. The results of the
subgroup of four remaining studies using routine data generated risk models to predict emergency
admission were favourable, although none was from the UK.30
Contractual incentives to adopt risk models
Despite the lack of evidence concerning effectiveness, over the past few years in the UK, a range of
contracts has promoted and financially incentivised the use of emergency admission risk models in general
practice. For example, NHS England’s Enhanced Service Specification. Avoiding Unplanned Admissions:
Proactive Case Finding and Patient Review for Vulnerable People enhanced service committed funds of
£480M over 3 years (2014–17).18 Through ‘more personalised care’, the initiative aimed to improve the
quality and co-ordination of care for high-risk patients to improve their health and well-being and reduce
hospital admissions and emergency department (ED) attendances.18 It funded practices to create a register
of patients at high risk of avoidable unplanned admissions, for proactive case management.
Such initiatives have prompted further development of risk tools and widespread take-up in the UK. It is
estimated that over 7500 English GP practices have participated in the enhanced service initiative, which
generally relies on predictive risk scores to identify patients for selection for case management – over 95%
of all practices (NHS Digital, 2015, personal communication).
Wales also introduced a variation to the general practice contract in 2013/14, encouraging the use of
EARP tools to support hospital avoidance.31 This work was funded through quality and productivity
indicators within the Quality and Outcomes Framework (QOF) contract, and aligned with an ‘increased
focus on integration of services’, and a vision of additional services within primary and community care.31
Box 1 lists the relevant quality and productivity indicators (QPIs) for the 2013/14 financial year. Practices
were encouraged to participate in this work, but it was not mandatory.
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Introducing the Predictive RIsk Stratification Model
This study relates to an evaluation of the Predictive RIsk Stratification Model (PRISM), an EARP tool
introduced in Wales. PRISM is a web-based emergency admission predictive risk tool commissioned by the
Welsh Assembly (now Welsh Government), with development led by the NHS Wales Informatics Service
(NWIS – formerly Informing Healthcare). PRISM was closely aligned to the chronic conditions management
model and framework,14 and built on a similar model in England (the combined predictive model).32
PRISM provides individual risk scores for patients and stratifies general practice population into four levels
based on the individual patient risk of an emergency admission to hospital in the following 12 months.
The tool generates a predicted risk (out of 100%) of emergency admission for each patient on a practice
list. It also stratifies patients into four risk groups according to the relative risk within the practice as a
whole. So, for example, using the default stratification, the 0.5% of patients with the highest practice risk
will appear at level 4; those in the top 0.5 –5% in level 3 (moderate risk); those between 5% and 20% in
level 2 (low risk); and the remainder in level 1 (very low risk).33 PRISM was developed and tested (validated)
for accuracy of prediction on hospital and GP records of 300,000 people in Wales (10% of the Welsh
population), from which 37 variables with the highest predictive power were selected. The variables used
to develop PRISM were drawn from routinely available data on inpatient, outpatient and primary care
episodes and from the Welsh Index of Multiple Deprivation (WIMD), which includes data on employment,
income, housing, environment, education and health.
Following initial testing in 25 practices, PRISM distribution to all general practices in Wales was planned for
April 2010. In anticipation, our original research proposal involved a study across three areas of Wales.
However, this distribution did not proceed. We revised our study plan following discussions with Abertawe
BOX 1 Quality and productivity indicators within QOF guidance for the General Medical Services 2013/14 contract
for Wales31
QP100W
The practice produces a list of 5% of patients in the practice who are predicted to be at significant risk of
unscheduled admission to secondary care or community-based alternatives (10 points).
QP101W
The practice identifies a minimum of 10% (with a maximum of 0.5% of the practice list) of those patients from
the list produced in indicator QP100W who would most benefit from review and ensures there is an active
management plan is in place for each patient. The active management plan must identify the lead clinician or
care co-ordinator and an appropriate review date. The frequency of each patient’s review should be
determined in light of their clinical and care needs. The practice will be responsible for ensuring that an
appropriate system is in place for monitoring and review of the patients identified (10 points).
QP102W
The practice has at least four meetings during the year to review the delivery of care for the patients identified
in QP16. These meetings should be open to all relevant professionals engaged in the delivery of care to this
group. The meetings should be used to review the clarity of care plans and the effectiveness of service delivery.
Patient and carer feedback should play a key role in informing this assessment. Participants should seek to
identify opportunities to improve systems of care and to enact changes where possible (22.5 points).
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Bro Morgannwg University Health Board (ABM UHB), which remained keen for PRISM to be introduced in
its area. Following an offer of support from NWIS to help with the technical support for PRISM, we were
able to propose a revised cluster randomised study in a single site. Following approval from the National
Institute for Health Research (NIHR) Health Services and Delivery Research (HSDR) programme and a study
extension, we carried out this study according to our published protocol,34 rather than our original project
description as submitted to the NIHR HSDR (then NHS Service Delivery and Organisation) programme.
The following chapters include a systematic review of the implementation of EARP models, followed by a
summary of methods and findings reported over four chapters: clinical effectiveness, cost-effectiveness,
findings from stakeholder consultation and a brief section on service user involvement. There follows a
discussion featuring research recommendations and conclusions. Appendices include documents associated
with data collection, training and supplementary information.
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Chapter 2 Systematic review of the costs, effects
and implementation of emergency admission risk
prediction models in primary care
Introduction
There is limited evidence on what works in reducing avoidable emergency admissions. There are many
local initiatives to prevent avoidable emergency admissions including risk prediction tools, case
management, hospital alternatives and telemedicine, but limited evidence on what works.3
We carried out a systematic review of studies reporting effects, costs and implementation of using risk
prediction models in primary care to identify patients with chronic conditions at risk of future
emergency admissions.
Methods
We registered the systematic review with PROSPERO – the International Prospective Register Of Systematic
Reviews – on 14 April 2015 (reference number CRD42015016874), and outlined our methods in a protocol
publication.35 We carried out the review in accordance with Preferred Reporting Items for Systematic
Reviews and Meta-Analyses guidelines.36
Search strategy
We searched the following electronic databases: Applied Social Sciences Index and Abstracts via ProQuest,
Cumulative Index to Nursing and Allied Health Literature via EBSCOhost, The Cochrane Library and
Cochrane Central Register of Controlled Trials and Economic Evaluations, Health Management Information
Consortium via Ovid, ISI Web of Science, MEDLINE via EBSCOhost and Scopus. We also hand-searched BMC
Family Practice, the British Journal of General Practice and the International Journal of Integrated Care, all
known to have published related work. We searched references and citations of included articles, undertook
a further search using the names or other identifiers of risk models identified in included studies, and
consulted experts in EARP. Our systematic review protocol35 provides a detailed listing of the search terms.
We selected 2005 as the earliest publication date, to precede relevant policy initiatives that prompted the
development of the risk tool,5,14,37,38 and to ensure relevance to contemporary primary and community care.
Searches were completed to the end of May 2015.
Study selection
We included studies reporting use of risk prediction models within primary care. Our inclusion criteria are
shown in Table 2.
Two reviewers (MRK and KN) independently assessed initial eligibility of identified studies by screening
titles, abstracts and keywords. Two reviewers (MRK and BAE) independently assessed potentially eligible
full texts for inclusion. Disagreements were resolved through discussion.
Data extraction
Mark Kingston and Hayley Hutchings extracted data independently and in duplicate from all eligible
studies. Disagreements were managed by consensus. A standardised data extraction form, building on
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guidance from the NHS Centre for Reviews and Dissemination39 was developed, tested and subsequently
used following minor adjustments.
We sought to extract data based on a primary outcome of the number of emergency hospital
admissions, and:
l other health-care resource use, implementation costs, reported facilitators and barriers, and clinicians’
and patients’ views, notably satisfaction
l study characteristics (setting, objectives, design and methods)
l study population, notably selection criteria
l nature and purpose of risk prediction model
l implementation of risk prediction model – who used it and how?
Additional data were sought from authors when necessary.
Quality assessment
Two reviewers (MRK and HH) independently assessed general study quality as strong, moderate or weak,
resolving any differences through discussion with a third reviewer (BAE). To account for a range of study
designs we used two bias assessment tools. Thomas et al.’s 2004 tool is suitable for quantitative study
designs.40 This tool assesses study design, sample selection, identification and analysis of confounders,
blinding of outcome assessors and participants, validity and reliability of data collection methods, and
nature and extent of withdrawals. We also used the Walsh and Downe framework to appraise the
qualitative studies according to their scope and purpose, design, sampling, analysis, interpretation,
reflexivity, ethical dimensions and relevance.41
Data synthesis
We grouped and tabulated included studies according to their characteristics, including narrative
summaries of risk prediction models used, how they were implemented and reported effects. Owing to
the range of study design and limited overlap in study outcomes, it was not appropriate to undertake
meta-analysis or to undertake statistical tests for heterogeneity.42
We used narrative synthesis to review qualitative data on model implementation, and staff and patients
views, informed by the framework developed by Popay et al.43
TABLE 2 Systematic review eligibility criteria
Criterion Description
Population Patients registered with general practices, or consulting primary or community care practitioners
Intervention Models in primary care using routine data to predict risk of hospital admission for patients with,
or at risk of, chronic conditions
Exclusion: models that rely on patient-reported (questionnaire or interview) data
Comparators External (e.g. trial) or internal (e.g. cohort). None for qualitative studies
Outcomes Clinical effectiveness or cost-effectiveness, views of patients or health professionals on EARP models,
or implementation of model
Study design Studies that report empirical data
Published 2005–15; no language restriction
Exclusion: commentaries or editorials
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Results
Search results
Our initial electronic database search identified 10,244 papers, with a further 11 identified through other
sources. Following the removal of duplicates, 6621 papers were screened by title and abstract, with 215
reviewed in full-text format. Thirteen papers, from 11 studies, met all criteria and underwent full data
extraction (Figure 1).7,44–55
Quality assessment
An overview of the results of the quality assessment can be found in Tables 3 and 4. Most studies were
rated as being of low quality.
Settings
Of the 11 studies, eight were European, consisting of four studies (and five papers) from England,48,49,52,54,55
two (related studies) in Germany,27,46 one in Scotland44 and one in Spain.53 Three studies were undertaken
in North America, one in Canada45 and two in the USA (yielding three papers).47,50,51 A summary of studies
is presented in Table 5.
All studies related to interventions in primary and community care, including one study that randomised
patients to community-based care on discharge from hospital.45
All papers were published from 2010 onwards with reported data collection or coverage between 2005
and 2014.
Records after duplicates removed
(n = 6621)
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Records screened
(n = 6621)
Full-text articles 
assessed for eligibility
(n = 215)
Records excluded
(n = 6406)
Records identified through
database searching 
(n = 10,244)
Records identified
through other sources 
(n = 11)
• Citation and reference
   searches, n = 3
• Hand-searches, n = 7
• Expert suggestion, n = 1
Full-text articles 
excluded, with reasons
(n = 202)
• No routine data emergency
   admission risk prediction
   model involved, n = 143
• Development or validation
   of a risk model only, n = 21
• Non-primary care setting, n = 9
• No empirical data
   (e.g. protocol, editorial), n = 29
Articles included in review
(n = 13 from 11 studies)
• From database searches, n = 8
• From other sources, n = 5
FIGURE 1 Search results PRISMA flow diagram.
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TABLE 4 Quality assessment of qualitative papers
Author
(year of publication)
Scope and
purpose Design
Sampling
strategy Analysis Interpretation Reflexivity
Ethical
dimensions
Relevance and
transferability
Overall quality
rating
Abell et al. (2010)52 B B A B C C A B
Sauto Arce et al.
(2014)53
B B B C C C B B C
Freund et al. (2012)27 B B A B B C B B B
Hall et al. (2011)54 B B A B B C A A B
McEvoy et al. (2011)55 B B A B C C B B B
A, no or few flaws, the study credibility, transferability, dependability and confirmability is high; B, some flaws, unlikely to affect the credibility, transferability, dependability and/or
confirmability of the study; C, some flaws which may affect the credibility, transferability, dependability and/or confirmability of the study.
TABLE 3 Quality assessment of quantitative papers
Author (year of publication) Selection bias Design Confounders Blinding
Data collection
methods
Withdrawals
and dropouts
Overall quality
rating
Baker et al. (2012)44 Weak Moderate Weak Weak Strong Moderate Weak
Dhalla et al. (2014)45 Strong Strong Moderate Weak Strong Strong Strong
Freund et al. (2011)46 Weak Weak Weak Weak Weak Moderate Weak
Levine et al. (2012)47 Weak Strong Moderate Moderate Moderate Moderate Moderate
Reilly et al. (2011)48 Moderate Moderate Weak Weak Moderate Weak Weak
Roland et al. (2012)49 Moderate Moderate Strong Weak Moderate Weak Weak
Takahashi et al. (2012)50 Weak Strong Moderate Weak Moderate Moderate Weak
Upatising et al. (2013)51 Weak Strong Moderate Weak Moderate Moderate Weak
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TABLE 5 Characteristics of included studies
Author (year
of publication) Country Aim Design and methods Description of interventions
Data collection/
coverage
Abell et al.
(2010)52
Manchester, UK To explore processes that influence
patient selection for case
management and to explore the
factors within the service that
promote a differential service
Uncontrolled prospective cohort study
1. Postal questionnaire – managers
with lead responsibility for case
management in PCTs (n= 10)
2. Follow-up interviews with
managers (n= 8)
3. Tracking of case-managed patients
from 10 PCTs through hospital
utilisation data (n = 2728)
There were no comparative data
available related to effects of
predictive risk stratification on
processes or outcomes of care
Various methods including predictive risk
tools used to identify patients at risk of
unplanned hospital admissions, eligible
for case management. Case management
through a range of primary care staff
(e.g. community matrons, district nurses,
community nurses) across 10 PCTs. No
control group
2007–8
Sauto Arce
et al. (2014)53
Basque area,
Spain
To explore implementation of a risk
tool
Qualitative. Three focus groups with
users (12 GPs and 11 nurses)
Predictive Risk Stratification tool to
identify target populations for services
such as secondary prevention activities by
primary care practice staff for patients
with hypercholesterolaemia, high blood
pressure, or type 2 diabetes mellitus, not
suffering heart failure or ischaemic heart
disease
December 2011
Baker et al.
(2012)44
Nairn, UK To describe results ACP aimed at
reducing unplanned hospitalisations
of older patients who are frail
Before-and-after comparison.
Comparative analysis of ACP vs. usual
care – cases identified by use of
predictive risk tool
Patients identified through use of
predictive risk tool (Nairn Case Finder).
Case management (ACP) featuring care
plans for older patients who are frail.
Supported by case managers (1.2 WTE),
care workers (2 WTE), physiotherapists
(1 WTE) and OTs (0.5 WTE)
April 2007 to
November 2008
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TABLE 5 Characteristics of included studies (continued )
Author (year
of publication) Country Aim Design and methods Description of interventions
Data collection/
coverage
Dhalla et al.
(2014)45
Toronto, ON,
Canada
To explore whether or not a virtual
ward could improve health
outcomes and reduce re-admissions
after hospital discharge in a
high-risk population
Parallel-group randomised trial with
patients randomised at hospital
discharge in a 1 : 1 ratio to either the
virtual ward model of care or usual
care. Eligibility for trial determined by
use of predictive model for risk of
readmission (LACE). No comparative
process or outcome data related to
predictive risk stratification available –
all patients identified for virtual ward
management using predictive risk tool
Virtual ward, admitted on day of
discharge from hospital, with care
co-ordinator (similar to case manager),
p/t pharmacist, p/t nurse or nurse
practitioner, f/t physician, clerical
assistant. Regular MDT discussion, care
plans, liaison with primary care physician,
home visit by co-ordinator. Further
follow-up in home, in hospital clinic, or
elsewhere (e.g. family physicians office).
Average discussion 6.3 times in MDT
team meetings, 2.8 home visits
29 June 2010 to
2 June 2014
Freund et al.
(2011)46
South-west
Germany
To compare patient selection for
care management interventions
by physicians and by predictive
modelling
Observational study comparing
patients selected by predictive model
with those selected by physicians
Study relates to testing performance of
predictive risk tool, as part of intervention
development process
Freund et al.
(2012)27
South-west
Germany
To explore how physicians select
patients for care management
and how risk prediction may
complement their case finding
Qualitative: 12 interviews with
physicians from 10 primary care
practices
Study relates to views about use of
predictive risk tool to identify patients
for case management, as part of
intervention development process
Not reported
Hall et al.
(2011)54
London, UK To evaluate how community
matrons select their case load
Qualitative service evaluation.
Interviews with seven community
matrons and two GPs
Case selection, potentially for case
management via community matrons
Not reported
Levine et al.
(2012)47
Three Los
Angeles county
regions, CA,
USA
To assess the efficacy of a home
care programme designed to
improve access to medical care for
older adults with multiple chronic
conditions at risk of hospitalisation
RCT in which participants were
assigned to the home care intervention
(Choices for Healthy Ageing
programme) or usual care. Routine
data, costs and telephone patient
satisfaction questionnaires. Eligibility
for trial determined by use of predictive
model for risk of readmission (SCAN).
No comparative process or outcome
data related to predictive risk
stratification available – all patients
identified for home care programme
management using predictive risk tool
Home care intervention programme –
early identification and treatment
of exacerbation of the illness;
patient-specific health education;
self-management or caregiver
management of the disease; advance
care planning and other psychosocial
issues. Care delivered via interdisciplinary
team, with core team members consisting
of physician, nurse practitioner, nurse
care manager and a social worker
January to July 2008
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Author (year
of publication) Country Aim Design and methods Description of interventions
Data collection/
coverage
McEvoy et al.
(2011)55
Northern
England, UK
The evaluation aimed:
1. to assess the quality of the
organisational infrastructure
2. to obtain a better
understanding of the key
influences shaping
service development
3. to identify potential changes in
practice that may help improve
service quality
Formative evaluation self-completion
questionnaire and semistructured
interview. Predictive risk tool (PARR)
used to identify patients for case
management. No comparative process
or outcome data available
Case management for high-intensity
service users via three community
matrons who acted as both advanced
clinical practitioners and case managers,
six case managers and an administrator
February 2007 to
August 2008
Reilly et al.
(2011)48
Manchester, UK Evaluate the implementation and
impact of case management for
long-term conditions in 10 PCTs
Cross-sectional postal survey,
interviews and retrospective cohort
analysis. Various case finding methods
used including predictive risk
stratification and direct referral,
handsearching
Predictive risk stratification not part of
intervention. Case management through
a range of primary care staff (e.g.
community matrons, district nurses,
community nurses) across 10 PCTs
July 2007 interviews;
1 July 2005 to
1 October 2006
cohort analysis
Roland et al.
(2012)49
UK Evaluation of English integrated
care pilots
Questionnaire to staff and patients.
Analysis of secondary care utilisation
using HES data on 3646 patients and
17,311 matched controls. Various
case finding methods used including
predictive risk tools. Before/after
comparison of outcomes for case
management
Predictive risk tool not necessarily part
of intervention. Virtual wards, with
nurse-led case management. Plus focus
on delivery system redesign and
improved clinical information systems
Staff questionnaires :
summer 2010 and
spring 2011. Patient
questionnaires:
autumn 2009 and
autumn 2010
Takahashi et al.
(2012)50
Rochester, MN,
USA
To determine the difference in
hospitalisations and emergency
room visits in older adults using
telemonitoring vs. standard care
RCT. Eligibility for trial determined by
use of predictive model for risk of
readmission (ERA). All patients
identified for telemonitoring
intervention using predictive risk tool.
Comparative analysis of outcomes of
telemonitoring
The telemonitoring intervention included
usual medical care and telemonitoring
case management. Using telemonitoring
the participant’s blood pressure, pulse,
oxygen saturation, blood glucose level
and weight were measured as per an
individualised protocol, based on their
medical condition. Usual care included
various types of face-to-face visits,
telephone services and home health care
available to all primary care patients.
Home health care includes provision of
home health nursing and/or physical and
occupational therapist visits
November 2009 to
July 2012
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TABLE 5 Characteristics of included studies (continued )
Author (year
of publication) Country Aim Design and methods Description of interventions
Data collection/
coverage
Upatising et al.
(2013)51
Rochester, MN,
USA
To evaluate the effectiveness of
home telemonitoring in reducing
the decline of worsening frailty
states in older adults aged
≥ 60 years with comorbid health
problems
Secondary analysis of RCT data.50
Eligibility for trial determined by use of
predictive model for risk of readmission
(ERA). All patients identified for
telemonitoring intervention using
predictive risk tool. Comparative
analysis of outcomes of telemonitoring
The telemonitoring intervention included
usual medical care and telemonitoring
case management. Using telemonitoring
the participant’s blood pressure, pulse,
oxygen saturation, blood glucose level,
and weight were measured as per an
individualised protocol, based on their
medical condition. Usual care included
various types of face-to-face visits,
telephone services and home health care
available to all primary care patients.
Home health care includes provision of
home health nursing and/or physical and
occupational therapist visits
November 2009 to
July 2012
ACP, anticipatory care planning; f/t, full time; HES, Hospital Episode Statistics; MDT, multidisciplinary team; OT, occupational therapist; p/t, part time; RCT, randomised controlled trial;
WTE, whole-time equivalent.
CO
STS,EFFECTS
A
N
D
IM
PLEM
EN
TA
TIO
N
O
F
EM
ERG
EN
CY
A
D
M
ISSIO
N
RISK
PRED
ICTIO
N
M
O
D
ELS
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
14
Study designs
Study designs comprised three randomised controlled trials,45,47,50 three cohort studies,44,48,56 one
cross-sectional study55 and one further observational study.46 Three wholly qualitative studies were
included,27,53,54 with qualitative methods also featuring in two others.52,55
Risk tools identified
The majority of studies reported the use of a single tool predicting emergency admissions to hospital.
Three studies reported findings relating to the use of multiple risk tools, as applied in different PCT
areas,48,52,56 although none provided a disaggregation of results by area or tool used. The Patients at Risk
of Re-hospitalisation (PARR) tool was used in five studies.48,49,52,54,55 PARR uses data on prior hospitalisations
to predict risk of rehospitalisation and, hence, calculates risk only for those patients with a previous
admission. The combined predictive model was reported in three studies,48,49,52 with single references to
the Elder Risk Assessment (ERA),50 Case Smart Suite Germany,46 Length of stay, Acuity, Comorbidities, ED
visits in previous 6 months (LACE),45 Nairn Case Finder,44 High Impact User Manager52 and Adjusted Clinical
Groups (ACGs).53 An unnamed tool developed by the Senior Care Action Network Health Plan was used
for the Levine et al. study.47
All except two tools were reported as predicting the likelihood of an emergency hospital admission
(or re-admission in the case of the PARR tool), within 12 months. The LACE tool predicts risk within
30 days45 and the ERA tool51 predicts risk within 24 months. The time span for the ACG tool used in
Sauto Arce et al.’s qualitative study53 was not provided.
Only one paper explicitly addressed risk tool technical performance – Baker et al.44 – reporting an area
under the receiver operating characteristic (ROC) curve of 0.794 for the Nairn Case Finder. A number of
papers did include a reference45,48,50–55 to resources where details of the development and validation of the
respective risk tools could be found. No technical performance details or references were included in
three papers.46,47,56
Risk tools users
Identification of who used the risk tools was included in all studies, except three (Table 6).47,48,55
Interventions
Predictive risk stratification was generally used as a tool for identifying patients suitable for a further
intervention (e.g. virtual ward), rather than as a formal part of that intervention. In some cases, a predictive
risk tool was used as one of several methods of case-finding. No studies reported comparative data about
processes or outcomes related to predictive risk stratification. In each of the RCTs, predictive risk tools were
used to identify patients eligible for the trial – and were therefore used in both trial arms.
With regard to the follow-on (secondary) interventions, eight of the studies focused on case (or care)
management of patients at high risk of emergency admission to hospital.44–48,52,54,55 Two studies featured
the use of telemedicine46,50 as part of an overall package of care. A range of primary care and community
staff delivered, or were proposed to deliver, these secondary interventions. This included the use of
community matrons48,52,54,55 – senior nurses with a care co-ordination function,54 who were introduced
following Department of Health funding in support of the care of patients with long-term conditions.60
The intended use of multidisciplinary teams (MDTs) was noted in five studies,44,45,47,49,54 and virtual wards
featured in three.45,54,56 The virtual ward model is based on the use of predictive models to identify those at
risk of emergency admission, and the provision of a period of intensive, multidisciplinary case management
at home using the processes and staff associated with hospital wards.56 One study related to gathering
evidence to inform the development of an intervention.46
Main quantitative results
There were no comparative data available related to effects of predictive risk stratification on processes or
outcomes of care.
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TABLE 6 Summary of risk models
Author (year
of publication)
Risk prediction
model
Outcome and time span
of risk model Validation
Population risk model
applied to Users of risk model Case selection method
Abell et al.
(2010)52
PARR; combined
predictive model
PARR: likelihood of
rehospitalisation within the
next 12 months
Combined model: risk of
emergency admission within
the next 12 months
Not discussed, but
reference supplied for
PARR tool development
and validation paper
(see Billings et al.57)
Unspecified number of
patients across 10 PCTs
providing case
management services
Case managers
including community
matrons
Risk models (10/10 PCTs);
referrals from professionals
(10/10); criteria (threshold)
(9/10); and, assessment
framework (4/10), disease
registry (3/10) and other
(3/10)
Sauto Arce
et al. (2014)53
ACGs Risk score for health costs,
risk score for risk of
admission to hospital.
Time span not reported
Not discussed. Link to ACG
website provided
2.2 million people in
Basque Health Service
area
GPs and primary care
nurses
Risk score and presence of
diabetes mellitus, high
blood pressure or
hypercholesterolaemia
Baker et al.
(2012)44
Nairn Case Finder Risk of admission to hospital
within next 12 months
Reports area under the
ROC curve of 0.794. Refers
to appendix for further
information
General practice with
10,860 patients
Practice staff From each monthly list, the
1% of patients with the
highest risk of admission
were defined as the ACP
cohort, along with all care
home patients
Dhalla et al.
(2014)45
LACE Predict the risk of death or
non-elective re-admission
within 30 days after
discharge
Not discussed, but
reference provided to
development and
validation paper
(see van Walraven et al.58)
30,143 patients
discharged from four
Toronto hospitals
A research
co-ordinator assessed
patient eligibility at
each hospital
Risk model only
Freund et al.
(2011)46
Case Smart Suite
Germany
Likelihood of hospitalisation
within the next 12 months
No details provided 6026 beneficiaries of
a statutory health
insurance programme
in Germany
Primary care
physicians
Mix (study explored case
selection by physician and by
risk model)
Freund et al.
(2012)27
Case Smart Suite
Germany
Likelihood of hospitalisation
within the next 12 months
No details provided 6026 beneficiaries of
a statutory health
insurance programme
in Germany
Primary care
physicians
Mix (study explored case
selection by physician and by
risk model)
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Author (year
of publication)
Risk prediction
model
Outcome and time span
of risk model Validation
Population risk model
applied to Users of risk model Case selection method
Hall et al.
(2011)54
PARR PARR: likelihood of
rehospitalisation within the
next 12 months
Not discussed but
reference supplied for
PARR tool development
and validation paper
(see Billings et al.57)
No details provided Community matrons
(data supplied by
e-mail by PCT)
Mix (PARR) referrals and
identification by community
matrons
Levine et al.
(2012)47
Unnamed tool
developed by SCAN
Health Plan
At risk of hospitalisation.
Time span not provided
No details provided 1362 patients eligible
from three Los Angeles
county regions
Not specified Risk model only (intervention
and control)
McEvoy et al.
(2011)55
PARR Risk of re-admission within
12 months
Not discussed but
reference to development
and validation paper
provided (see Billings
et al.57)
High-risk patients in
northern England
Not specified (likely
to be community
matrons/GPs)
Not specified though
all had a PARR score of
> 40, indicating that there
was a high risk they would
require emergency
re-admission to hospital
Reilly et al.
(2011)48
PARR; combined
predictive model;
High Impact User
Manager (Dr Foster)
PARR and High Impact User
Manager: risk of re-admission
within 12 months
Combined predictive model:
risk of emergency admission
with 12 months
Not discussed, but
reference supplied for
PARR tool development
and validation paper
(see Billings et al.57)
Unspecified number of
patients across 10 PCTs
providing case
management services
Case managers
including community
matrons
Risk model and clinician
referral (referrals in all
10 sites)
Roland et al.
(2012)49
PARR; combined
predictive model
PARR: risk of re-admission
within 12 months
Combined predictive model:
risk of emergency admission
with 12 months
No details provided Six integrated care pilot
sites in England
Varies across six sites,
but includes GPs and
case managers
Mix of risk profiling tools,
medical history and clinical
judgement to identify older
people at risk
Takahsahi et al.
(2012)50
ERA Risk of admission to hospital
within 2 years
Reference provided to
development of ERA tool
(see Crane et al.59)
Residents of four Mayo
Clinic sites in Minnesota
Not specified Risk model (and aged
≥ 60 years)
Upatising et al.
(2013)51
ERA Risk of admission to hospital
within 2 years
As above Residents of four Mayo
Clinic sites in Minnesota
Not specified Risk model (and aged over
≥ 60 years)
ACP, anticipatory care plan; SCAN, Senior Care Action Network.
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Main qualitative results
Organisational issues, staff attitudes towards risk prediction models, together with staff skills and access to
computer equipment affected use within primary and community care (Table 7).
Primary and community care context
Political, organisational and cultural issues were reported to affect how risk prediction models were introduced
and used. Lack of organisational leadership and guidance meant that staff took individual decisions about if
and how to use the model.55 GPs and nurses were more likely to accept and use risk prediction models if they
were involved in developing the implementation process, could see how it fitted into their practice and had
confidence in the organisation promoting its use.53 According to GPs, the structure of general practice and the
dependencies of patients forced them into delivering reactive care. Against a backdrop of multiple new
initiatives, they said limited time and heavy workload prevented them working differently.53
Staff attitudes
Existing knowledge of risk prediction processes and an understanding of its principles were reported to
affect willingness to use risk prediction models in included studies. Support for new ways of working was
also required.27,53–55 GPs and nurses who perceived risk prediction as a population health management
approach were more likely to use a risk model to identify patients at higher risk, especially those they did
not already know, in order to prevent patients becoming ill or more ill.53 Hall et al.54 reported that
community matrons also welcomed a system which could identify patients before they presented to hospital
and those high users of services who were not known to their GP. However, the community matrons said
effective multidisciplinary working was necessary in order to deliver selected care to high-risk patients and
this depended on a common understanding and outlook between staff from different disciplines.
Health-care staff recognised that risk prediction tools could successfully identify high-risk patients,53,54
although concerns about the reliability of tools limited their use. Data could be out of date, inaccurate or
not provide new information.53,54 Confidence in risk prediction data was affected by which data were
included in the algorithm. Those tools with the widest data sources (ideally health and social data from a
whole population) were reported to be most popular because they were perceived to be most equitable
and highlighted the most appropriate patients for treatment.53 However, staff who lacked confidence in
the model data or who prioritised clinical experience and knowledge were less likely to use risk models.27
Studies reported that staff used risk prediction alongside other information sources to get the fullest
picture of a patient’s needs.52–55
TABLE 7 Barriers to, and facilitators of, the use of risk prediction models
Barriers Facilitators
Not an organisational priority55 Supportive organisational processes for risk prediction models53
Difficult to fit use of model into reactive way of
working53,54
Individual and organisational support for a population
management approach to primary care delivery53
Low interest in using risk prediction models and new
ways of working54,55
Training for staff53,54
Priority placed on personal and clinical knowledge over
risk model information27
Interest in new approaches to primary care delivery54
Questions over accuracy and timeliness of risk model
data27,53
Confidence and skills in IT54
Inadequate access to IT equipment54
IT, information technology.
COSTS, EFFECTS AND IMPLEMENTATION OF EMERGENCY ADMISSION RISK PREDICTION MODELS
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Information technology skills and access to equipment
Limited access to the risk prediction model was a common issue for staff who worked in the community.
Hall et al.54 reported that community matrons wanted access to a patient’s data on a computer system
and to understand the systems they were using in order to make best use of risk prediction data. McEvoy
et al.55 reported that staff in one site could use systems of colleagues in social services, community services
and secondary care, but many staff were denied access to all data in another site. Although McEvoy et al.55
and Abell et al.52 did not describe how case managers accessed risk prediction data, both reported that
collaborative working was difficult for staff and delayed use of the risk prediction tool until pragmatic
solutions were agreed to meet information governance requirements. Lack of information technology (IT)
skills also inhibited staff from using risk prediction models.53,54
Discussion
To the best of our knowledge, this is the first review of studies into costs, effects and implementation of
EARP tools. Our review highlights the shortage of high-quality evidence in this area. Given the small
number of heterogeneous studies and the predominant use of predictive risk tools to identify patients,
rather than as part of an intervention, our review did not provide strong evidence for or against the use of
EARP models. A search for unpublished articles was beyond the scope of this review, although we consider
it unlikely that our findings would have been greatly affected.
The studies included demonstrate heterogeneity in interventions. It is important to note that emergency
admission predictive risk tools can form part of a complex intervention, which may vary according to the
nature of the target population and delivery – although most featured case management based on
identified high-risk patients. Case selection approaches varied, with some interventions including patients
referred by health-care professionals rather than identified by risk tool, but not differentiating outcomes
in relation to the different recruitment approaches. In some cases, the use of mixed methods of case
selection illustrated a lack of intervention fidelity. It is not possible to separate out effects of the predictive
risk tool from those of the associated (secondary) intervention in the published studies, as none reported
comparative data about processes or outcomes related to predictive risk stratification.
A handful of studies included staff feedback on the use of risk prediction tools. These data indicated that,
although there was support for the use of the tools, there were concerns over the accuracy of models and
access to data. The review revealed a deficit of evidence regarding patient perspectives.
There was poor quality of reporting in relation to the technical performance of the tools.
This review supports the need for further studies that address important gaps in our understanding of the
effectiveness of EARP tools. The Predictive Risk Stratification: A Trial in Chronic Conditions Management
(PRISMATIC) study aims to address this gap.
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Chapter 3 Methods
Study aim
To evaluate the introduction of PRISM in primary care.
Objectives
The objectives of the study were to:
1. measure the effects on service usage, particularly emergency admissions to hospital
2. assess the effects of PRISM on quality of life and satisfaction
3. assess the technical performance of PRISM
4. estimate the costs of PRISM implementation and its effects
5. describe the processes of change associated with PRISM.
Design
We carried out a mixed-methods, progressive, cluster randomised trial with a quantitative evaluation and
health economic analysis sited within a health board in south-west Wales and qualitative fieldwork across
the whole of Wales. The trial site, ABM UHB, is the second largest of seven health boards in Wales, serving
> 500,000 people. The 77 general practices are arranged in three localities (Swansea, Neath Port Talbot and
Bridgend) and 11 community networks (local groupings of practices, health, social care, and voluntary sector
professionals) (Table 8). We invited all of these practices to participate and included those that volunteered.
Based on the distribution of practices willing to participate we created 11 study clusters (Table 9), based
as closely as possible on these community networks. The practices were grouped to ensure as limited
contamination across practices within the intervention and control phases as possible.
The study fulfilled the last of the three major steps (that of evaluating clinical performance), in researching
multivariable prognostic models identified by the recent series in the British Medical Journal.23
To ensure that all participating practices had the opportunity to implement and use the intervention during
the study period, we used a progressive cluster randomised trial design (also known as randomised
multiple interrupted time series or stepped-wedge design).61–63 As the trial progressed, the number of
intervention practices increased and the number of control practices fell (Figure 2). This design protects
against some sources of bias, including inherent differences and contamination between practices, as well
as the ‘resentful demoralisation’ of controls deprived of the intervention.
All participating practices began as control practices without the trial intervention, received the intervention
(PRISM package and training) and, thereafter, were able to use PRISM with clinical and technical support.
Swansea Trials Unit (STU) used random number tables to choose the order in which practice clusters
received the intervention, stratified by locality. We concealed when this would happen from practices until
6 weeks before the planned start of the intervention, when we notified them by telephone and e-mail.
We arranged training before the start of the intervention.
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TABLE 8 Abertawe Bro Morgannwg University Health Board general practice structuresa
Locality Network Practices (n) Population (n)
Neath Port Talbot Neath 8 56,640
Afan 10 50,603
Upper Valleys 5 30,615
Subtotal 23 137,858
Bridgend Bridgend North 9 51,251
Bridgend East 6 67,394
Bridgend West 4 34,099
Subtotal 19 152,744
Swansea Llwchwr 6 45,233
Penderi 6 37,715
Cwmtawe 5 42,392
CityHealth 10 55,437
BayHealth 8 68,047
Subtotal 35 248,824
Total 77 539,426
a Source data: ABM UHB.
TABLE 9 The PRISMATIC study clustersa
Locality Cluster Practices (n) Population (n)
Neath Port Talbot Afan B 3 15,033
Neath A 4 25,332
Neath B 4 31,179
Upper Valleys 3 9856
Afan A 3 16,807
Bridgend Bridgend East 2 25,696
Bridgend North 4 22,544
Swansea Bayhealth 2 28,332
Cwmtawe 2 17,691
Llwchwr 2 17,155
Penderi/City 3 19,804
Total 32 229,429
a Source data: ABM UHB.
METHODS
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Intervention
We describe the intervention according to the Template for Intervention Description and Replication
checklist, as summarised below and in Table 10:
l Name PRISM intervention.
l Why? Identification of patients at risk of emergency admission can support preventative allocation of
resources and reduce that risk.
l What (materials)? PRISM software and user-friendly PRISM handbook.
l What (procedures)? Practice-based training, clinical support through two locally appointed ‘GP
champions’, and telephone and e-mail ‘help desk’.
l Who provided? Primary care team.
l How? We installed PRISM software on practice PCs. Whenever possible, one of the GP champions and
the PRISMATIC project manager delivered the training. Thereafter the GP champions provided clinical
support, and the primary care service desk at NWIS provided technical support.
l Where? We initiated PRISM intervention in each of 32 participating practices within ABM UHB.
l When and how much? All practices received one training session on PRISM. We provided extra training
on request. Clinical support from GP champions was also available on request throughout the
intervention phase. Each practice nominated a PRISMATIC GP lead, responsible for co-ordinating their
practice’s participation in the research and intervention, to include engagement with other clinical and
practice staff as required.
l Tailoring Individual practices were advised that they could alter the default risk settings on PRISM tool
and were given flexibility with which to use the tool within their practice.
l Modifications None.
l How well? We delivered the intervention as planned in all 32 practices.
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FIGURE 2 Randomised multiple interrupted time series study design overview. Reproduced from Hutchings HA,
Evans BA, Fitzsimmons D, Harrison J, Heaven M, Huxley P, et al. Predictive risk stratification model: a progressive
cluster randomised trial in chronic conditions management (PRISMATIC) research protocol. Trials 2013;14:301.34
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Outcomes
We compared between intervention and control phases.
Primary outcome
l Emergency hospital admissions.
Secondary outcomes
l ED attendances.
l Primary care events.
l Outpatient attendances.
l Emergency admission bed-days.
l Health-related quality of life (Short Form questionnaire-12 items; SF-12).
l Patient satisfaction.
l NHS implementation costs.
l NHS recurrent costs.
Although not an effectiveness outcome per se, we compared deaths between groups to check for
unexpected effects.
We also explored in detail:
l technical performance of the PRISM tool – predicted compared with actual emergency admissions
to hospital
l practitioner, commissioner and policy-maker views about PRISM implementation, adoption and effects.
Methods
To address our study objectives, we used anonymised linked routine data on processes of health care for
all patients registered at the participating practices. We sent postal questionnaires to a sample of patients.
TABLE 10 Components of the intervention
Component Description
PRISM software Installed on computers in each practice and activated when the practice begins the intervention
Practice-based training 1-hour session delivered in the practice by a GP champion to PRISM lead GP, the PM and any
other interested staff
GP champions Two local GPs employed for two sessions per month to support practices in clinical use of PRISM
Technical help desk Telephone and e-mail support provided in office hours by NWIS to address enquiries about
technical aspects of using PRISM
PRISM handbook 25-page, user-friendly handbook explaining how to set up and access PRISM, demonstrating the
range of functions available in PRISM, and suggesting how to use it within the practice
PM, practice manager.
Adapted from Hutchings HA, Evans BA, Fitzsimmons D, Harrison J, Heaven M, Huxley P, et al. Predictive risk stratification
model: a progressive cluster-randomised trial in chronic conditions management (PRISMATIC) research protocol. Trials
2013;14:301.34 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed
under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
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We were aware that the highest-risk patients were likely to be older and have more chronic conditions
and, as a result, be less likely to return the questionnaire. In order to ensure representation from this
highest risk group, we weighted the sampling frame to include proportionally more patients at higher
levels of risk. We also conducted focus groups and one-to-one interviews with service providers,
commissioners and policy-makers. Figure 2 shows the progress of the trial and the points at which we
collected data.
Data collection and sources
Table 11 outlines how we addressed our study objectives, the data sources we used and the times when
we collected those data.
Clinical effectiveness outcomes
Anonymised linked data
We used routine data from the Secure Anonymised Information Linkage (SAIL) databank64 to compare
services (emergency, acute and primary care) delivered to patients across the spectrum of risk – between
intervention and control phases. The SAIL databank includes routine Welsh hospital data on emergency
admissions (ED data set), secondary care (Patient Episode Database for Wales) and general practice data.
We derived PRISM risk scores from GP data and linked these to data on health service use for all study
patients who did not dissent from the postal survey.
Postal questionnaires
We sent postal questionnaires to sampled patients at three points: at baseline, and at 6 and 18 months
after initiating PRISM in the first study practice. The questionnaire comprised three validated tools: the
adapted Client Service Receipt Inventory65 to estimate individual health service use; the Quality of Care
Monitor (QCM66) to measure patient satisfaction; and the SF-1267 to measure patient-reported outcomes.
We aimed to recruit samples of 800 patients stratified by risk level to complete the questionnaires at each
time point (Table 12). This equated to around 70 patients per practice for screening at each time point.
To ensure representation from the very small risk groups 3 and 4 (4.5% and 0.5% of patients), we
sampled proportionately more from these groups. We excluded patients who were aged < 18 years or
> 100 years, or had recently left a participating practice. NWIS undertook this sampling from their
anonymised PRISM data set so that selected patients were identifiable only by their practices. Those
practices then checked their lists of sampled patients to assess their suitability to receive questionnaires.
They excluded patients who lacked the capacity, support or resilience to complete questionnaires. No
additional patients were selected at this stage if patients were excluded. Participating practices then sent
questionnaires packs (letter from GP, information sheet, consent form, questionnaire and business reply
envelope), direct to approved patients. The letter asked patients to return completed questionnaires and
consent forms direct to the study team. Completed consent forms gave us access to patients’ demographic
information. Practices sent a second pack to patients who had not responded to the first after 2 weeks.
The two subsequent surveys followed the same approach. Practices checked that the original sampled
patients were still alive and suitable to participate, and sent them follow-up questionnaires. NWIS then
replaced each patient lost to follow-up by another patient of the same age, sex and risk level.
Clinical effectiveness analysis
We complied with STU’s standard operating procedure (SOP) on statistics. We undertook primary analysis
by treatment allocated. Our primary outcome was the number of emergency admissions per patient,
analysed as binary, count and rate variables and, hence, modelled using an appropriate generalised linear
model in which we were able to take account of explanatory factors (including whether or not the
participant’s practice had yet adopted PRISM) and covariates, including baseline observations, time-varying
covariates and days at risk.
DOI: 10.3310/hsdr06010 HEALTH SERVICES AND DELIVERY RESEARCH 2018 VOL. 6 NO. 1
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snooks et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
25
TABLE 11 Overview of data sources employed in the study, matched to study objectives
Objective Data source Sample Collection time
1. Measure effects on
service usage, particularly
emergency admissions to
hospital
Anonymised routine
linked data (including
PRISM data)
All patients from participating practices Baseline
6 months
18 months
Questionnaire data:
CSRI
Random sample of patients from
participating practices (n= 800 at each time
point)
Baseline
6 months
18 months
2. Assess the effect of
PRISM on quality of life
and patient satisfaction
Questionnaire data:
SF-12, QCM
Random sample of patients from
participating practices (n= 800 at each time
point)
Baseline
6 months
18 months
3. Assess the technical
performance of PRISM
PRISM data PRISM risk data for patients at participating
practices
Baseline
6 months
18 months
Anonymised routine
linked data
Routine health data Baseline
6 months
18 months
4. Estimate costs of
PRISM implementation
and its effects
Anonymised routine
linked data (including
PRISM data)
All patients from participating practices Baseline
6 months
18 months
Questionnaire data:
SF-12 was used to
derive SF-6D score
Random sample of patients from
participating practices (n= 800 at each time
point)
Baseline
6 months
18 months
Structured interviews PRISM users from all participating practices
(n = up to 40)
18 months
5. Describe processes of
change associated with
PRISM
Focus groups GPs, practice nurses and managers from
participating practices (n= 4); local health
services managers and community staff
managers (n = 1)
Baseline
Interviews GPs from participating practices who were
unable to attend focus groups (n = 12)
Health board managers from sites not
participating in main study (n = 6);
policy-makers and NHS managers (n= 5)
Interviews PRISM users from half of all participating
practices, purposively sampled (n= 16
practices)
After 3 months
following PRISM
going live (mid-trial
point) and at the end
of the intervention
(end of the trial)
Questionnaire PRISM users from remaining half of all
participating practices (n= 16 practices)
Focus group Local health services managers and
community staff managers (n= 1)
18 months
Interviews ABM UHB health service managers (n= 3)
CSRI, Client Service Receipt Inventory; QCM, Quality of Care Monitor; SF-6D, Short Form questionnaire-6 Dimensions.
Adapted from Hutchings HA, Evans BA, Fitzsimmons D, Harrison J, Heaven M, Huxley P, et al. Predictive risk stratification
model: a progressive cluster-randomised trial in chronic conditions management (PRISMATIC) research protocol. Trials
2013;14:301.34 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed
under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
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Outcomes were analysed using an appropriate generalised linear mixed model; specifically, we used linear
models for measurement outcomes (assuming normality, also assessed via residual diagnostics), in which
study practice was considered as a random factor; logistic regression for binary (yes/no) outcomes; negative
binomial regression models for counts; we also analysed SF-12 and QCM scores for participants returning
questionnaires using a repeated measures linear model. Analyses, which always included a PRISM effect,
considered the following covariates and factors: gender, age (in years) at study day 1, an overall WIMD
score and, separately, its health component (both taken from 2011), an initial PRISM score (dated around
study day 1), seasonality, trend and ‘days at risk’ in the control and intervention phases.
Models also included a participant-level random factor to account for paired ‘control’ and ‘intervention’
observations from participants. Modelling progressed by eliminating, in turn and starting with the least
significant, all covariates and factors found to be not statistically significant (that is, with a coefficient with
a p-value > 0.05), and concluded when all remaining covariates and factors were statistically significant.
Raw and adjusted comparisons between groups were made, with some indication of the extent of the
intracluster correlation coefficient (ICC) in variables between participants at the same study practice, and
details of statistically significant factors and covariates. The adjusted comparisons reflected the nature of
the variable under consideration: we present an odds ratio (OR) for logistic regression models for binary
variables; an incidence or event ratio, Λ from negative binomial models for count variables, and an additive
group effect (Δ, in the same units as the dependent variable) for linear models for continuous variables.
To test the effect of the positive skewness on the statistical results, data were log-transformed and the
generalised linear model re-run as described above.
Predictive risk stratification model risk groups
Each participant was assigned to one of four PRISM risk groups, based on the PRISM score at study day 1
and its relative position within the PRISM scores for the participant’s practice. Within each study practice,
PRISM risk group 1 comprises those participants with the lowest 80% of scores in that practice. PRISM risk
group 2 comprises those participants with the next 15% of scores, and PRISM risk group 3 comprises
those participants with the next 4.5% of ranked scores, so that PRISM risk group 4 comprises those
participants whose PRISM score is in the top 0.5% of scores for that practice (i.e. those who are predicted
to be at the highest risk of emergency hospital admission). PRISM risk groups for the complete sample are
formed by combining the practice-level groups.
Technical performance
To investigate the technical performance of the PRISM tool, we focused on data available prior to the
introduction of PRISM (to avoid potential contamination between its predictive ability and its use) and,
TABLE 12 Sampling for participant-completed questionnaires by risk group
PRISM risk level (default score range) Proportion of sample (%)
Sample (number of patients)
for screening in each practice
Level 4 (50–100) 20 15
Level 3 (20–50) 50 35
Level 2 (10–20) 15 10
Level 1 (0–10) 15 10
Total sample 100 70
Reproduced from Hutchings HA, Evans BA, Fitzsimmons D, Harrison J, Heaven M, Huxley P, et al. Predictive risk
stratification model: a progressive cluster-randomised trial in chronic conditions management (PRISMATIC) research
protocol. Trials 2013;14:301.34 This article is published under license to BioMed Central Ltd. This is an Open Access article
distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
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consistent with the interpretation that the PRISM risk score is a probability of an emergency admission in
12 months, sought to analyse data on PRISM scores and emergency admissions in a 1-year period.
Health economics
Health economic analysis
We undertook an evaluation of the costs from the perspective of the UK NHS. Costs were assigned to the
resources utilised by each patient in the 32 trial practices. These consisted of the PRISM implementation
costs, primary care costs and secondary care costs (including ED attendances, emergency admissions,
outpatient visits, and elective and emergency inpatient stays). Unit costs (pounds sterling, cost year 2014)
were derived from published information.68 In view of the time scale of each phase (control and intervention)
of the project not exceeding 1 year, no discounting was applied to the costs or benefits. Cost differences
between the two study phases were determined and used in conjunction with differences in the primary
outcome (emergency admissions) to undertake a cost-effectiveness analysis. The Short Form questionnaire-6
Dimensions (SF-6D) scores were used to undertake a cost–utility analysis. Other secondary outcomes were
included in a cost–consequences analysis.
Resource use and costs
Predictive risk stratification model implementation costs
We estimated the cost of PRISM implementation, based on the roll-out of the PRISM software across
32 general practices in the ABM UHB area, using information and data obtained within the trial.
The base-case costs were derived from the general practices in the trial. The figures do not include the
PRISM software development costs.
Implementation of the PRISM software in general practices required several individual steps, which were
considered and costed separately as detailed below.
The pre-activation phase The pre-activation phase consisted of distributing information sharing
agreements (ISAs), which was co-ordinated by the trial team members. The ISAs were completed and
returned to NWIS by the general practice’s Caldicott Guardian [i.e. the GP or practice manager (PM)
responsible for protecting the confidentiality of patient and service user information and enabling
appropriate information sharing]. This process was evaluated as GP/PM opportunity costs [for GPs, General
and Personal Medical Services (GMS) activity, excluding direct care staff costs and without qualification],
from the NHS perspective using published unit costs.68 Following receipt of completed ISAs, NWIS sent the
PRISM activation details (a set of four passwords) to the practice Caldicott Guardian via e-mail.
Predictive risk stratification model activation and set-up phase Three potential cost drivers were
identified during the PRISM activation and set-up phase, comprising NWIS IT support, GP training and
capital investment (i.e. equipment costs).
NHS Wales Informatics Service information technology support The activation or set-up phase of
the trial involved the distribution and download of the PRISM software onto general practice computer
hardware. This also reflected real practice for general practices to gain access to PRISM. Using the
passwords e-mailed to the Caldicott Guardian, PRISM was activated within the British Medical Journal
Informatica’s Audit+ clinical system, which runs on all general practice computers in NHS Wales. Activation
instructions were provided by the trial team in a two-page Microsoft Word document (Microsoft
Corporation, Redmond, WA, USA), and usually the PM proceeded with activation. Any general practice
requiring help during the downloading and activation of the software could telephone the NWIS IT help
desk for assistance. When telephone assistance did not solve the issue, an IT information officer provided
on-site assistance during a visit to the general practice. The formal electronic application for access to the
PRISM software and NWIS verification (by the NWIS governance team) was not assessed and costed as it
was expected to require very little time or resources.
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The second component assessed for cost was the monitoring of the activation status of the PRISM
software as practice staff went through the process of downloading software (a cost incurred by NWIS).
An information officer (NHS band 4) monitored the status of PRISM software activation and reported
back to each practice. This involved the first data transfer of files and confirmation that data had been
uploaded. NWIS support staff costs were taken from the Agenda for Change NHS 2014 pay scale.69
General practitioner training The second resource-intensive component of the set-up phase was GP
training. Two GPs were employed during the trial to deliver training on using the PRISM software to
designated GP staff in all participating general practices. These GPs were paid £62.50 per hour as part of
the trial. The GP trainers were trained by the trial team and then provided the training to GPs in each trial
practice. The practice GP opportunity costs were also assessed for those GPs in practice spending time
being trained on the use of PRISM. GP opportunity costs (GMS activity, excluding direct care staff costs
and without qualification) were estimated using published unit costs.70
Capital investment (cost of equipment) There was a requirement for NWIS to download relatively large
numbers of data from the participating general practices onto their own servers to activate the scoring
process. During the trial no new servers were acquired as NWIS used current capacity and as such no costs
were allocated for this resource. No equipment costs were therefore considered.
Predictive risk stratification model running costs
Running and maintenance costs of the PRISM tool for NWIS were expected to be minimal. An IT staff
member at NWIS was expected to oversee the monthly data uploads from GP surgeries, activate PRISM
scoring and confirm updates to general practices. NWIS also provided ongoing IT help desk support. This
support was primarily set up as an e-mail support system. NWIS support staff costs were taken from the
Agenda for Change NHS 2014 pay scale.69
An evaluation tool was developed which was made up of five questions to capture practice staff activity with
regard to using the software and data generated by PRISM in reviewing patient care. Practice staff were
asked to provide information on frequency and duration of use as well as the job title of the member of staff
who would usually work with PRISM. This evaluation took place at 3–9 months after implementation and at
the end of the trial. User login data were also provided by NWIS to establish the activity within general
practices. General practice staff time spent using the PRISM software was considered as GP or PM opportunity
costs (for GPs, GMS activity, excluding direct care staff costs and without qualification), and costed using
published unit costs.70
Primary care resource use and costs
Primary care resource use was derived from SAIL, which delivers data on the number of GP event-days on a
patient level. Owing to the fact that SAIL does not provide specification of the nature of the GP event, GP
events were costed following the publication of Trends in Consultation Rates in General Practice 1995/96 to
2008/09: Analysis of the QResearch® Database in 2009 by the NHS Information Centre and the Department
of Health.71 It was assumed in the base case that 82% of GP events are surgery visits of 11.7 minutes’
duration, 15% are telephone consultations (of 7.1 minutes’ duration) and 3% are home visits (30 minutes’
duration assumed, including travel time).70 Of these, 62% would be undertaken by a GP and 38% by a
practice nurse resulting in a unit cost per GP event of £32.10. In the sensitivity analysis, the impact of lowest
available cost (all appointments done by nurses) of £10.20 and highest available cost (all appointments done
by GP) of £45.40 on the results were investigated.
Secondary care resource use and unit costs
The number of ED attendances (admitted and discharged), emergency admission-related inpatient stays,
outpatient visits and elective inpatient stays were derived on a patient level through SAIL. Unit costs were
taken from NHS Reference Costs 2014/1568 and weighted for specialties and activity. Because the target
population of PRISM is mostly older patients suffering from chronic conditions, we excluded paediatric and
obstetric codes from the analysis. Emergency admission-related inpatient stays were costed according to
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actual length of stay for each individual patient as observed in the study. However, owing to unavailability
of length of stay data, elective inpatient stays were costed, assuming a length of stay of 5.4 days,
according to the national average weighted by specialties and activity.68 Table 13 summarises the unit costs
used in the base-case analysis and ranges used for the sensitivity analysis.
Cost-effectiveness analysis
We calculated the incremental cost per emergency admission avoided. Owing to the difference in duration
of the control and intervention phases, as a result of the stepped-wedge trial design, the control and
intervention phase data of the primary and secondary health-care costs were adjusted for loss to follow-up
(e.g. patients who died in the control phase and no data were available for the intervention phase) and
annualised. Difference in total cost data between the control and intervention phase were then modelled
using a generalised linear model incorporating an appropriate discrete distribution; consistent with the
statistical analyses employed. Analyses always included a PRISM effect and considered gender, age
(in years) at study day 1, an overall WIMD score and, separately, its health component (both taken from
2011), an initial PRISM score (dated around study day 1), season and trends as covariates and factors.
Models also included a participant-level random factor to account for paired ‘control’ and ‘intervention’
observations from participants. Modelling progressed by eliminating all covariates and factors found to be
not statistically significant (that is, with a coefficient with a p-value of > 0.05) starting with the least
significant, and concluded when all remaining covariates and factors were statistically significant. To test
the effect of the positive skewness inherent to cost data on the statistical results, total cost data were
log-transformed and the generalised linear model rerun as described above.
The incremental cost of the intervention was calculated as the difference between the cost in the
intervention phase (implementation cost of PRISM plus the primary and secondary care costs, as observed
during the study intervention period) and the control phase (primary and secondary care costs, as observed
during the study control period). This was then compared with the adjusted number of emergency
admissions for both trial phases to generate an incremental cost-effectiveness ratio (ICER). Generally, the
results of cost-effectiveness analyses are expressed as ICERs calculated by dividing the cost difference
between the two alternatives being compared by the difference in the effect/benefit.
Cost–utility analysis
Differences in total health-care cost and SF-6D scores derived from the SF-12 questionnaires completed by
a subset of participants were used to calculate the incremental cost per quality-adjusted life-year (QALY)
gained. In cost–utility analysis, the effect is expressed in QALYs, which incorporates quantity of life
(additional life-years) and quality of life into one measure. Thus, by dividing the difference in costs by the
difference in QALYs, cost per QALY can be calculated for each comparison.
TABLE 13 Unit costs (in £) applied to health-care resource use in the base-case analysis
Parameter Base-case unit cost (£) (lower, upper for sensitivity analysis)
ED attendance (discharged) 113.60 (94.30, 128.50)
ED attendance (admitted) 191.60 (152.00, 220.80)
Emergency admission-related bed-day (short stay) 541.30 (369.00, 631.00)
Emergency admission-related bed-day (long stay) 458.20 (326.70, 540.10)
Outpatient visit 110.60 (67.60, 127.80)
Inpatient stay 3605.50 (2624.30, 4299.10)
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Generally, the National Institute for Health and Care Excellence (NICE) considers an intervention
cost-effective if one of the following applies:
1. The intervention is less costly and more clinically effective than all other relevant alternatives. In this
case, no ICER is calculated as the strategy in question dominates the alternatives.
2. The intervention has an ICER of < £20,000 per QALY compared with the next best alternative. This
means that an investment of up to £20,000 in order to achieve an additional QALY is considered
cost-effective.
The ICER is generally compared with the willingness-to-pay threshold of £20,000 per QALY gained as
‘accepted’ by NICE. A cost-effectiveness acceptability curve is produced to illustrate the probability of the
intervention being cost-effective at different thresholds.
If the intervention is less effective and more costly than the comparator, the intervention is considered
dominated. In this case, no ICER or cost-effectiveness acceptability curve is produced.
Cost–consequence analysis
We presented a tabular representation of costs versus changes in primary and secondary outcomes in a
cost–consequence analysis. The cost–consequence approach presents all relevant outcome measures
alongside the costs (without combining them into an ICER), to leave decision-makers the option to form
their own view of relative importance.
Health economics: sensitivity analysis
Deterministic (univariate) sensitivity analyses investigated the robustness of the results to changes in
estimated costs and outcomes. All ICERs were recalculated after changing the value of a range of
parameters individually to estimate the robustness of the ICER (Table 14).
Probabilistic sensitivity analysis with changes to the values of all chosen parameters [usually within the
95% confidence intervals (CIs) or a reasonable, defined range], used bootstrap resampling to determine
the probability that the intervention was cost-effective when all uncertainty associated with the individual
parameters was considered. The results of the probabilistic sensitivity analysis were expressed as
percentage probability that the intervention was cost-effective.
Budget impact analysis
The budgetary impact of the adoption of the PRISM scoring tool in primary care was estimated from a NHS
perspective based on the differences between the cost of emergency admissions and total cost, as
obtained as part of the trial. We calculated the total budget impact per 100,000 patients registered in the
TABLE 14 Parameter changes for univariate sensitivity analysis
Parameter Change from base case
PRISM pre-activation Minimum (all done by PM) and maximum (all done by GP) cost
PRISM activation support Minimum (no site visits required) and maximum (all surgeries need site visit
to assist with set-up) cost
PRISM opportunity time for GP surgeries Minimum and maximum time spent during trial period
Number of emergency admissions 95% CI
Primary care costs Minimum (all done by nurse) and maximum (all done by GP) cost
Secondary care costs Lower and upper quartile costs for all secondary cost components, as
reported in NHS Reference Costs 2014/1568
CI, confidence interval.
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trial GP surgeries, as observed over the trial period. For transparency, unadjusted and adjusted analyses
are presented.
Deterministic sensitivity analysis used the lower and upper quartile unit costs – weighted across Healthcare
Resource Groups and for activity – to estimate worst- and best-case scenarios of PRISM budget impact.
Stakeholder views
Focus groups, interviews and questionnaire
We collected qualitative data from GPs and practice staff, at baseline and after launching the PRISM
intervention, to explore current practice in chronic conditions management and changes initiated by PRISM
(see Table 11 for details regarding numbers of focus groups planned). Questions explored attitudes,
expectations and experience relating to predictive risk stratification, specifically the PRISM tool, including
barriers to and facilitators of use.
Before activating PRISM, we conducted four focus groups with staff from participating practices, two in
the largest locality within the health board, and one in each of the other two localities. We interviewed
GPs who could not take part in a focus group, by telephone or face to face. We also conducted a focus
group with senior managers and community-based practitioners. Focus groups were used to explore
different views and experiences by encouraging group interaction.72
We also interviewed GPs and practice staff after activating PRISM to gain information in more depth about
the adoption, use and perceived effectiveness of PRISM. We purposively sampled half the participating
practices and sampled a PRISM user in each for interviews face to face between 3 and 6 months after
PRISM was activated in their practice, and again at the end of the intervention phase, approximately
18 months after activation in the first practices. This enabled us to describe changes over time. We asked
the other participating practices to complete online questionnaires at the same time points. We used
responses from early adopters to inform later interviews. This enabled us to explore variations between
participating practices.
In addition, at 18 months, we interviewed a senior manager within ABM UHB to explore area-wide issues in
patient management and the effects of PRISM in general practices. Two other managers declined because
they had moved to other roles. To gain historical, managerial and political insights into the development
and scope of PRISM, we also interviewed six managers (health services commissioners and policy-makers)
with all-Wales perspectives at baseline, either face to face or by telephone. We also conducted six
interviews with seven respondents (one interview had two respondents) from non-participating health
boards across Wales to examine their experience of PRISM and their views of its role and potential.
We contacted all respondents by e-mail. Three experienced researchers from the study team (BAE, AP and
MRK) conducted all focus groups and interviews, lasting between 30 and 90 minutes. We recorded and
transcribed these, with participants’ consent, after giving a participant information sheet explaining their
purpose. We made field notes after each focus group or interview.
Qualitative analysis
We recorded and transcribed the focus groups and interviews and analysed them thematically. We chose
this approach as it is a systematic and transparent method of analysis that generates themes from the
explicit and implicit ideas contained in the original accounts of participants. Four team members
(researchers BAE, MRK, AP and service user SW) read the transcripts and developed a coding framework.
One researcher then led the analysis with the others independently supporting key stages of coding,
generating themes and interpretation, thus encouraging a critical stance to test and confirm findings.73–75
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We used normalisation process theory (NPT)76,77 to inform our understanding of how the PRISM innovation
came into practice. NPT is a conceptual framework to explain implementation of innovations in health
care.78 NPT offers four constructs to describe how innovation comes into normal practice:
1. How people understand the innovation and its purpose (coherence).
2. What decisions people take about using it, based on perceived advantages (cognitive participation).
3. What people do to bring the innovation into everyday use (collective action).
4. How the innovation is reviewed, modified or abandoned (reflexive monitoring).77
Normalisation process theory suggests that each of these tasks is shaped by factors that promote or inhibit
the extent to which participants look on a new practice as meaningful.
Sample size and power
We derived data on the number of emergency admissions per patient, the primary outcome for this study,
from routine data, in principle, for all non-dissenting patients. We expected SAIL to yield data on about
250,000 people. We excluded people not registered with a study practice on day 1, and defined their final
date in the study as the earliest of the date of death, the date of registration with another practice
(including another study practice) or the end of the study. The Consolidated Standards of Reporting Trials
(CONSORT) flow chart (see Figure 3) recorded the numbers dissenting or withdrawing from the study, or
otherwise leaving before its end.
In considering sample sizes for postal questionnaires measuring secondary outcomes, we identified few
general practice studies with ICCs of > 0.01. This led us to seek 800 respondents in each of the three
questionnaire phases to detect differences in resource use between current intervention and control
practices across the spectrum of risk. This would allow us to have 80% power when using a 5%
significance level to detect a difference of 15% in the proportion of patients at defined risk levels receiving
specified resources.
Missing data
Following the STU’s SOP on statistics, we adopted a consistent approach to missing data relating to
effectiveness or cost-effectiveness except where individual outcome measures required variation in that
approach. Although SAIL yielded data on our primary outcome for non-dissenting participants, some
individual data were missing. We summarised the frequency of missing data for each variable, which
directly influenced sample sizes, and hence the statistical power of analyses.
Project management
We organised the review, approval and adoption of the trial by STU. In undertaking the trial, we adhered
to all relevant STU SOPs in the conduct, management and monitoring of the study. We set up a Research
Management Group (RMG), which was responsible for the strategic management of the trial. This RMG
met quarterly and comprised the chief investigator, all co-applicants, all research staff, two service users
and two local participating GPs. We managed operational issues through a monthly research team
meeting which was made up of the researchers, clerical support, the principal investigator and one of the
co-applicants. We set up a data management task and finish group to oversee all data management and
analysis issues. We used the STU SOP on data management to develop a data management plan, outlining
details of data entry, coding, security and storage, including any related processes to promote data quality.
We set up an independent Trial Steering Committee (TSC) that provided overall oversight and ensured
the rigorous conduct of the trial. In addition, we organised an independent Data Monitoring and Ethics
Committee (DMEC) which had oversight of the data management and analysis issues and which fed
information into the TSC. We organised TSC meetings every 6 months, with the DMEC being held just
prior to these meetings. The TSC was made up of an independent chairperson with an interest in
emergency care, an academic in primary care, a consultant in public health, a statistician and two service
users (with no previous involvement in the trial). The DMEC was chaired by the statistician with experience in
trials and was also attended by the consultant in public health, the academic GP and the two service users.
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We adopted the principles outlined in STU’s SOPs on quality assurance and we carried out independent trial
monitoring through the STU.
Service user involvement
In accordance with STU’s SOP for service user inclusion,79 we recruited two service users who acted
throughout the study as collaborators in our research partnership.80,81 As members of the RMG, they
attended the quarterly meetings responsible for strategic and operational decisions about the study. They
contributed, as equal team members, in all meetings to ensure we considered patients’ perspectives at all
stages of the study.
We recruited these service users through Service Users with Chronic Conditions Encouraging Sensible
Solutions (SUCCESS), a group of patients and carers engaged in research linked to the chronic conditions
management policy in Wales (URL: www.invo.org.uk/posttypeconference/an-alternative-success-model/).
The two service users linked the study to the wider SUCCESS group by reporting back on the study and
seeking feedback from the SUCCESS group to inform their contributions.
We recruited two service users to the TSC through Involving People (URL: www.wales.nhs.uk/sites3/
page.cfm?orgid=1023&pid=59261) to ensure their independence. We followed best practice by ensuring
all users received honoraria, expenses, training and support, a named contact, information and networking
opportunities.81 We used the notes of meetings and other documents, including attendance records and
draft papers, to describe their contributions to research structures and processes.
Ethics
We obtained full ethics approval for the main protocol and all subsequent amendments from the
Multicentre Research Ethics Committee for Wales (reference number 10/MRE09/25). We received research
and development permissions to conduct the trial across Wales, and Information Governance Review Panel
permission to use the SAIL databank.
We complied with the CONSORT guidelines82 for reporting randomised trials and completed the CONSORT
checklist when presenting findings from the trial. We also completed the CONSORT extension checklists
for cluster trials, patient-reported outcomes, abstracts and harms.
Changes to the published protocol
The follow-up qualitative interviews/questionnaires were carried out at the end of the intervention phases
(between October 2014 and January 2015). They were originally planned for 9 months after implementation
of the intervention within each network.
We originally intended to compare time to first emergency admission but revised this plan without carrying
out this analysis – on consideration, we concluded that emergency admissions per patient per year at risk
would be the most appropriate analysis for this highly skewed data.
We did not include mortality as an outcome in our original protocol. We think it is important to document
this as part of the study and have included it within Chapter 4.
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Chapter 4 Clinical effectiveness
Participant flow
Figure 3 covers participant flow over the study period, extending from 1 February 2013 until 30 September
2014, based on specific dates within that period. Figure 3 gives (for each interval between such dates) the
numbers of participant histories ending as a result of deregistration at a study practice (categorised as due
to death, or for any other reason), and partitioned by study practice status (based on a ‘treatment allocated’
date) at the date of deregistration, and participant transfers from the control to intervention phase.
Figure 4 reprises the ‘stepped-wedge’ study design, and provides the transfer of first GP champion
practices, then other study practices (grouped into 11 clusters each with a common, randomly allocated
intervention date), from control to intervention phase. Some practices were unable to facilitate PRISM
receipt and training in their allocated month, and hence their receipt dates occurred later in the
intervention phase in Figure 4.
Clinical effectiveness results
Data analysed and baseline characteristics
We have history of NHS contacts over the study period [from 1 February 2013 (study day 1) until
30 September 2014] on 230,114 participants, 15 of whom spent the whole study period in hospital.
We were therefore able to include outcomes from routine NHS records in control and/or intervention
phases on 230,099 participants. Table 15 summarises various characteristics of these participants, both
overall and by PRISM risk group.
Durations in the control and intervention phases
As Figure 4 illustrates, the study design includes a relatively short initial period in which all participants are
in the control phase, and a longer final period in which all participants still registered at a study practice
are in the intervention phase; between these periods, participants transfer from one phase to another as
the PRISM tool is made available at their practices. This design means that the mean length of time spent
by a participant in the intervention phase is longer than in the control phase. Table 16 summarises these
durations based on the ‘treatment allocated’ date at which the PRISM risk tool becomes available in
study practices.
Outcomes from anonymised routine linked NHS data
Tables 17–22 present the results of primary and secondary outcomes derived from anonymised routine
linked NHS data sets. We provide raw and adjusted comparisons between groups, ICC in variables
between participants at the same study practice, and details of statistically significant factors and
covariates. The adjusted comparison reflects the nature of the variable under consideration: we present an
OR for logistic regression models for binary variables; an incident or event rate ratio Λ from negative
binomial models for count variables, and an additive group effect (Δ, in the same units as the dependent
variable) for linear models for continuous variables.
Table 17 covers the primary outcome, emergency hospital admissions, in which we summarise separate
analyses of a binary variable (whether or not a participant had any emergency hospital admission in each
phase); a count variable (the number of such admissions); and a measurement variable (an annualised rate
of such admissions, based on the ‘days at risk’ of such an admission, which excludes days in which
participants were known to be hospitalised). Thus, ‘days at risk’ features explicitly in the analysis of rates of
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32 GP practices allocated to 
11 clusters
• Patients, n = 231,907
Patients’ GP practice moved 
from control to intervention
(n = 16,822)
Patients excluded
(n = 1808 + x)
• Dissented from study, n = 90
• Hard Read Code requesting no
   data linkage, n = 15
• NHS contact information 
   unavailable, n = 1688
• Hospitalised (an inpatient)
   throughout, n = 15
• Patients, n = 230,099
• Practices, n = 32
Control
• Deaths, n = 673
• Other deregistrations, n = 3564
Baseline
1 February 2013
(day 1)
• Deaths, n = 10
• Other deregistrations, n = 34
• Patients, n = 209,040
• Practices, n = 29
Control
• Patients, n = 16,778
• Practices, n = 3
Intervention
• Deaths, n = 366
• Other deregistrations, n = 2438
14 May 2013
(day 103)
(n = 63,667)
• Deaths, n = 121
• Other deregistrations, n = 576
• Patients, n = 142,569
• Practices, n = 19
Control
• Patients, n = 79,748
• Practices, n = 13
Intervention
• Deaths, n = 235
• Other deregistrations, n = 1591
14 August 2013
(day 195)
(n = 72,225)
• Deaths, n = 266
• Other deregistrations, n = 1736
• Patients, n = 68,518
• Practices, n = 10
Control
• Patients, n = 149,971
• Practices, n = 22
Intervention
• Deaths, n = 91
• Other deregistrations, n = 424
14 November 2013
(day 287)
(n = 58,897)
• Deaths, n = 474
• Other deregistrations, n = 2069
• Patients, n = 9106
• Practices, n = 3
Control
• Patients, n = 206,325
• Practices, n = 29
Intervention
• Deaths, n = 2
• Other deregistrations, n = 17
14 February 2014
(day 379)
(n = 9087)
• Deaths, n = 497
• Other deregistrations, n = 2453
• Patients, n = 0
• Practices, n = 0
Control
• Patients, n = 212,462
• Practices, n = 32
Intervention
14 May 2014
(day 468)
• Deaths, n = 477
• Other deregistrations, n = 4027
• Patients, n = 207,958
• Practices, n = 32
Intervention
14 August 2014
(day 560)
• Deaths, n = 266
• Other deregistrations, n = 4781
• Patients, n = 202,911
• Practices, n = 32
Intervention
30 September 2014
(day 607)
FIGURE 3 Patient flow for primary outcome.
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GP cluster
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patients)
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Baseline questionnaires 6-month questionnaires 18-month questionnaires
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FIGURE 4 Intervention allocation months and actual receipt dates.
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TABLE 15 Baseline demographic and clinical characteristics for participants
Variable Proportion %
Gender
Group
All
Female 115,251/230,098 50.1
Male 114,847/230,098 49.9
PRISM risk group 1
Female 89,610/182,954 49.0
Male 93,344/182,954 51.0
PRISM risk group 2
Female 18,534/34,311 54.0
Male 15,777/34,311 46.0
PRISM risk group 3
Female 5820/10,292 56.5
Male 4472/10,292 43.5
PRISM risk group 4
Female 598/1129 53.0
Male 531/1129 47.0
Mean SD n
Age at study day 1 (years)
Group
All 41.2 23.4 230,099
PRISM risk group 1 36.6 20.5 182,955
PRISM risk group 2 56.7 25.2 34,311
PRISM risk group 3 69.8 21.4 10,292
PRISM risk group 4 70.2 22.1 1129
WIMD score (2011)
Group
All 24.03 16.26 226,298
PRISM risk group 1 23.32 15.96 180,085
PRISM risk group 2 26.66 17.23 33,754
PRISM risk group 3 27.31 17.15 10,026
PRISM risk group 4 27.58 17.05 1093
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TABLE 15 Baseline demographic and clinical characteristics for participants (continued )
Mean SD n
WIMD health component (2011)
Group
All 27.08 22.09 226,298
PRISM risk group 1 26.26 21.80 180,085
PRISM risk group 2 29.99 23.02 33,754
PRISM risk group 3 30.97 22.88 10,026
PRISM risk group 4 31.57 22.53 1093
PRISM score
Group
All 6.53 6.89 228,687
PRISM risk group 1 4.16 1.61 182,955
PRISM risk group 2 11.49 3.18 34,311
PRISM risk group 3 26.15 7.97 10,292
PRISM risk group 4 60.87 13.63 1129
SD, standard deviation.
TABLE 16 Durations of the control and intervention phases for participants
Variable Mean SD n
Days in the control phase
Group
All 226.3 91.3 230,099
PRISM risk group 1 226.9 91.0 182,955
PRISM risk group 2 226.7 91.2 34,311
PRISM risk group 3 219.2 93.8 10,292
PRISM risk group 4 202.3 99.1 1129
Days in the intervention phase
Group
All 364.0 101.3 220,698
PRISM risk group 1 365.3 100.0 176,217
PRISM risk group 2 362.5 102.1 32,936
PRISM risk group 3 349.2 113.4 9356
PRISM risk group 4 318.8 128.1 898
SD, standard deviation.
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TABLE 17 Primary outcome: emergency hospital admission – analysis by ‘treatment allocated’ date
Outcome Group
Phase (uncorrected for phase duration)
Adjusted comparison 95% CI
ICC
Intervention Control Estimate 95% CI
Proportion of participants
with one or more
emergency hospital
admission: proportion (%)
Alla 15,743/220,683 (7.1) 10,870/230,087 (4.7) OR = 1.444 (p< 0.001) 1.395 to 1.495 0.0009 0.0005 to 0.0015
Risk group 1b 7746/176,214 (4.4) 5029/182 to 952 (2.7) OR = 1.199 (p< 0.001) 1.144 to 1.257
Risk group 2c 4521/32,929 (13.7) 3031/34 to 307 (8.8) OR = 1.665 (p< 0.001) 1.561 to 1.776
Risk group 3d 2881/9352 (30.8) 2230/10 to 288 (21.7) OR = 1.941 (p< 0.001) 1.784 to 2.112
Risk group 4e 497/897 (55.4) 504/1128 (44.7) OR = 1.707 (p< 0.001) 1.400 to 2.081
Number of emergency
hospital admissions per
participant: mean (SD) [n]
Allf 0.1045 (0.5323) [220,683] 0.0635 (0.3429) [230,087] Λ= 1.429 (p< 0.001) 1.385 to 1.474 0.0007 0.0004 to 0.0011
Risk group 1
g
0.0557 (0.3107) [176,214] 0.0337 (0.2247) [182,952] Λ= 1.226 (p< 0.001) 1.171 to 1.284
Risk group 2h 0.2095 (0.8218) [32,929] 0.1188 (0.4805) [34,307] Λ= 1.630 (p< 0.001) 1.538 to 1.728
Risk group 3i 0.5362 (1.2799) [9352] 0.3193 (0.7471) [10,288] Λ= 1.716 (p< 0.001) 1.623 to 1.814
Risk group 4j 1.3088 (2.0484) [897] 0.8688 (1.4037) [1128] Λ= 1.389 (p< 0.001) 1.225 to 1.575
Numbers of emergency
hospital admissions per
participant per year at risk:
mean (SD) [n]
Allk 0.1666 (2.0794) [220,683] 0.1607 (2.1634) [230,087] Δ = 0.005 (p= 0.425) –0.007 to 0.016 0.0001 0 to 0.0002
Risk group 1l 0.0663 (0.7455) [176,214] 0.0636 (0.6987) [182,952] Δ = 0.002 (p= 0.351) –0.002 to 0.006
Risk group 2m 0.3663 (3.6970) [32,929] 0.2943 (2.3583) [34,307] Δ = 0.053 (p= 0.019) 0.009 to 0.097
Risk group 3n 1.0509 (5.4392) [9352] 1.0655 (6.9002) [10,288] Δ = –0.035 (p= 0.684) –0.204 to 0.134
Risk group 4o 3.3003 (10.9239) [897] 3.4817 (15.3970) [1128] Δ = –0.063 (p= 0.915) –1.216 to 1.090
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Outcome Group
Phase (uncorrected for phase duration)
Adjusted comparison 95% CI
ICC
Intervention Control Estimate 95% CI
Log-transformed numbers
of emergency hospital
admissions per participant
per year at risk: mean (SD)
[n]
Allp 0.0664 (0.2762) [220,683] 0.0566 (0.2819) [230,087] ΔL = 0.011 (p< 0.001) 0.010 to 0.013 0.0007 0.0004 to 0.0011
Risk group 1q 0.0355 (0.1811) [176,214] 0.0294 (0.1879) [182,952] ΔL = 0.0061 (p< 0.001) 0.005 to 0.007
Risk group 2r 0.1326 (0.3888) [32,929] 0.1065 (0.3794) [34,307] ΔL = 0.0260 (p< 0.001) 0.021 to 0.031
Risk group 3s 0.3454 (0.6267) [9352] 0.2987 (0.6484) [10,288] ΔL = 0.0609 (p< 0.001) 0.045 to 0.076
Risk group 4t 0.7978 (0.9315) [897] 0.7344 (0.9761) [1128] ΔL = 0.1097 (p= 0.002) 0.040 to 0.179
SD, standard deviation.
Significant covariates and factors (p< 0.001 unless otherwise stated) are:
a Age at study day 1; WIMD score; PRISM score; days at risk; seasonality; and trend.
b Age at study day 1; WIMD score (p = 0.006); PRISM score (p< 0.001); days at risk; and trend.
c WIMD score; PRISM score; days at risk (p= 0.001); and seasonality.
d Gender (p = 0.004); WIMD score; PRISM score; days at risk (p= 0.003); and seasonality.
e PRISM score.
f Age at study day 1; gender (p = 0.031); WIMD score; PRISM score; days at risk; seasonality; and trend.
g Age at study day 1; gender (p = 0.047); WIMD score (p= 0.006); PRISM score; days at risk; seasonality (p = 0.015); and trend.
h WIMD score; PRISM score; days at risk; and seasonality.
i Gender (p = 0.001); WIMD score; PRISM score; and seasonality (p= 0.001).
j Age at study day 1 (p= 0.028); PRISM score; and days at risk.
k Age at study day 1; gender (p = 0.033); WIMD score; PRISM score; seasonality; and trend (p= 0.012).
l Age at study day 1; PRISM score; and seasonality.
m Age at study day 1; WIMD score (p = 0.001); WIMD health component (p= 0.028); PRISM score; seasonality; and trend (p= 0.012).
n Age at study day 1; gender (p = 0.017); WIMD health component (p= 0.002); PRISM score; and seasonality.
o PRISM score (p = 0.003); and seasonality.
p WIMD score; PRISM score; seasonality; and trend.
q Age at study day 1; WIMD health component (p= 0.007); PRISM score; seasonality; and trend.
r Age at study day 1 (p= 0.001); WIMD score; WIMD health component (p= 0.044); PRISM score; seasonality; and trend (p= 0.039).
s Age at study day 1; gender; WIMD score; PRISM score; and seasonality.
t PRISM score; and seasonality (p= 0.003).
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admissions, and is included as a potential covariate in the analysis of binary and count variables. Table 18
and so on follow broadly the same format for selected secondary outcomes; Table 21, on inpatient visits,
considers only the days per year each participant is hospitalised in each phase.
Table 17 shows, following adjustment for length of time in each phase and all other significant covariates,
an increase in the proportion of participants who experienced an emergency admission to hospital in the
intervention phase compared with the control phase. The number of emergency admissions per participant
was also higher in the intervention phase. These data are highly skewed, with most participants (> 90%) not
experiencing any admissions, but a few experiencing multiple admissions. Analysis using log-transformed
data is therefore appropriate, and shows an increase of 1% in emergency admissions per participant per year
at risk in the intervention phase. These effects were consistent across risk groups, and increased with
predicted risk level.
Table 18 shows, following adjustment for length of time in each phase and all other significant covariates,
an increase in the proportion of participants who attended the ED in the intervention phase compared with
the control phase. The number of ED attendances per participant was also higher in the intervention phase.
These data are also highly skewed, with most participants (> 80%) not experiencing any attendances, but a
few attending on multiple occasions. Analysis using log-transformed data is therefore appropriate, and
shows an increase of 3% in emergency admissions per participant per year at risk in the intervention phase.
These effects were consistent across risk groups, and increased with predicted risk level.
Table 19 shows a more mixed picture. Following adjustment for length of time in each phase and all other
significant covariates, we found a decrease in the proportion of participants with GP event-days recorded
in the intervention phase compared with the control phase, an effect that was consistent across risk
groups. However, the number of days when GP activity was recorded per participant per year at risk was
higher in the intervention phase. Although these data are less skewed, with most participants (> 80%)
experiencing event-days, the rate of events is still heavily weighted to the smaller numbers at highest
predicted risk of emergency admission to hospital. Analysis using log-transformed data is, again, therefore,
appropriate, and shows an increase of 1% in days on which GP activity was recorded per participant per
year at risk in the intervention phase. This effect was reversed among the two highest risk groups.
Table 20 also shows a mixed picture. Following adjustment for length of time in each phase and all other
significant covariates, we found overall no difference in the proportion of participants with outpatient visits
in the intervention phase compared with the control phase, with varying effects across the risk groups.
Analysis using log-transformed data shows an increase of 5% in outpatient attendances per participant per
year at risk in the intervention phase, an effect related to an increase in the two lowest risk groups.
Table 21 shows, following adjustment for length of time in each phase and all other significant covariates,
no effect in mean bed-days per patient per year at risk. However, these data are highly skewed, with most
participants (> 90%) not experiencing any hospital stays, but a few attending on multiple occasions and
some with very long lengths of stay. Analysis using log-transformed data is therefore appropriate, and
shows an increase of 3% in mean bed-days per participant per year at risk in the intervention phase. This
effect was consistent across risk groups, and increased with predicted risk level.
Table 22 shows mortality by practice cluster. We have not carried out full, adjusted analyses for this
variable as this was not a formally set outcome; however, we present this as a background check of safety
and have found no clear effect associated with trial phase.
Table 23 illustrates that there was not a large variation in the profile of PRISM scores between clusters of
practices (mean range between 5.76 to 7.44 out of a maximum of 100).
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TABLE 18 Secondary outcome: ED attendances analysis by ‘treatment allocated’ date
Outcome Group
Phase (uncorrected for phase duration)
Adjusted comparison 95% CI
ICC
Intervention Control Estimate 95% CI
Proportion of participants
with one or more ED
attendance: proportion (%)
Alla 43,991/220,683 (19.9) 30,350/230,087 (13.2) OR = 1.116 (p < 0.001) 1.092 to 1.141 0.0038 0.0023 to 0.0057
Risk group 1b 31,075/176,214 (17.6) 20,688/182,952 (11.3) OR = 1.047 (p = 0.001) 1.019 to 1.074
Risk group 2c 8471/32,929 (25.7) 6017/34,307 (17.5) OR = 1.221 (p < 0.001) 1.161 to 1.283
Risk group 3d 3684/9352 (39.4) 2925/10,288 (28.4) OR = 1.495 (p < 0.001) 1.384 to 1.614
Risk group 4e 510/897 (56.9) 535/1128 (47.4) OR = 1.257 (p = 0.033) 1.018 to 1.552
Number of ED attendances
per participant: mean (SD)
[n]
Allf 0.3200 (0.8863) [220,683] 0.1894 (0.6139) [230,087] Λ= 1.115 (p < 0.001) 1.095 to 1.136 0.0037 0.0022 to 0.0056
Risk group 1g 0.2649 (0.7164) [176,214] 0.1543 (0.5143) [182,952] Λ= 1.045 (p < 0.001) 1.022 to 1.068
Risk group 2h 0.4464 (1.1010) [32,929] 0.2589 (0.7155) [34,307] Λ= 1.226 (p < 0.001) 1.177 to 1.277
Risk group 3i 0.7951 (1.7995) [9352] 0.4820 (1.0669) [10,288] Λ= 1.380 (p < 0.001) 1.306 to 1.459
Risk group 4j 1.5385 (2.82864) [897] 1.1135 (2.3650) [1128] Λ= 1.173 (p = 0.012) 1.036 to 1.327
Numbers of ED
attendances per participant
per year at risk: mean (SD)
[n]
Allk 0.3613 (1.7877) [220,683] 0.3593 (2.1014) [230,087] Δ= 0.006 (p= 0.299) –0.005 to 0.016 0.0013 0.0007 to 0.0020
Risk group 1l 0.2705 (1.0942) [176,214] 0.2658 (1.0969) [182,952] Δ= 0.005 (p= 0.148) –0.002 to 0.011
Risk group 2m 0.5453 (2.7529) [32,929] 0.4941 (1.9043) [34,307] Δ= 0.044 (p= 0.010) 0.011 to 0.077
Risk group 3n 1.1663 (4.1921) [9352] 1.2432 (6.2355) [10,288] Δ= –0.066 (p= 0.340) –0.122 to 0.146
Risk group 4o 3.0370 (8.3959) [897] 3.235 (14.4377) [1128] Δ= –0.134 (p= 0.793) –1.093 to 0.908
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TABLE 18 Secondary outcome: ED attendances analysis by ‘treatment allocated’ date (continued )
Outcome Group
Phase (uncorrected for phase duration)
Adjusted comparison 95% CI
ICC
Intervention Control Estimate 95% CI
Log-transformed numbers
of ED attendances per
participant per year at risk:
mean (SD) [n]
Allp 0.1802 (0.4035) [220,683] 0.1528 (0.4259) [230,087] ΔL = 0.030 (p< 0.001) 0.028 to 0.032 0.0034 0.0021 to 0.0052
Risk group 1
q
0.1506 (0.3542) [176,214] 0.1253 (0.3755) [182,952] ΔL = 0.026 (p< 0.001) 0.024 to 0.029
Risk group 2r 0.2477 (0.4793) [32,929] 0.2084 (0.4928) [34,307] ΔL = 0.040 (p< 0.001) 0.034 to 0.047
Risk group 3s 0.4390 (0.6540) [9352] 0.3887 (0.7000) [10,288] ΔL = 0.058 (p< 0.001) 0.042 to 0.075
Risk group 4t 0.8096 (0.9094) [897] 0.7649 (0.9543) [1128] ΔL = 0.074 (p= 0.035) 0.005 to 0.143
SD, standard deviation.
Significant covariates and factors (p< 0.001 unless otherwise stated) are:
a Age at study day 1; gender; WIMD score; PRISM score; days at risk; seasonality; and trend (p= 0.016).
b Age at study day 1; gender; WIMD score; PRISM score; days at risk; seasonality; and trend (p= 0.016).
c Age at study day 1; gender (p = 0.001); WIMD score (p= 0.030); PRISM score; and days at risk.
d Age at study day 1; PRISM score; days at risk; and seasonality (p= 0.006).
e Age at study day 1 (p= 0.036); PRISM score; and days at risk.
f Age at study day 1; gender; WIMD score; PRISM score; days at risk; and seasonality.
g Age at study day 1; gender; WIMD score; PRISM score; days at risk; seasonality; and trend (p= 0.031).
h Age at study day 1; gender (p = 0.002); WIMD score (p= 0.004); PRISM score; and days at risk.
i Age at study day 1; PRISM score; and days at risk.
j PRISM score; days at risk; and seasonality (p= 0.004).
k Age at study day 1; gender; PRISM score; seasonality; and trend.
l Age at study day 1; gender; WIMD score; PRISM score; seasonality; and trend.
m Age at study day 1; PRISM score; and seasonality.
n PRISM score; and seasonality.
o PRISM score; and trend.
p Age at study day 1; gender; WIMD score; PRISM score; and trend.
q Age at study day 1; gender; WIMD score; PRISM score; seasonality; and trend.
r Age at study day 1; gender (p = 0.009); WIMD score (p= 0.029); PRISM score; and seasonality.
s Age at study day 1 (p= 0.003); PRISM score; and seasonality.
t PRISM score.
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TABLE 19 Secondary outcome: GP event-days – analysis by ‘treatment allocated’ date
Outcome Group
Phase (uncorrected for phase duration)
Adjusted comparison 95% CI
ICC
Intervention Control Estimate 95% CI
Proportion of participants
with one or more GP
event-days: proportion (%)
Alla 185,814/220,683 (84.2) 185,372/230,087 (80.6) OR = 0.697 (p< 0.001) 0.683 to 0.712 0.1603 0.1047 to 0.2215
Risk group 1b 143,792/176,214 (81.6) 140,582/182,952 (76.8) OR = 0.733 (p< 0.001) 0.717 to 0.750
Risk group 2c 31,249/32,929 (94.9) 32,774/34,307 (95.5) OR= 0.2718 (p< 0.001) 0.245 to 0.302
Risk group 3d 8942/9352 (95.6) 9892/10,288 (96.2) OR = 0.384 (p< 0.001) 0.322 to 0.459
Risk group 4e 856/897 (95.4) 1079/1128 (95.7) OR = 0.495 (p< 0.001) 0.307 to 0.796
Number of GP event-days
per participant: mean (SD)
[n]
Allf 13.275 (16.268) [220,683] 8.389 (11.020) [230,087] Λ= 0.960 (p< 0.001) 0.957 to 0.964 0.0372 0.0230 to 0.0544
Risk group 1g 9.330 (11.374) [176,214] 5.738 (7.385) [182,952] Λ= 0.966 (p< 0.001) 0.961 to 0.971
Risk group 2h 26.393 (19.607) [32,929] 16.792 (13.446) [34,307] Λ= 0.961 (p< 0.001) 0.955 to 0.967
Risk group 3i 38.538 (25.942) [9352] 25.108 (18.923) [10,288] Λ= 0.966 (p< 0.001) 0.955 to 0.977
Risk group 4
j
46.641 (32.218) [897] 32.072 (25.518) [1128] Λ= 0.912 (p< 0.001) 0.879 to 0.946
Numbers of GP event-days
per participant per year at
risk: mean (SD) [n]
Allk 14.075 (32.593) [220,683] 14.100 (23.124) [230,087] Δ= 0.139 (p= 0.011) 0.032 to 0.246 0.0165 0.0101 to 0.0244
Risk group 1l 9.418 (13.673) [176,214] 9.319 (12.548) [182,952] Δ= 0.044 (p= 0.113) –0.010 to 0.098
Risk group 2m 29.239 (43.279) [32,929] 27.784 (24.957) [34,307] Δ= 0.301 (p= 0.196) –0.155 to 0.756
Risk group 3n 47.186 (109.44) [9352] 46.590 (53.813) [10,288] Δ= 1.973 (p= 0.002) 0.741 to 3.204
Risk group 4o 67.297 (68.665) [897] 78.721 (120.98) [1128] Δ= –8.383 (p= 0.035) –16.186 to 0.581
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TABLE 19 Secondary outcome: GP event-days – analysis by ‘treatment allocated’ date (continued )
Outcome Group
Phase (uncorrected for phase duration)
Adjusted comparison 95% CI
ICC
Intervention Control Estimate 95% CI
Log-transformed numbers
of GP event-days per
participant per year at risk:
mean (SD) [n]
Allp 2.027 (1.260) [230,087] 2.015 (1.292) [230,087] Δ= 0.011 (p< 0.001) 0.007 to 0.014 0.1118 0.0716 to 0.1580
Risk group 1q 1.755 (1.157) [176,214] 1.723 (1.193) [182,952] ΔL = 0.023
(p< 0.001)
0.018 to 0.027
Risk group 2r 3.019 (0.999) [32,929] 3.052 (0.935) [34,307] ΔL = 0.042
(p< 0.001)
–0.049 to 0.035
Risk group 3s 3.512 (0.993) [9352] 3.545 (0.947) [10,288] ΔL = –0.031
(p< 0.001)
–0.044 to 0.018
Risk group 4t 3.860 (1.069) [897] 3.955 (1.076) [1128] ΔL = –0.090
(p< 0.001)
–0.139 to 0.041
SD, standard deviation.
Significant covariates and factors (p< 0.001 unless otherwise stated) are:
a Age at study day 1; gender; WIMD score; WIMD health component; PRISM score; days at risk; seasonality; and trend.
b Age at study day 1; gender; WIMD score; WIMD health component; PRISM score; days at risk; seasonality (p= 0.005); and trend.
c Age at study day 1; gender (p = 0.001); WIMD score; WIMD health component; PRISM score; days at risk; seasonality; and trend.
d Age at study day 1; WIMD score; WIMD health component; PRISM score (p= 0.032); days at risk; seasonality (p= 0.001); and trend.
e WIMD score; WIMD health component; PRISM score (p= 0.008); and days at risk.
f Age at study day 1; gender; WIMD score; WIMD health component; PRISM score; days at risk; seasonality; and trend.
g Age at study day 1; gender; WIMD Score; WIMD health component; PRISM score; days at risk; seasonality; and trend.
h Age at study day 1; gender; WIMD Score; WIMD health component; PRISM score; days at risk; seasonality; and trend.
i Age at study day 1; gender (p = 0.020); WIMD score; WIMD health component; PRISM score; days at risk; seasonality; and trend.
j Age at study day 1; WIMD score; WIMD health component (p= 0.001); days at risk; seasonality (p= 0.001); and trend.
k Age at study day 11; gender; WIMD score; WIMD health component; PRISM score; seasonality; and trend.
l Age at study day 1; gender; WIMD score; WIMD health component; PRISM score; seasonality; trend; WIMD health component (p< 0.001); and PRISM score (p< 0.001).
m Age at study day 1; gender; WIMD score; WIMD health component; PRISM score; seasonality; and trend.
n Age at study day 1; WIMD score (p = 0.011); PRISM score; and seasonality.
o Age at study day 1 (p= 0.012); and PRISM score (p= 0.019).
p Age at study day 1; gender; WIMD score; WIMD health component; PRISM score; seasonality; and trend.
q Age at study day 1; gender; WIMD score; WIMD health component; PRISM score; seasonality; and trend.
r Age at study day 1; gender; WIMD score; WIMD health component; PRISM score; seasonality; and trend.
s Age at study day 1; WIMD score; WIMD health component; PRISM score; seasonality; and trend.
t Age at study day 1 (p= 0.003); WIMD score; WIMD health component (p= 0.001); and seasonality.
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TABLE 20 Secondary outcome: outpatients visits – analysis by ‘treatment allocated’ date
Outcome Group
Phase
Adjusted comparison 95% CI
ICC
Intervention Control Estimate 95% CI
Proportion of participants
with one or more
outpatient visits: proportion
(%)
Alla 81,619/220,683 (37.0) 67,324/230,087 (29.3) OR = 1.015 (p= 0.177) 0.993 to 1.038 0.0039 0.0023 to 0.0059
Risk group 1b 52,954/176,214 (30.1) 40,532/182,952 (22.2) OR = 1.082 (p< 0.001) 1.055 to 1.110
Risk group 2c 20,495/32,929 (62.2) 18,459/34,307 (53.8) OR= 0.880 (p< 0.001) 0.835 to 0.927
Risk group 3d 7055/9352 (75.4) 7153/10,288 (69.5) OR = 0.785 (p< 0.001) 0.708 to 0.870
Risk group 4e 740/897 (82.5) 862/1128 (76.4) OR = 0.788 (p= 0.200) 0.547 to 1.135
Number of outpatient visits
per participant: mean (SD)
[n]
Allf 1.5446 (3.4375) [220,683] 0.9439 (2.3067) [230,087] Λ= 1.002 (p= 0.717) 0.990 to 1.014 0.0022 0.0012 to 0.0033
Risk group 1g 1.0590 (2.6408) [176,214] 0.6089 (1.7004) [182,952] Λ= 1.050 (p< 0.001) 1.033 to 1.067
Risk group 2h 3.0792 (4.6168) [32,929] 1.9572 (3.2040) [34,307] Λ= 0.956 (p< 0.001) 0.937 to 0.975
Risk group 3i 4.8505 (6.1833) [9352] 3.1632 (4.2297) [10,288] Λ= 0.955 (p= 0.002) 0.927 to 0.983
Risk group 4
j
6.7592 (8.5298) [897] 4.5142 (5.3923) [1128] Λ= 0.936 (p= 0.073) 0.870 to 1.006
Numbers of outpatient
visits per participant per
year at risk: mean (SD) [n]
Allk 1.717 (9.746) [220,683] 1.704 (9.984) [230,087] Δ= 0.035 (p = 0.158) –0.014 to 0.085 0.0004 0.0002 to 0.000
Risk group 1l 1.086 (5.630) [176,214] 1.022 (4.543) [182,952] Δ= 0.058 (p < 0.001) 0.028 to 0.088
Risk group 2m 3.417 (11.207) [32,929] 3.460 (13.720) [34,307] Δ= –0.015 (p = 0.846) –0.172 to 0.141
Risk group 3n 6.547 (27.087) [9352] 6.693 (27.846) [10,288] Δ= –0.006 (p = 0.984) –0.618 to 0.606
Risk group 4o 13.503 (65.558) [897] 13.833 (59.869) [1128] Δ= –0.147 (p = 0.955) –5.246 to 4.952
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TABLE 20 Secondary outcome: outpatients visits – analysis by ‘treatment allocated’ date (continued )
Outcome Group
Phase
Adjusted comparison 95% CI
ICC
Intervention Control Estimate 95% CI
Log-transformed numbers
of outpatient visits per
participant per year at risk:
mean (SD) [n]
All
p
0.5266 (0.7975) [220,683] 0.4760 (0.8213) [230,087] ΔL= 0.055 (p< 0.001) 0.051 to 0.058 0.0034 0.0020 to 0.005
Risk group 1
q
0.3919 (0.6812) [176,214] 0.3344 (0.6859) [182,952] ΔL= 0.056 (p< 0.001) 0.053 to 0.060
Risk group 2r 0.9752 (0.9311) [32,929] 0.9280 (0.9881) [34,307] ΔL= 0.050 (p< 0.001) 0.040 to 0.060
Risk group 3s 1.3791 (1.0361) [9352] 1.3605 (1.0996) [10,288] ΔL= 0.025 (p= 0.016) 0.005 to 0.046
Risk group 4t 1.7931 (1.1689) [897] 1.7711 (1.2411) [1128] ΔL= –0.007 (p= 0.851) –0.076 to 0.063
SD, standard deviation.
Significant covariates and factors (p< 0.001 unless otherwise stated) are:
a Age at study day 1; gender; WIMD score; PRISM score; days at risk; seasonality; and trend.
b Age at study day 1; gender; WIMD score; PRISM score; days at risk; seasonality; and trend.
c Age at study day 1; gender; WIMD score; PRISM score; days at risk; seasonality; and trend (p= 0.010).
d Age at study day 1 (p= 0.002); gender; WIMD health component; PRISM score; and days at risk.
e Age at study day 1;days at risk; and seasonality (p= 0.001).
f Age at study day 1; gender; PRISM score; days at risk; seasonality; and trend.
g Age at study day 1; gender; WIMD score; PRISM score; days at risk; seasonality; and trend.
h Age at study day 1; gender; WIMD score; PRISM score; days at risk; seasonality; and trend (p= 0.001).
i Age at study day 1 (p= 0.002); gender; WIMD health component; PRISM score; days at risk; and seasonality.
j Age at study day 1; WIMD score (p = 0.012); PRISM score (p= 0.018); days at risk; and seasonality.
k Age at study day 1; gender; WIMD score; PRISM score; seasonality; and trend.
l Age at study day 1; gender; WIMD score; PRISM score; seasonality; and trend (p= 0.001).
m Age at study day 1; gender (p = 0.019); WIMD score; PRISM score; seasonality; and trend (p= 0.001).
n PRISM score; and seasonality.
o Seasonality (p= 0.025); and trend (p= 0.007).
p Age at study day 1; gender; WIMD score; PRISM score; and seasonality.
q Age at study day 1; gender; WIMD score; PRISM score; and seasonality.
r Age at study day 1; gender; WIMD score; PRISM score; and seasonality.
s Age at study day 1 (p= 0.001); gender; WIMD score; and PRISM score.
t Age at study day 1; WIMD score (p = 0.020);PRISM score (p= 0.024); seasonality (p = 0.028); and trend (p= 0.045).
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TABLE 21 Secondary outcome: length of stay in hospital – analysis by ‘treatment allocated’ date
Outcome Group
Phase, mean (SD) [n]
Adjusted comparison 95% CI
ICC
Intervention Control Estimate 95% CI
Days per year hospitalised
per participant
Alla 0.728 (5.886) [220,683] 0.792 (9.934) [230,087] Δ = –0.010 (p= 0.628) –0.051 to 0.031 0 n/a
Risk group 1b 0.263 (3.316) [176,214] 0.276 (7.577) [182,952] Δ = 0.006 (p= 0.660) –0.020 to 0.032
Risk group 2c 1.620 (8.711) [32,929] 1.631 (12.165) [34,307] Δ = 0.002 (p= 0.975) –0.147 to 0.151
Risk group 3d 5.157 (15.314) [9352] 5.613 (22.571) [10,288] Δ = –0.148 (p= 0.549) –0.633 to 0.336
Risk group 4e 13.384 (25.907) [897] 15.148 (33.928) [1128] Δ = –1.121 (p= 0.360) –3.522 to 1.280
Log-transformed days per
year hospitalised per
participant
Allf 0.1251 (0.5271) [220,683] 0.0996 (0.5070) [230,087] ΔL = 0.029 (p< 0.001) 0.026 to 0.031 0.0007 0.0004 to 0.0011
Risk group 1g 0.0621 (0.3374) [176,214] 0.04707 (0.3170) [182,952] ΔL = 0.015 (p< 0.001) 0.013 to 0.017
Risk group 2h 0.2635 (0.7631) [32,929] 0.1976 (0.7157) [34,307] ΔL = 0.066 (p< 0.001) 0.056 to 0.076
Risk group 3i 0.6993 (1.2060) [9352] 0.5711 (1.2056) [10,288] ΔL = 0.150 (p< 0.001) 0.120 to 0.180
Risk group 4
j
1.4642 (1.5466) [897] 1.3158 (1.6480) [1128] ΔL = 0.197 (p< 0.001) 0.073 to 0.320
n/a, not available; SD, standard deviation.
Significant covariates and factors (p< 0.001 unless otherwise stated) are:
a Age at study day 1; gender (p = 0.006); WIMD score; PRISM score; and seasonality.
b Age at study day 1; PRISM score; and seasonality.
c Age at study day 1; WIMD score; PRISM score; and seasonality.
d Age at study day 1; gender (p = 0.017); WIMD health component; PRISM score; and seasonality.
e Age at study day 1 (p= 0.022); and PRISM score.
f Age at study day 1; gender (p = 0.014); WIMD score; PRISM score; seasonality; and trend.
g Age at study day 1; PRISM score; seasonality (p= 0.002); and trend.
h Age at study day 1; WIMD score; PRISM score; seasonality; and trend (p = 0.026).
i Age at study day 1; gender (p = 0.003); WIMD health component; and seasonality.
j Age at study day 1 (p= 0.008); and PRISM score.
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TABLE 22 Mortality by practice cluster by ‘treatment allocated’ date
Cluster
Treatment allocated
date
Phase
Intervention Control
Proportion
of deaths
Deaths per
1000 patients
per year
Proportion
of deaths
Deaths per
1000 patients
per year
1 30 April 2013 229/16,822 9.57 43/17,061 10.45
2 31 May 2013 305/24,645 9.26 97/25,166 11.82
3 30 June 2013 259/21,879 9.43 82/22,442 8.95
4 31 July 2013 169/17,143 8.43 82/17,754 9.37
5 31 August 2013 322/30,295 9.80 170/31,193 9.43
6 30 September 2013 231/27,349 8.42 166/28,624 8.78
7 31 October 2013 174/14,581 13.00 143/15,246 12.59
8 30 November 2013 125/18,067 8.28 130/19,596 8.01
9 31 December 2013 134/24,470 7.29 205/25,849 8.69
10 31 January 2014 105/16,360 9.64 154/17,440 8.85
11 28 February 2014 58/9087 10.84 95/9728 9.09
Weighted average (based on cluster size) 9.25 9.58
TABLE 23 Predictive risk stratification model risk score at study day 1 (1 February 2013) by practice cluster
Cluster
PRISM risk scores
Mean (SD) [n: ≈missing]
Minimum, maximum
Risk group 1 Risk group 2 Risk group 3 Risk group 4
1 7.31 (7.37) [17,017: ≈44] 1.68, 9.49 7.44, 21.31 16.64, 50.70 46.72, 99.55
2 6.63 (7.02) [25,120: ≈46] 1.72, 9.04 6.93, 20.72 14.90, 54.21 44.82, 96.49
3 6.52 (7.00) [21,788: ≈654] 1.78, 9.41 4.07, 20.39 6.76, 53.81 19.40, 98.81
4 6.56 (6.84) [17,718: ≈36] 1.72, 8.39 8.01, 19.25 17.52, 49.12 42.14, 97.05
5 6.61 (6.66) [31,167: ≈26] 1.72, 8.85 7.44, 19.89 15.98, 48.39 37.21, 91.13
6 5.76 (6.18) [28,408: ≈216] 1.69, 7.02 6.79, 16.21 15.78, 41.84 41.98, 96.35
7 7.44 (7.46) [15,231: ≈15] 1.74, 11.57 8.62, 23.11 19.05, 54.66 47.28, 99.84
8 6.97 (7.36) [19,547: ≈49] 1.72, 9.65 8.12, 21.95 17.59, 60.48 48.91, 99.64
9 5.84 (6.45) [25,764: ≈85] 1.68, 7.06 6.77, 16.55 15.59, 46.02 44.24, 98.66
10 6.28 (6.89) [17,217: ≈223] 1.72, 7.639 7.41, 17.44 16.93, 51.20 48.45, 97.85
11 6.85 (7.03) [9710: ≈18] 1.84, 8.84 6.76, 20.18 12.49, 49.44 35.72, 89.91
All clusters 6.53 (6.89) [228,687: ≈1412] 1.68, 11.57 4.07, 23.11 6.76, 60.48 19.40, 99.84
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Self-reported outcomes
We analysed data from 2362 questionnaire responses from 1403 distinct participants; these responses
yield SF-12 Mental Health Component and Physical Health Component scores data, and hence SF-6D
values, and a quality of care measure. As questionnaires were sent to a sample deliberately skewed
towards those with higher PRISM scores, we separately summarise characteristics of respondents in
Table 24.
Table 25 shows no difference in Mental Health Component scores but higher (improved) Physical Health
Component scores in respondents in the intervention phase, with a trend towards greater improvement in
those in the higher-risk groups. However, no differences were evident when questionnaire responses were
summarised by an overall SF-6D. Satisfaction scores were slightly lower overall in the intervention phase,
although there was no clear pattern across risk groups.
Technical performance
Data analysed
As Figure 3 shows, relatively few participants (based on ‘treatment allocation’ dates) were still in the
control phase on 31 January 2014. To mitigate this reduction, we therefore included in this part of
the analysis data from the ‘lead-in’ period from 1 August 2012 to 31 January 2013 and used this in
conjunction with the corresponding data from study day 1 onwards. The earliest PRISM score within this
extended window is dated 2 September 2012 and is available for 96,314 out of the 230,999 participants.
Just over half (n = 51,570) of these 96,314 participants were still in the control phase on 31 July 2013 and
this subsample of 51,570 participants is the basis of the analysis in this section. Table 26 summarises the
characteristics of these participants.
TABLE 24 Baseline demographic and clinical characteristics for questionnaire respondents
Variable Proportion %
Gender
Group
All
Female 736/1403 52.5
Male 667/1403 47.5
PRISM risk group 1
Female 119/217 54.8
Male 98/217 45.2
PRISM risk group 2
Female 201/374 53.7
Male 173/374 46.3
PRISM risk group 3
Female 346/670 51.6
Male 324/670 48.4
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TABLE 24 Baseline demographic and clinical characteristics for questionnaire respondents (continued )
Variable Proportion %
PRISM risk group 4
Female 68/140 48.6
Male 72/140 51.4
Mean SD n
Age at study day 1 (years)
Group
All 68.2 16.4 1403
PRISM risk group 1 50.1 15.5 217
PRISM risk group 2 67.8 14.6 374
PRISM risk group 3 73.6 13.5 670
PRISM risk group 4 71.3 15.0 140
WIMD (2011)
Group
All 27.87 16.67 1379
PRISM risk group 1 23.06 14.57 217
PRISM risk group 2 28.51 16.70 369
PRISM risk group 3 28.98 17.00 654
PRISM risk group 4 28.68 16.95 137
WIMD (2011) health component
Group
All 31.58 22.58 1379
PRISM risk group 1 26.74 20.73 217
PRISM risk group 2 32.76 22.54 369
PRISM risk group 3 32.46 23.40 654
PRISM risk group 4 31.92 20.80 137
PRISM score
Group
All 23.14 17.33 1401
PRISM risk group 1 4.26 1.86 217
PRISM risk group 2 12.77 3.98 374
PRISM risk group 3 27.09 9.15 670
PRISM risk group 4 61.19 14.00 140
SD, standard deviation.
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TABLE 25 Quality of life and care measures: analysis by ‘treatment allocated’ date
Outcome Group
Phase, mean (SD) [n]
Adjusted comparison 95% CI
ICC
Intervention Control Estimate 95% CI
SF-12 Mental Health Component Alla 43.77 (9.67) [1410] 44.62 (9.47) [662] Δ= –0.720 (p = 0.060) –1.469 to 0.030 0.0164 0.0063 to 0.0320
Risk group 1b 49.44 (8.34) [242] 49.03 (8.07) [83] Δ= 1.736 (p = 0.037) 0.106 to 3.366
Risk group 2c 43.72 (8.97) [381] 45.18 (8.85) [163] Δ= –0.802 (p = 0.268) –2.222 to 0.618
Risk group 3d 42.54 (9.53) [659] 44.13 (9.80) [322] Δ= –1.187 (p = 0.040) –2.317 to 0.056
Risk group 4e 39.61 (10.35) [127] 41.45 (9.10) [94] Δ= –1.911 (p = 0.084) –4.079 to 0.258
SF-12 Physical Health Component Allf 41.72 (9.20) [1410] 40.07 (7.30) [662] Δ= 1.465 (p < 0.001) 0.774 to 2.157 0.0091 0.0024 to 0.0210
Risk group 1g 34.41 (9.09) [242] 36.77 (7.62) [83] Δ= –4.385 (p < 0.001) –6.106 to 2.664
Risk group 2h 41.90 (8.18) [381] 40.65 (7.12) [163] Δ= 0.882 (p = 0.159) –0.345 to 2.108
Risk group 3i 43.54 (8.45) [659] 40.18 (7.15) [322] Δ= 3.205 (p < 0.001) 2.218 to 4.191
Risk group 4j 45.56 (8.76) [127] 41.61 (7.11) [94] Δ= 4.103 (p < 0.001) 2.230 to 5.977
SF-6D score Allk 0.6380 (0.0682) [1467] 0.6382 (0.0719) [692] Δ= –0.002 (p = 0.584) –0.008 to 0.004 0.0097 0.0026 to 0.0222
Risk group 1l 0.6293 (0.0687 [247] 0.6417 (0.0773) [83] Δ= –0.019 (p < 0.001) –0.034 to 0.003
Risk group 2m 0.6387 (0.0716) [399] 0.6408 (0.0752) [166] Δ= –0.003 (p= 0.649) –0.015 to 0.010
Risk group 3n 0.6414 (0.0673) [690] 0.6375 (0.0700) [341] Δ= 0.002 (p = 0.628) –0.006 to 0.010
Risk group 4o 0.6347 (0.0598) [130] 0.6333 (0.0687) [102] Δ= 0.002 (p = 0.787) –0.013 to 0.017
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TABLE 25 Quality of life and care measures: analysis by ‘treatment allocated’ date (continued )
Outcome Group
Phase, mean (SD) [n]
Adjusted comparison 95% CI
ICC
Intervention Control Estimate 95% CI
Quality of care Allp 4.196 (0.737) [1408] 4.268 (0.695) [660] Δ= –0.074 (p = 0.014) –0.133 to 0.015 0.0392 0.0198 to 0.0651
Risk group 1
q
4.188 (0.720) [189] 3.957 (0.860) [62] Δ= 0.169 (p = 0.095) –0.030 to 0.368
Risk group 2r 4.244 (0.694) [391] 4.275 (0.716) [162] Δ= –0.080 (p = 0.156) –0.191 to 0.031
Risk group 3s 4.200 (0.736) [697] 4.360 (0.607) [340] Δ= –0.107 (p = 0.008) –0.186 to 0.029
Risk group 4t 4.040 (0.867) [130] 4.130 (0.762) [96] Δ= –0.100 (p = 0.291) –0.286 to 0.086
SD, standard deviation.
Significant covariates and factors (p< 0.001 unless otherwise stated) are:
a Age at study day 1 (p= 0.003); WIMD health component; and PRISM score.
b Age at study day 1 (p= 0.029); WIMD score; and PRISM score (p = 0.016).
c Age at study day 1; and WIMD score (p= 0.031).
d Age at study day 1 (p= 0.003); gender (p= 0.048); WIMD health component (p = 0.001); and PRISM score (p = 0.027).
e Age at study day 1 (p= 0.007); and WIMD health component (p = 0.013).
f WIMD score; and PRISM score.
g WIMD score; and PRISM score.
h Age at study day 1 (p= 0.001).
i Age at study day 1; WIMD score; and PRISM score.
j WIMD health component (p= 0.043).
k Age at study day 1; WIMD health component (p= 0.027); and PRISM score (p= 0.028).
l Age at study day 1.
m Age at study day 1.
n Age at study day 1 (p= 0.003).
o Age at study day 1; and WIMD health component (p= 0.049).
p Age at study day 1; WIMD score (p = 0.018); WIMD health component (p= 0.007); and PRISM score (p= 0.007).
q Age at study day 1 (p= 0.009).
r Age at study day 1 (p= 0.005); WIMD score (p = 0.026); and WIMD health component (p= 0.009).
s Age at study day 1 (p= 0.019).
t None.
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TABLE 26 Baseline demographic and clinical characteristics for the technical performance subsample
Variable Proportion %
Gender
Group
All
Female 25,454/51,570 49.4
Male 26,116/51,570 50.6
PRISM risk group 1
Female 19,763/41,119 48.1
Male 21,356/41,119 51.9
PRISM risk group 2
Female 4172/7834 53.3
Male 3662/7834 46.7
PRISM risk group 3
Female 1385/2367 58.5
Male 982/2367 41.5
PRISM risk group 4
Female 134/250 53.6
Male 116/250 47.4
Mean SD n
Age at study day 1 (years)
Group
All 42.2 23.2 51,570
PRISM risk group 1 37.4 20.2 41,119
PRISM risk group 2 58.1 24.7 7834
PRISM risk group 3 71.1 20.9 2367
PRISM risk group 4 70.9 19.9 250
WIMD (2011)
Group
All 23.79 19.24 50,256
PRISM risk group 1 22.92 20.68 40,090
PRISM risk group 2 26.94 20.59 7644
PRISM risk group 3 28.09 21.44 2281
PRISM risk group 4 28.72 19.24 241
WIMD (2011) health component
Group
All 26.55 24.09 50,256
PRISM risk group 1 25.69 23.64 40,090
PRISM risk group 2 29.56 25.53 7644
PRISM risk group 3 31.09 25.36 2281
PRISM risk group 4 30.81 25.46 241
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Analysis
The data are summarised, first, as a ROC curve (Figure 5) and, second, again consistent with interpreting a
PRISM score, as a probability of an emergency hospital admission in 12 months, by comparing observed
and expected numbers of emergency hospital admissions between 1 August 2012 and 31 July 2013, for
both the overall subsample and the PRISM risk group (Table 27).
TABLE 26 Baseline demographic and clinical characteristics for the technical performance subsample (continued )
Mean SD n
Study PRISM score
Group
All 6.42 6.71 51,570
PRISM risk group 1 4.08 1.61 41,119
PRISM risk group 2 11.25 3.07 7834
PRISM risk group 3 25.44 7.49 2367
PRISM risk group 4 59.48 13.13 250
PRISM score at 2 September 2012a
Group
All 6.08 6.31 51,570
PRISM risk group 1 4.04 1.76 41,119
PRISM risk group 2 10.39 4.13 7834
PRISM risk group 3 22.77 10.47 2367
PRISM risk group 4 48.42 21.02 250
SD, standard deviation.
a There is strong correlation between PRISM score at 2 September 2012 and the study PRISM score (from early 2013),
with r = 0.885 across all 51,570 participants in this subsample.
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FIGURE 5 Receiver operating characteristic curve based on PRISM scores in September 2012 and emergency
hospital admission between 1 August 2012 and 31 July 2013. Diagonal segments are produced by ties.
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The area under the ROC curve is 0.749, indicating fair agreement. Table 27 shows that overall PRISM
performed well, with some variation – fewer than expected admissions at risk level 1, but more admissions
than expected at risk levels 2–4.
TABLE 27 Observed and expected emergency admissions in technical performance subsample
Group Average PRISM score n
Number of emergency hospital admissions from
1 August 2012 to 31 July 2013
Observed Expected
All 6.08 51,570 3213 3133.8
PRISM risk group 1 4.04 41,119 1141 1659.8
PRISM risk group 2 10.39 7834 1078 814.0
PRISM risk group 3 22.77 2367 808 538.9
PRISM risk group 4 48.42 250 186 121.1
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Chapter 5 Health economics results
Predictive risk stratification model implementation costs
Pre-activation and activation costs
Table 28 summarises the resource use and costs associated with the PRISM pre-activation phase, PRISM
activation and set-up, and NWIS activity, during activation of the software in general practices. Processing
of the ISAs was estimated to take 20 minutes from discussion with the research team. The different
downloading and activation scenarios are shown with associated costs. These were based on support
requirements in the actual trial general practices.
TABLE 28 Cost components of PRISM activation in general practices
Cost component/resources required Staff involved
Cost (£)
Unit Overall
Pre-activation phase
General practice staff opportunity costs:
processing ISAs approximately 20 minutes
per practice (the calculations are based on
32 practices)
GP; PM 109.00/hour,a 36.33 per
practice; 13.95/hour,a 4.65 per
practice
1162.56;
148.80
It was assumed for the base case that in
50% of cases a GP would do the ISA
655.68
Activation phase
Distribution of PRISM software: intended to be an internet-based system of downloading required software with IT support
via telephone help desk or IT tech visit if required
Scenario 1
Successful download of PRISM software via
the internet by practice staff (PM): average
time taken was 20 minutes per practice
(calculations based on 32 practices either
successfully activating PRISM software
without assistance or failing to initially
activate software and requiring further
assistance)
PM 13.95/hour,a 4.65 per practice 148.80
Scenario 2
Help required from the IT help desk via
telephone for guidance to download the
PRISM software:
l 19 practices required IT help desk
assistance during trial
l Average telephone assistance lasted
15 minutes
IT help desk: band 4
information officer,
19 calls × 15 minutes
10.58/hour,b 2.65 per practice 50.26
Help required from the IT help desk via
telephone for guidance to download the
PRISM software:
l 19 PMs required assistance via
telephone during trial
l Average telephone assistance lasted
15 minutes
PM opportunity cost:
19 calls × 15 minutes
13.95/hour,a 3.49 per practice 66.26
continued
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The total cost of PRISM activation was £1423.00 equating to £44.00 per practice. This cost of setting up
PRISM represents the costs incurred during the trial period. Resource use and cost of GP trainers are shown in
Table 29. The costs include GP trainer training, GP trainer time during training, as well as GP opportunity cost.
Training of trainers and practice GPs cost £9709.00 in total and £303.00 per practice, which means that
setting up PRISM in general practices (pre-activation and activation cost, NWIS activation support and GP
training), during the trial period cost £11,131.00 in total and £348.00 per practice.
Predictive risk stratification model running and maintenance costs
The tasks required and costs of PRISM on a regular basis are summarised in Table 30.
The annual running costs were calculated using the unit cost of each component of operating and
maintaining the PRISM software system and deriving an annual cost from the unit cost. Running monthly
data uploads were calculated at £79 per month, which equates to £952 per year for all practices. It was
estimated that maintenance of the PRISM software would be required every 2 years and calculated to cost
£2048, which equates to £1024 per year.
The staff cost (opportunity cost) of participating general practices was calculated as part of the implementation
costs for the PRISM scoring tool. Two general practices (numbers 13 and 30) were excluded from this analysis.
Practice 13 was the GP champion practice working alongside the trial research team and hence logged into
the PRISM software far more frequently than would be expected from routine use (29 times). Practice 30 was
also initially a GP champion practice, but dropped out after approximately 1 month. The high frequency of
logins by GPs during this early phase was also considered non-routine use.
TABLE 28 Cost components of PRISM activation in general practices (continued )
Cost component/resources required Staff involved
Cost (£)
Unit Overall
Scenario 3
Site visit required by NWIS IT technician to
download the PRISM software:
l 11 practices requested a site visit from
an NWIS IT technician
l Average time spent at practice for IT
technician was 40 minutes + 1 hour of
travel time
l Travel costs: in the national roll-out
phase it is anticipated that one of the
NWIS regional hubs would send out
IT assistance to general practices, with
a travel distance of approximately
30 miles from the hub. Trial travel
costs were based on £0.45 per mile
(£13.50 per one way trip)
IT technician; band 4
information officer, 11
practices × approximately
1 hour 40 minutes of IT
technician time + travel
£10.58/hourb (£0.18/minute),
40 minutes = £7.05; 1-hour
travel, £10.58; £27.00, travel
expenses; £44.63 per practice
490.93
NWIS backend costs during the set-up phase
l Monitoring activation status and
reporting back to practice
l Initial data extraction (first data transfer
of files in practice)
l NWIS provides confirmation of uploads
Assumed 1 hour in total for all 32 practices
IT technician; band 4
information officer
£10.58/hourb £10.58
a Source: Personal Social Services Research Unit 2014.83
b Source: Agenda for Change NHS 2014 pay scale.69
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Frequency of use was determined using login data obtained from the NWIS, which collected activity by:
1. the number of practice staff users per practice
2. the number of logins per practice
3. which staff members logged on and how many times each logged on.
However, the login statistics from NWIS did not provide information on how much time was spent using
the PRISM software. Average length of time spent using PRISM software/data was therefore derived from
the interviews held with general practice staff and the corresponding online questionnaire. However, there
are several limitations associated with the following data.
l The 9-month questionnaire data were incomplete; only 12 out of 31 practices analysed provided data
(10 practices did not respond to the online questionnaire and nine practices indicted that there was no
regular pattern of use).
l Using the 12 available responses regarding the ‘time spent using PRISM’, a mean time of 60 minutes
was calculated and imputed for practices that did not respond to the online survey and practices that
responded that there was ‘no regular pattern’ of using PRISM software.
l The available data did not specify which member of staff used PRISM for the length of time indicated if
there was more than one user per practice; therefore, it has been assumed that the time spent using
PRISM is an indication of time spent by the practice staff member who was the main PRISM user in
that practice but is also applied to any other users in the practice, costs are weighted by the number of
logins per PRISM user to get an approximate practice cost of using the PRISM software.
TABLE 29 Cost of GP training
Cost component/resource used Staff involved
Cost (£)
Unit Overall
Training costs of GP PRISM trainer who carried out training in trial practices on behalf of NWIS
Training of GP champions to deliver PRISM training
(2.5 hours of GP time at a rate agreed during trial)
GPs participating in the trial were paid £62.50 per
hour. Trial team members travelled to the GPs to
deliver training
Two trainer GPs
× 2.5 hours
62.50/hour 312.50
Training session in general practice on how to use
PRISM software (it was assumed that GP trainers
would deliver training in 1-hour sessions)
It was estimated that a GP trainer from each region
would be available to deliver PRISM training with
an average travel distance of 30 miles = 1 hour of
travel time (travel to practice and travel back)
Trial travel costs were based on £0.45 per mile
Trainer GP × 1-hour
training and 1-hour travel
cost (plus fuel costs)
62.50/hour; 125.00
per practice; plus
27.00 fuel costs
4000.00 plus
864.00 =
4864.00
Additional PRISM training (four practices requested
extra training during trial)
Trainer GP × 2 hours
(training plus travel)
62.50/hour;
125.00 × 4;
27.00 fuel
500.00 plus
108.00 =
608.00
Trainee GP opportunity costs: 1 hour of training on
PRISM software for each participating general
practice plus extra training (one GP trainee per
practice assumed)
Trainee GP × 36 109.00/hour 3924.00
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l The ‘time spent using PRISM’ is a graded response which has been interpreted as follows:
¢ approximately 1 hour = 60 minutes
¢ 1–2 hours = 90 minutes
¢ > 2 hours = 120 minutes
¢ up to 15 minutes = 15 minutes
¢ up to 30 minutes = 30 minutes
¢ up to 45 minutes = 45 minutes.
Table 31 shows the available data on frequency and duration of PRISM use by different users within the
participating practices.
The overall staff cost in the first 9 months post implementation for all 30 trial practices included in the
analysis was £9182.00. This equates to a mean cost of £296.00 per practice. The minimum staff cost for a
practice was £21.00 where a PM logged into PRISM three times for approximately 30 minutes per time
over a 9-month period. The maximum cost per practice was £1186.00, where there were seven GP logins
and two PM logins for approximately 90 minutes per login, over a 9-month period.
TABLE 30 Cost components of PRISM maintenance (provider costs)
Cost component/resource used Staff involved
Cost (£)
Unit Overall
Running monthly data uploads and providing e-mail support
for general practices: the IT support tasks carried out by
NWIS to maintain the running of the PRISM software are
listed below:
1. Loading of demographic data received from GP surgeries
2. Loading of clinical data from GP surgeries
3. Refresh PRISM database with GP data and secondary
care data (inpatients/outpatients)
4. PRISM score data
5. Confirming updates to general practices via the PRISM
website (10-minute activity)
6. E-mail support for PRISM enquiries (during the trial NWIS
have received fewer than five e-mail enquiries per
month)
NWIS estimate that these tasks take approximately 1 day of
IT staff time per month for all 32 practices
IT technician; band
4 information officer
10.58/hour;
7.5 hours
79.35 per month
Maintenance/updates of PRISM software: NWIS estimate
that PRISM software would be further developed and
updated every 2 years. This would take approximately
15 days of a band 7 IT technician’s time
Investment in new servers in the longer term: servers would
be expected to be upgraded every 3–4 years
It is estimated that it would take 30 days to migrate and
update systems
No new servers were required for the trial use of PRISM and
no costs were allocated
Band 7 IT technician 18.22/hour;
136.65/day
2048.25 every
2 years
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TABLE 31 Frequency and duration of PRISM use by different general practice users and associated costs
Practice
ID
Number
of PRISM
users per
practice
Number
of logins
Average
time
(minutes)
spent
using
prism
Staff using PRISM
Total
cost (£)
per
practice
GP PM Practice nurse
Other administration
(band 3 IT
administrator)
Number
of logins
Cost (£) by
time used
(£109.00/hour)
Total
GP cost
Number
of logins
Cost (£) by
time used
(£13.95/hour)
Total
PM cost
(£)
Number of
logins and
cost (£) per
hour
(£41.00)
Total
cost (£)
Number of
logins and
cost (£) per
hour (£9.22)
Total
cost (£)
1 1 2 60 N/A 2 13.95 27.90 27.90
2 2 11 90 6 163.50 981.00 5 20.93 104.65 1085.65
3 4 12 45 3 81.75 245.25 N/A 7 × 6.92 48.44 293.69
4 2 6 90 3 163.50 490.50 N/A 490.50
5 2 9 60 3 109.00 327.00 6 13.95 83.70 410.70
6 1 8 60 8 109.00 872.00 N/A 872.00
7 4 9 60 1 109.00 109.00 1 13.95 13.95 2 × 41 82 5 × 9.22 46.10 251.05
8 2 9 90 7 163.50 1144.50 2 20.93 41.86 1186.36
9 2 10 60 1 109.00 109.00 9 13.95 125.55 234.55
10 2 7 15 3 27.25 81.75 4 3.49 13.96 95.71
11 1 6 60 N/A 6 13.95 83.70 83.70
12 1 9 60 N/A 9 13.95 125.55 125.55
13 3 29 60 N/A 0.00 0.00
14 2 11 60 3 109.00 327.00 8 13.95 111.60 438.60
15 1 9 30 N/A 9 6.98 62.82 62.82
16 1 5 60 N/A 5 13.95 69.75 69.75
17 1 3 60 N/A 3 13.95 41.85 41.85
18 1 4 60 N/A 4 13.95 55.80 55.80
19 2 8 60 1 109.00 109.00 7 13.95 97.65 206.65
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TABLE 31 Frequency and duration of PRISM use by different general practice users and associated costs (continued )
Practice
ID
Number
of PRISM
users per
practice
Number
of logins
Average
time
(minutes)
spent
using
prism
Staff using PRISM
Total
cost (£)
per
practice
GP PM Practice nurse
Other administration
(band 3 IT
administrator)
Number
of logins
Cost (£) by
time used
(£109.00/hour)
Total
GP cost
Number
of logins
Cost (£) by
time used
(£13.95/hour)
Total
PM cost
(£)
Number of
logins and
cost (£) per
hour
(£41.00)
Total
cost (£)
Number of
logins and
cost (£) per
hour (£9.22)
Total
cost (£)
20 6 15 60 8 109.00 872.00 2 13.95 27.90 899.90
21 1 7 60 N/A 7 13.95 97.65 97.65
22 2 9 60 N/A 9 13.95 125.55 125.55
23 2 6 120 4 163.50 654.00 2 20.93 41.86 695.86
24 1 5 60 N/A 5 13.95 69.75 69.75
25 1 6 30 N/A 6 6.98 41.88 41.88
26 2 4 60 1 109.00 109.00 4 13.95 55.80 164.80
27 1 7 60 N/A 7 13.95 97.65 97.65
28 2 7 60 7 109.00 763.00 N/A 763.00
29 2 7 60 N/A 5 13.95 69.75 2 × 9.22 18.44 88.19
30 1 11 60 11 109.00 1199.00 N/A 1199.00
31 1 3 30 N/A 3 6.98 20.94 20.94
32 1 6 60 N/A 6 13.95 83.70 83.70
N/A, not any.
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Overall costs of setting up and operating Predictive RIsk Stratification Model software
The overall cost of PRISM was calculated over 1 year based on the trial intervention phase duration.
Costs associated with general practice staff using the PRISM software were calculated by extrapolating the
9-month cost of £9182 to 12 months resulting in a yearly staff opportunity cost of £12,242, which equates
to £408 per practice. The total annual cost of operating and maintaining the PRISM software tool across
the general practices of the trial area are therefore estimated to be £14,218.60 and £473.95 per practice.
This means that use of the PRISM software might be estimated to cost £25,350.00 and thus £822.00 per
general practice in year 1 (includes activation and training), and would be expected to cost £474.00 per
practice in every subsequent year (this figure does not include discounting). These figures are based on trial
figures, include staff opportunity cost but exclude any server or other hardware requirements.
The 32 practices included in the study had 230,099 patients registered at the beginning of the study, of
which 220,683 were included in the intervention phase analysis, equating to a PRISM implementation cost
of £0.12 per patient.
Cost analysis of primary and secondary health care
The mean annualised costs of primary and secondary care per patient, as observed in the control and
intervention phases, are summarised in Table 32.
Table 33 summarises the differences in total health-care costs after adjustment for covariates for the entire
patient cohort and individual risk groups.
The difference between the total cost in the control phase and intervention phase was found to be
statistically significant (p < 0.001) in the overall cohort and for risk groups 1 and 2. Differences were no
longer statistically significant in risk groups 3 and 4. Statistical significance (p < 0.001) remained after
log-transformation.
Health-care costs per patient in the intervention phase were generally slightly higher, but £3 lower in
primary care and £0.05 lower for ED attendances followed by admission. The main cost drivers were found
to be inpatient stays (elective and emergency) and GP visits. These differences were based on raw data
(i.e. unadjusted for covariate effects).
TABLE 32 Mean health-care costs (annualised, in £) per patient during the control and intervention phase
Health-care provision
Phase, mean cost (SD)
Difference in cost (£)Intervention Control
ED attendances (discharged) 30.10 (97.70) 29.90 (120.60) 0.19
ED attendances (admitted) 13.30 (107.40) 13.30 (126.50) –0.05
Outpatient visits 173.10 (407.60) 172.60 (427.30) 0.43
Elective inpatient stays 549.30 (3978.50) 545.00 (4436.50) 4.31
Emergency-related inpatient stays 418.50 (4052.40) 406.10 (5131.30) 12.34
GP events 364.57 (446.56) 367.69 (446.32) –3.12
Total cost 1548.26 (6226.39) 1534.54 (7260.49) 13.72
SD, standard deviation.
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Including all primary and secondary care costs and after covariate adjustment, the total cost difference between
the control and intervention phase shows an increase of £75.91 (total health-care costs only) and £76.03
(total health-care costs and PRISM implementation costs) per patient, respectively, in the intervention phase.
Cost-effectiveness analysis
All costs were annualised to account for the difference in the duration of the control and intervention
phases. Base-case analysis showed a small difference in total health-care costs between the control and
intervention phases (see Table 25). This was mainly attributable to the relatively small implementation cost
of PRISM per patient and the marginal cost increases per patient during the intervention phase. The clinical
effectiveness analysis found an increase in the number of emergency admissions from 0.1607 [standard
deviation (SD) 2.1634] per patient in the control phase to 0.1666 (SD 2.0794) per patient during the
intervention phase. Therefore, no emergency admissions were avoided while an incremental cost of £0.12
per patient per year was spent to implement PRISM in general practice. The intervention is therefore less
effective and more costly than the control and can hence be concluded to be dominated by the control.
As a consequence, no ICERs were calculated as the PRISM tool cannot be considered cost-effective.
Sensitivity analysis
The parameter changes applied in the one-way sensitivity analysis are outlined in Table 34.
The results appeared robust in the univariate sensitivity analysis and did not change significantly from base
case. Based on the difference in number of emergency admissions between control and intervention
phase, the intervention remained dominated by the control (routine practice) in all analyses.
Total health-care costs ranged from £965.00 (SD £5165.00) to £1995.00 (SD £8667.90) in the control phase
and from £976.00 (SD £4415.50) to £2010 (SD £7459.50) in the intervention phase. Covariate-adjusted
incremental costs per patient incurred in the intervention phase (including PRISM implementation), ranged
TABLE 33 Mean total health-care costs (annualised, in £) per patient (overall and per risk group) during the control
and intervention phase
Group
Phase, mean cost (SD) [n] Adjusted comparison
Intervention Control Estimated (p-value) 95% CI
Alla 1548.26 (6226.34)
[220,683]
1534.54 (7260.49)
[230,087]
Δ = 75.91 (p< 0.001) 45.83 to 105.99
Risk group 1b 867.60 (3895.53)
[176,214]
808.59 (4784.65)
[182,952]
Δ = 60.85 (p< 0.001) 37.98 to 83.72
Risk group 2c 3266.72 (9119.38)
[32,929]
3182.73 (9687.06)
[34,307]
Δ = 136.62 (p= 0.020) 21.58 to 251.67
Risk group 3d 7027.45 (14,538.30)
[9352]
7428.90
(17,412.04) [10,288]
Δ = 133.50 (p= 0.446) –209.78 to 476.78
Risk group 4e 15,570.46 (23,732.79)
[897]
15,879.08
(26,475.56) [1128]
Δ = 907.56 (p= 0.300) –809.96 to 2625.07
Significant covariates (p< 0.001 unless otherwise stated) are:
a Age; WIMD 2011 score; PRISM score; seasonality; and trend (p= 0.007).
b Gender (p= 0.002); age; WIMD 2011 score; PRISM score; and seasonality.
c Age; WIMD 2011 score; PRISM score; seasonality; and trend (p= 0.026).
d Gender; age; WIMD 2011 health component score; PRISM score; and seasonality.
e WIMD 2011 score (p= 0.010); WIMD 2011 health component score (p= 0.038); and PRISM score.
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from £45.83 to £105.99. Considering the pooled uncertainty of all parameters, probabilistic sensitivity analysis
showed a probability of the intervention being cost-effective of 21% if a willingness-to-pay threshold of
£3666.00 (average cost of an emergency admission-related inpatient stay68) was assumed.
Cost–utility analysis
Utility scores (QALYs) were slightly lower in the intervention phase (0.6382) than in the control phase (0.638;
see Table 36). After adjustment for covariate effects, the difference of –0.002 was not statistically significant
(p= 0.584). Considering the higher cost of the PRISM scoring tool and generally higher health-care cost in
the intervention phase, the intervention is dominated by the control. No ICER was therefore generated for the
cost per QALY gained. Probabilistic sensitivity analysis showed that the probability that the intervention is
cost-effective at a willingness-to-pay threshold of £20,000 is 46% when all parameter uncertainty is considered.
Cost–consequence analysis
Table 35 summarises the results of the cost–consequence analysis.
TABLE 34 Parameter changes applied in the deterministic sensitivity analysis
Parameter
Base
case
Sensitivity
analysis Change from base case
PRISM pre-activation (£) 655.68 148.80–1162.56 Use minimum (all done by PM) and
maximum (all done by GP) cost
PRISM activation support (£) 490.93 0.00–1428.16 Assume minimum (no site visits required)
and maximum (all surgeries need site
visit to assist with set-up) cost
PRISM opportunity cost for GP surgeries
(for 12 months, £)
394.91 27.92–1581.81 Use minimum and maximum time spent
during trial period
Difference in number of emergency admissions
per patient per year at risk
0.016 0.004–0.027 Use 95% CI to recalculate ICER
Primary care costs (£) 32.05 10.21–45.43 Minimum (all done nurse) and maximum
(all done by GP) cost
ED attendance (discharged) cost (£) 113.60 94.30–128.50 Lower and upper quartile costs reported
NHS Reference Costs 2014/1568
ED attendance (admitted) cost (£) 191.6 152.00–220.80 Lower and upper quartile costs reported
in NHS Reference Costs 2014/1568
Outpatient visits cost (£) 110.6 67.60–127.80 Lower and upper quartile costs reported
in NHS Reference Costs 2014/1546
Elective inpatient stays (£) 3605.50 2624.30–4299.10 Lower and upper quartile costs reported
in NHS Reference Costs 2014/1568
Emergency admission-related inpatient stay per
bed-day (short stay, £)
541.30 369.00–631.00 Lower and upper quartile costs reported
in NHS Reference Costs 2014/1568
Emergency admission-related inpatient stay per
bed-day (long stay, £)
458.20 326.70–540.10 Lower and upper quartile costs reported
in NHS Reference Costs 2014/1568
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Budget impact of the Predictive RIsk Stratification Model in the study area
The annualised budget impact of PRISM per 100,000 population in the trial area during the intervention
phase is detailed in Table 36.
During the 1-year duration of the intervention phase, the total cost of primary and secondary care was
£1.370M higher than the annualised health-care costs in the control phase. Taking into consideration the
implementation costs of PRISM of £11,487 per 100,000 population, this results in an increased cost of
£1.382M per 100,000 patients per year.
TABLE 35 Clinical effectiveness and cost-effectiveness outcomes (adjusted where appropriate):
cost–consequence analysis
Cost/health impact
Phase
Difference p-valueIntervention Control
Annual costs (£) impact
Implementation cost: total 25,349.61 0.00 25,349.61
Implementation cost per GP practice 821.79 0.00 821.79
Implementation cost per patient 0.12 0.00 0.12
Primary care cost per patient 364.57 (SD 446.56) 367.69 (SD 446.32) –3.12
ED attendances (discharged) 30.10 (SD 97.70) 29.90 (SD 120.60) 0.19
ED attendances (admitted) 13.30 (SD 107.40) 13.30 (SD 126.50) –0.05
Outpatient visits 173.10 (SD 407.60) 172.60 (SD 427.30) 0.43
Elective inpatient stays 549.30 (SD 3978.50) 545.00 (SD 4436.50) 4.31
Emergency-related inpatient stays 418.50 (SD 4052.40) 406.10 (SD 5131.30) 12.34
Total health-care cost per patient per
year
1548.26 (SD 6226.39) 1534.54 (SD 7260.49) 75.91 (adjusted:
45.83 to 105.99)
< 0.001
Health impact
Number of emergency admissions per
patient per year at risk
0.1666 (SD 2.0794) 0.1607 (SD 2.1634) 0.005 (adjusted:
–0.0074 to 0.016)
0.425
Number of A&E attendances per
patient per year at risk
0.3613 (SD 1.7877) 0.3593 (SD 2.1014) 0.006 (adjusted:
–0.005 to 0.016)
0.299
Number of GP event-days per patient
per year at risk
14.075 (SD 32.593) 14.100 (SD 23.124) 0.139 (adjusted:
0.032 to 0.246)
0.011
Number of outpatient visits per patient
per year at risk
1.717 (SD 9.746) 1.704 (SD 9.984) 0.035 (adjusted:
–0.014 to 0.085)
0.158
SF-12 mental health score 43.77 (SD 9.67)
[n= 1410]
44.62 (SD 9.47)
[n = 662]
–0.720 (adjusted:
–1.469 to 0.030)
0.060
SF-12 physical health score 41.72 (SD 9.20)
[n= 1410]
40.07 (SD 7.30)
[n = 662]
1.465 (adjusted:
0.774 to 2.157)
< 0.001
SF-6D utility scores 0.6380 (SD 0.0682)
[n= 1467]
0.6382 (SD 0.0719)
[n = 692]
–0.002 (adjusted:
–0.008 to 0.004)
0.584
A&E, accident and emergency.
Notes
Values in brackets represent 95% CI unless indicated otherwise.
n (control phase)= 230,087; n (intervention phase)= 220,683 unless otherwise indicated.
HEALTH ECONOMICS RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
68
The results of the deterministic sensitivity analysis show that, using the lower and upper quartile unit costs
for primary and secondary care, the estimated budget impact of PRISM in the trial area over 1 year and
100,000 population in the intervention phase can be expected to have been between £1102M and
£1.477M and £11.02 and £14.77 per patient, respectively. Furthermore, after adjustment for covariate
effects, the rise in health-care costs that coincided with the PRISM scoring tool in the trial area and 1-year
intervention phase gave an estimated increase in budgetary impact to a mean £7.591M (95% CI £4.583M
to £10.599M) per 100,000 population.
Limitations of the health economic analysis
There are several limitations associated with the economic analysis.
The implementation cost for the PRISM scoring tool was costed according to the procedure and use as
recorded in the trial. Any changes in routine use will result in costs to differ from the ones reported here.
Hospital admissions in the SAIL database are coded as elective, emergency and other. As there was no
indication about the nature of ‘other hospitalisation’, these were excluded from the economic analysis,
which might introduce bias by underestimating actual hospitalisation costs.
No length of stay data were available for this study for elective inpatient stays. They were therefore costed
according to the national average as reported in the NHS Reference Costs 2014/15,68 which will introduce
bias. However, this was addressed in the sensitivity analysis.
Any hospitalisations that started in the control phase and lasted while the patient’s GP surgery entered the
intervention phase were counted entirely as a control phase hospitalisation. However, hospitalisation
length of stay was censored at the end of the study. Hence, the analysis will underestimate the true
hospitalisation costs during the intervention phase. Although this will introduce bias, considering that the
intervention phase was already found to be more costly, this will not change the direction of the results.
Secure anonymised information linkage records GP event-days. However, the nature of the interaction is
unknown. We have therefore costed GP event-days according to consultation trends in general practice,
which might not be entirely accurate as the trend data only includes the period between 1998 and 2008.
Effects of this were addressed in the sensitivity analysis.
Ideally, the economic evaluation would have been undertaken from a societal perspective. However, the
SAIL database does not capture patients’ out-of-pocket expenses or data on social and community care
usage. We planned to use questionnaire data (Client Service Receipt Inventory) to estimate the cost of
social care but because of the complexity of the data linkage with the SAIL database, social care costs
could not be included in the analysis, which will cause an underestimation of the true costs in both the
control and intervention phases.
TABLE 36 The PRISM budget impact in study area during intervention phase per 100,000 population per year
Budget impact (£)
Phase
DifferenceIntervention Control
Total health-care cost 154,821,008.00 153,450, 874.00 1,370,134.00
PRISM implementation cost 11,486.89 0.00 11,486.89
Total budget impact 154,832,495.00 153,450,874.00 1,381,621.00
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Although the cost difference between the intervention and control phase is statistically significant, this
result has to be interpreted with caution because of the large sample size included in the analysis and the
skewness of the data. Although generalised linear models and log-transformation are not ideal to address
the common problems with cost data (i.e. positive skewness, excess zeros, multimodality and heavy tails),
the sample size used in the analysis should be large enough for a near-mean distribution to be assumed
and so the number of large costs is sufficient for the answers not to be unduly influenced by a few, very
large, outlying costs.
The budget impact analysis only considered the trial population rather than an all-Wales or other per
country-based population. Further examination (e.g. to take into account differing demographic structures
across regions) would be needed to provide robust estimations of the impact of implementing PRISM over
a 5-year period. However, the trial-based analysis provides an illustration of the likely budgetary demands
(based on a 100,000 population) of the PRISM scoring tool on the NHS.
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Chapter 6 Stakeholder views: the Predictive RIsk
Stratification Model implementation and use
Introduction
The qualitative component of the PRISMATIC study was designed to describe how the PRISM tool was
understood, communicated, adopted and used by practitioners, managers, local commissioners and
policy-makers. In particular, it aimed to identify the processes of change associated with introducing and
implementing the PRISM tool within primary care services.
This chapter is structured roughly chronologically. We start by presenting the views of policy-makers
involved with development and roll-out of PRISM, and staff from Welsh health boards who were invited to
pilot PRISM within their chronic conditions management programmes. We then explore local aspects of the
context for the PRISMATIC study, by reporting on the expectations of and views on PRISM from community
health staff and health board staff in the ABM UHB areas at baseline of the study. We then examine the
process of adoption of PRISM in general practice within the PRISMATIC trial, through reporting the views
and experiences of staff from the 32 general practices at three time points: baseline, mid-trial and end of
trial. This analysis is informed by the NPT described in Chapter 3. The four components or tasks associated
with implementing innovation in normal health-care practice are summarised in Box 2. We conclude the
presentation of qualitative data with reflections from an AMB UHB manager at the end point of the
PRISMATIC trial intervention on the potential and use of the PRISM tool in their area.
This chapter also contains information on the implementation and use of PRISM from the surveys
administered to participating practices, to complement the interviews and focus groups.
Normalisation process theory suggests that each of these tasks is shaped by factors that promote or inhibit
the extent to which participants look on a new practice as meaningful.
Respondents
Table 37 summarises the stages in which each of the three main staff groups participated in the qualitative
data collection, as well as the number of staff involved.
Health services policy-makers, managers and community health staff
During 2013 we conducted face-to-face interviews with policy and health board managers (n = 12) to
explore the story of developing the PRISM tool. Six respondents had responsibility for supporting and
implementing chronic conditions management policy (including developing the PRISM tool) at an all-Wales
level and worked for the Welsh Government or an agency which advised the Welsh Government on this
BOX 2 Normalisation process theory: components of implementing innovation in health care
l How people understand the innovation and its purpose (coherence).
l What decisions people take about using it, based on perceived advantages (cognitive participation).
l What people do to bring the innovation into everyday use (collective action).
l How the innovation is reviewed, modified or abandoned (reflexive monitoring).77
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matter. The other six respondents had regional responsibility for planning and delivering chronic conditions
management services in Welsh health boards.
At baseline (before PRISM was introduced to GP practices), we conducted a focus group with seven ABM
UHB staff with a responsibility for the management, redesign and/or delivery of primary and/or community
care services. Two of them were practising nurses involved in delivering community care, and one was a
GP working in a management role at the time of the focus group. One respondent had a role which
spanned the whole of ABM UHB, whereas the remaining six respondents worked in a particular locality or
network. Six of the seven respondents were female. Part-way through the focus group, we presented a
handout explaining PRISM and giving examples of screenshots.
At the end of the trial, we interviewed one ABM UHB manager. Two other ABM UHB locality managers
declined to participate, saying they had changed roles and had no knowledge of the PRISM implementation.
We also circulated a short questionnaire about the PRISM implementation to members of the baseline ABM
UHB focus group, but none was returned completed.
Staff from general practitioner practices trialling the Predictive RIsk Stratification
Model tool
At baseline, we invited each GP who had been nominated as lead for PRISM in a participating practice
to attend one of four focus groups, along with other staff members (such as PM or nurse), if desired.
Thirty-three respondents attended focus groups: group A (GPs, n = 5; PMs, n = 4; nurses, n = 1), group B
(GPs, n = 4; PMs, n = 3; nurses, n = 1), group C (GPs, n = 7; PMs, n = 1), group D (GPs, n = 5; PMs,
n = 2). We also interviewed 10 GPs who were unable to attend a focus group, by telephone (n = 7) or in
person (n = 3); in one of the face-to-face interviews, the GP was joined by their PM. This gave a total of
44 participants from across all 32 practices. Part-way through the focus group or interview, we presented a
handout explaining PRISM and giving examples of screenshots.
At two time points after PRISM was introduced (at the mid-point and at the end of the trial), we carried out
follow-up data collection with respondents from the practices. For half of the participating practices (n = 16),
we interviewed the PRISM lead GP in order to understand how the tool was introduced and used over the
study period. The PM or practice nurse also contributed to a small number of these interviews. The mid-trial
interviews took place at the time when practices were preparing reports required for QOF: interviews with
practices who gained access to the tool early in the PRISMATIC trial occurred up to 6 months before the QOF
deadline, whereas later implementing practices were interviewed during the few months or weeks before
they submitted their reports. By the time of the interviews at the end of the trial, the QOF payment for
focusing on patients at high risk of emergency admissions had ended.
TABLE 37 Summary of qualitative data collection stages
Staff group
Time point
Baseline: pre PRISM
activation
Mid-trial: 3–6 months
post PRISM activation
End of trial: 18 months
post PRISM activation
All-Wales policy-makers and health
board staff
12 interviews Not interviewed Not interviewed
Local health board and community
staff
1 focus group (n = 7) Not interviewed 1 interview
General practice staff 4 focus groups (GPs,
n = 21; PMs, n= 10;
nurses, n = 2)
11 interviews (GPs,
n = 10; PMs, n= 1)
22 interviews (GPs,
n= 18; PMs, n= 4)
9 questionnaires (GPs,
n= 7; PMs, n= 2)
19 interviews (GPs,
n= 17; PMs, n= 2)
15 questionnaires (GPs,
n= 14; PMs, n= 1)
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At the same two time points (at the mid-point and at the end of the trial), we circulated a short
questionnaire based on the interview schedule to the other half of the lead GPs (n = 16) to identify any
experiences that diverged from those reported in interviews.
Characteristics of practices and respondents are described in Appendix 10.
Figure 6 illustrates the timing of mid-trial interviews with participating GPs in relation to the QOF
reporting deadline.
In the presentation of results in this chapter, quotations are selected to be illustrative and typical of
respondents’ comments unless otherwise stated. Where a respondent emphasised a word or phrase, that
emphasis is indicated by bold type. Quotations are identified by respondent role (GP, PM, practice nurse),
practice-unique identifier, time point (baseline, mid-trial, end of trial). For example, ‘GP01base’ would
identify a quotation from the baseline interview with the GP from practice number 1, ‘PM14end’ would
identify a quotation from a PM in the interview at the end of the trial at practice number 14. Quotations
for policy and health board managers are identified by PHB and the unique number (e.g. PHB01).
Views of health service managers at strategic level: pre implementation
How the Predictive RIsk Stratification Model risk tool was planned and developed
across Wales
This section presents results of interviews with policy-makers and health services managers (n = 12)
responsible for chronic condition management in Hywel Dda, Betsi Cadwaladr, Powys, Cardiff and Vale,
Cwm Taf, and Aneurin Bevan Health Boards.
Interview respondents reported broad support for the introduction of a risk prediction tool in Wales. One
commented that, at a Wales-wide meeting, ‘there was a complete consensus’ (PHB06) regarding the tool’s
development, driven in part by a focus on reducing emergency hospital admissions:
We’re demonstrating at the moment about 8–10 per cent increases in emergency admissions year on
year. So, it’s completely unsustainable, but it’s massive pressure on hospitals and we have to do far
more to stop people coming in.
PHB01
We knew that we had to look at these patients who were multiple admissions to hospital, and that
there was a keenness to stop people going into hospital, and to keep them in the community, and
keep them at home.
IPHB09
I think it’s critical. You should be able to plan, as far as you can, and try and understand where your
demands for health care are going to come from.
PHB07
Several respondents recalled that PRISM had been anticipated for some time. They indicated that there
were high levels of awareness and enthusiasm across different staff groups with a strategic interest in
chronic conditions management:
. . . there’s strong support amongst the audience, primarily the local health board, chronic condition
[staff?] and managers, planning implementation manager, they like the tool, want it, and were . . .
quite keen to say ‘well – but when are we going to get it?’
PHB 02
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QOF start
1 April 2013
QOF end
31 March 2014
51525354555 (weeks)
Practice 30
Practice 13
Practice 20
Practice 5
Practice 6
Practice 4 Practice 8 Practice 2 Practice 21 Practice 29 Practice 32 Practice 19
Practice 11 Practice 23 Practice 26 Practice 15
Practice 18
Practice 10
Practice 28
Practice 17
Practice 31 Practice 9
Practice 7
Practice 12
Practice 22
Practice 3
Practice 24 Practice 14
Practice 25 Practice 1 Practice 16 Practice 27
FIGURE 6 The timing of mid-trial interviews with participating GP practices in relation to the QOF reporting deadline.
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The work that we did on chronic conditions management when the national framework came out was
very much sort of looking at an overview of services overall . . . Within that we’ve always been waiting
for PRISM . . . because we always talked about ‘when PRISM comes we’ll do that’.
PHB10
Most respondents were aware that PRISM had initially been proposed as a tool to support the planning of
services. A minority of respondents expressed the opinion that this original vision was preferable to the
subsequent emphasis on use within GP practices:
. . . the original concept was based . . . on population, managing the needs and allocating the services
and support more appropriately to meet those needs . . . [. . .] the original concept was that it was a
locality tool that we could use to kind of do a population-based planning . . . and we got sucked
down into the primary care individual level.
PHB03
This scepticism about the role of the tool in case finding of at-risk patients at practice level could be linked to
the attitudes that respondents reported observing in some GPs at the time of the tool’s development and
piloting. Though some interest and openness to the tool was reported, respondents also identified many
aspects of caution and reluctance among GPs and practice colleagues. These included comments that:
l PRISM was a threat to professional autonomy:
. . . this way of working is not one that many people are comfortable with, because it takes the
initial responsibility of identifying people away from clinicians. And I think that that’s quite difficult
for many people to come to terms with.
PMB06
l there was a lack of evidence to justify it:
Some of them would say, ‘I will use it when I know more about it, when it’s more developed,
when it’s more understood’. . .
PMB02
l it would not provide new or timely information on patients:
The first thing that practices were coming up with was, ‘Well, we know who our top patients are,
we know who these patients in the top of the pyramid are, why would we need a piece of software
to do that?’ And it was actually trying to explain to them the concept of not just looking at those
patients who you knew were very ill, and were likely to be experiencing admissions, but it was those
people who were further down the pyramid, but starting to fall over into a higher need bracket.
PMB09
l it would generate additional work.
Constraints on implementation pre PRISMATIC
Several respondents reflected on the constraints on implementation of PRISM shortly after its development.
They reported their perception of the reasons at national level for the delay in Wales-wide implementation.
These reasons related to concerns about the accuracy and value of the tool; concerns about confidentiality
and patient security expressed by professional body representatives, including the British Medical
Association (BMA); a lack of central ownership and top-down drive to continue to develop and promote
PRISM; and a lack of GP champion to provide peer support and encouragement:
I think public health [representatives] didn’t have enough confidence that it [PRISM] was accurate; they
have their own parameters. GPs and the Welsh BMA, they had concerns about: was the supporting
infrastructure around confidentiality and patient security enough?
PMB02
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It was the BMA in the end who . . . had enough reservations that prevented us from making it more
widely available.
PMB03
There was no new development work, there was nobody really we could say was a PRISM person.
[. . .] which is a shame, because we invested a lot of effort initially to it and then suddenly it just died.
PMB05
There’s no other way GPs will engage, they will engage more with their own colleagues initially.
PMB08
Views of health service managers and community health providers at
local level: pre implementation
As we were interested in how PRISM would fit in with a wider picture of community-based provision, we
talked to other relevant members of the local health community in the ABM UHB area, by holding a focus
group with staff with responsibility for management, redesign and/or delivery of primary and/or community
care services. This focus group took place at baseline, before implementation of the tool through the
PRISMATIC study.
Awareness and understanding of the Predictive RIsk Stratification Model
Awareness of the PRISM tool among community health staff and managers at baseline was generally high,
largely because respondents had already come across it, and in some cases worked directly with it. It had
been an intrinsic component of a pilot virtual ward development in part of the ABM UHB area, when
piloted prior to the PRISMATIC study. Three respondents who had worked directly with it in their care role
reported responding to it favourably – ‘another weapon in the armoury’, as one said (respondent 6, focus
group E). However, they were also frustrated by technical hitches and delays, and the fact that, because of
the short-term nature of the pilot, use of PRISM became a ‘fizzled out firework’ (respondent 7, focus
group E).
Many of the respondents indicated a generally high level of understanding of the details of PRISM in terms
of its technical functioning, though there were still some uncertainties about, for example, the differences
between relative and absolute risk. A minority of respondents, despite feeling generally positive about the
potential benefits of PRISM, reported some specific concerns. Some of these concerns were around the
accuracy of the data and the fact that scores may not take full account of patients’ level of anxiety or
competence to self-manage. Respondents also identified a potential problem with the PRISM approach of
identifying relative risk, practice by practice – and as practice lists vary widely, this could produce inequity
as patients in the highest category of risk in one practice might actually be at much less risk than patients
in another practice, who were further down in the stratification:
Well, how do we make – how do we manage need across a whole population, not just at a practice level?
Respondent 5, focus group E
Respondents described their understanding of how PRISM could be used as a resource by practitioners in
order to support case finding of patients who might benefit from case management. This understanding of
the role of PRISM in case finding extended to take in the concept of ‘impactability’, and the selection from
a list of patients at high risk of being those for whom interventions would be offered:
Some of the concerns of GPs have been, they’re going to have this whole, you know, great tranche of
people. But, actually, you can keep select – you can select however many you want. You don’t have to
manage them all, you can select out those that are most at risk.
Respondent 1, focus group E
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One nurse saw value in using PRISM for case finding, but was uncertain about how to manage that
because she also had to accept referrals from GPs – who may, themselves, not have been using PRISM.
Another community nurse, working across four different practices, was concerned about another practical
challenge. As PRISM rolled out, she would have to visit each practice to access PRISM separately, and
would need to enter four different access codes.
In terms of delivering a model of proactive care, risk scores might be used as a basis of deciding not just
when a patient goes onto the nurse’s caseload, but also when they might be discharged:
I’d hate to be the bean counter, but actually that’s part of what I have to do. How do we make sure
we target our resources to the most effective area, and how do we ensure that people come out of
service as well as come in?
Respondent 5, focus group E
Discharge decisions are not necessarily straightforward, though, as patients’ needs and risk level can
fluctuate over time:
I have what I call a backburner, where I put – park people if you like, who are not technically on my
caseload, but I know they’re probably going to come back on.
Respondent 5, focus group E
Perceived opportunities and limitations of the Predictive RIsk Stratification Model
Respondents were generally aware of the wider debate which had taken place prior to PRISM’s introduction,
including the concerns expressed by the BMA and the local medical committee – about risks to confidentiality,
liability, and the possibility of being misled by regression to the mean – though respondents did not generally
endorse these concerns. One respondent suggested that, for those GP practices that had not signed up to the
PRISMATIC study, there was a list of anxieties that were still current:
. . . having spoken to some of the GPs, [comments I have received have been] ‘We don’t believe it will
add value’; ‘we already know [our high risk patients]’; and ‘. . . fear of all this additional work that we
will now have to do to manage people we didn’t know were risky before’.
Respondent 5, focus group E
In addition to its role in case finding, PRISM’s potential to support service development and planning was
extensively discussed by respondents in a number of different ways, particularly around remodelling of
care. As one health service manager with responsibility for service redesign said:
Clearly the PRISMATIC tool is of great interest to me in terms of how that can support redesign in the
community . . . if you start to understand what it is that determines risk, you then see where you’re
going to have the biggest impact, and where you need to direct your resources.
Respondent 1, focus group E
A number of respondents talked about the potential role of PRISM in supporting patients’ self-care and
self-management, and ‘explaining to them how that [risk score] can shift’ (respondent 1, focus group E).
Self-management was seen as something which would in itself need support services:
It’s about – it’s more than just managing the condition as well. It’s getting them to take ownership.
It’s about promoting their health and their self-preservation skills and that kind of thing. And it’s
developing that into the services and the teams that we plan.
Respondent 3, focus group E
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Respondents identified scope for PRISM to support strategic service development and management in
further ways. The first way was to measure the effectiveness of service change – instead of waiting to
see impact on admissions, see what change there is in risk scores. A second way would be to support
workforce modelling as part of service redesign. Third, respondents talked about the potential for using
PRISM as a way of benchmarking within a network:
[If] you can start to see maybe some networks, maybe some practices, have got these much higher risks
then – and then you try and work out why. Why is it they’re different? You can then target the education
to them, and so it sort of helps with that, as well as resources per se – it’s about education too.
Respondent 1, focus group E
There was an acknowledgement, though, that if the tool were seen as part of a performance
management regime, this could create resistance to its adoption in practices. In terms of the work of
putting PRISM into practice, respondents felt that practices were likely to vary greatly in their enthusiasm,
and that peer-to-peer influence would be helpful, particularly through the practice networks.
Views of general practitioners and practice staff on the Predictive RIsk
Stratification Model risk prediction tool
We now present the views of GPs and practice staff from data collected both before they had access to
the PRISM tool and while it was available for use in their practices (mid-trial and end-of-trial fieldwork).
To understand how these potential users perceived the technology and implemented it within their
health-care practice, we present findings in line with the theoretical framework offered by NPT. Table 38
presents a summary of key findings in relation to the four components of NPT, which we then expand on
in the text which follows.
TABLE 38 Summary of findings from interviews with general practice staff
NPT component
Questions to consider within the
NPT framework
Findings from interviews with GPs using
PRISMATIC
Coherence (i.e. meaning and
sense-making by participants)
Is the intervention easy to describe? GPs found the PRISM tool easy to understand
because they recognised the principles of risk
prediction
Is it clearly distinct from other
interventions?
PRISM predicted risk resulting from health and
social factors in contrast to condition-specific
risk tools
Does it have a clear purpose for all
relevant participants?
GPs and managerial staff recognised the
potential value of a formal, systematic process
for assessing patients’ risks alongside clinical
expertise
What benefits will the intervention
bring and to whom?
PRISM could complement current clinical
practice and intuitive risk assessments and
identify patients for case management
Are these benefits likely to be valued
by potential participants?
It could be a useful systematic contribution to
case-finding and identify patients at high risk
of emergency admissions, in line with policy
imperatives
Will it fit with the overall goals and
activity of the organisation?
The PRISM tool was perceived to fit within
local and national priorities to implement case
management, reduce unplanned health
demands and encourage self-management by
patients
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TABLE 38 Summary of findings from interviews with general practice staff (continued )
NPT component
Questions to consider within the
NPT framework
Findings from interviews with GPs using
PRISMATIC
Cognitive participation (i.e.
commitment and engagement
by participants)
Are target user groups likely to think
it is relevant and usable?
GPs found that PRISM was very relevant in
helping complete QOF requirements
Will they see the point of the
intervention easily?
PRISM could add to clinical judgement, was in
line with the emphasis on proactive care and
generally seemed to provide accurate data
What affects their willingness to
invest time, energy and work in it?
Protected time and financial incentives
encouraged GPs to use PRISM within routine
practice. Competing demands on time and
resources and technical problems limited their
willingness to use PRISM
Collective action (i.e. the work
participants do to make the
intervention function)
Will staff require extensive training
before they can use it?
Training provided practical information on
using PRISM. Ideas about how to use the data
in patient care came from focus groups, their
own aims or QOF
How will the intervention affect the
work of user groups?
GPs felt that PRISM helped them complete the
tasks required by QOF. Other use was
infrequent and inconsistent across GPs
Will it promote or impede their
work?
PRISM was easy to use, but technical problems
limited quick and regular access
How will use of the intervention be
divided among users?
The lead GP in each practice was the main
PRISM user and provided information for
discussion at multidisciplinary meetings
What effect will it have on
responding to patients’ needs?
GPs described four types of actions to respond
to patient needs:
1. reviewing care
2. promoting self-management
3. addressing non-medical needs
4. changing treatment and care
Reflexive monitoring (i.e.
participants reflect on or
appraise the intervention)
Will it be clear what effects the
intervention has had?
GPs were unsure of effects on emergency
admissions
Is it likely to be perceived as
advantageous for patients or staff?
PRISM raised GPs awareness of high-risk
patients. It was difficult to fit use of PRISM
into the reactive structure of practices
How are users likely to perceive the
intervention once it has been in use
for a while?
PRISM was not used in practices after the
completion of the QOF process
Can users/staff contribute feedback
about the intervention once it is in
use?
Lack of time and treatment options for
high-risk patients limited use of PRISM
Can the intervention be adapted or
improved on the basis of experience?
Respondents identified technical changes to
make PRISM more usable
Adapted from Murray E, Treweek S, Pope C, MacFarlane A, Ballini L, Dowrick C, et al. Normalisation process theory: a
framework for developing, evaluating and implementing complex interventions. BMC Med 2010;8:63.77 This article is
published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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Understandings and expectations of the Predictive RIsk Stratification Model tool
In this section, we describe how respondents discussed what they understood PRISM to be before they
started to use it, and how it offered something distinct from existing practice. These views relate to the
first component of the NPT framework – coherence or making sense of the intervention and are drawn
from the interviews and focus groups conducted at baseline.
The PRISM tool was not seen as something entirely new. Many respondents made a comparison between
the principles and process of PRISM and condition-specific risk prediction tools with which they were
already familiar, such as the Wells’ Criteria (estimating the probability of deep-vein thrombosis or pulmonary
embolism) and Framingham Risk Score (cardiovascular risk). Views varied on whether or not the PRISM
technology would be more accurate than the GPs’ own judgement. Although they strongly defended their
clinical expertise and patient knowledge, some respondents recognised that a formal and systematic
process could complement current clinical practice, including the ‘intuitive risk assessments’ (GP30base,
focus group D) they routinely carried out. Most agreed that risk scores needed to be interpreted by GPs,
informed by their knowledge of individual patient situations. It was also observed that the tool could
provide a technological rationalisation or justification for clinical decision-making:
We can always refer back to that tool that ‘this is the scoring system, that was the reason I admitted
this patient or they did not need admission’.
GP25base, focus group B
The dominant view was that PRISM was a potentially useful technological contribution to case-finding as
part of the current trend in general practice towards identifying individuals for case management, through
a more proactive, rather than reactive, model of care:
We want a systematic way rather than just seeing people opportunistically because they are ill, we
want to get there before they’re ill and on the point of going into hospital. We want to do it in a
more orderly manner.
GP30base, focus group D
Many respondents described the potential of PRISM in supporting policy imperatives to prevent admissions
– ‘something that we’re very much being pressured to do’ (GP16base, interview) – whereas at the same
time enabling practices to meet contractual and reporting responsibilities. PRISM was seen as being able to
help with the identification of patients at high risk of emergency admission, so that home-based nursing
care could be provided through a community support team:
That’s how I would go about it, you see, identifying the patients that may have a problem, put in
place, or mobilise forces that might be able to go in, and help a little bit – you know, if somebody has
a chest infection and they’re having difficulty in breathing, they’re in need of – intravenous antibiotics,
the [community support] team can do that at home – she doesn’t have to go in.
GP09base, interview
However, a range of reservations was expressed by many of the respondents. One was that, although the
tool might be able to identify patients at risk, its purpose would be limited in that it would not necessarily
be telling practice staff anything they did not already know:
I suppose, one of the overwhelming senses, was that if somebody were to give us a list of our top 100
patients, we’d say, ‘Well, yeah, you know, we already know about them.’ . . . We felt that the chance
of this churning out unexpected patients was probably pretty low.
GP15base, interview
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The second reservation was that, though patients may be identified as high risk, it was not necessarily
possible to do anything to mitigate that risk:
The idea is that you can predict who they are and you can do something about it, so they don’t need
to be going into hospital. And that sort of assumes lots of things, really. I mean, it assumes first of all
that you can predict it, but secondly it presumes that some of these things are modifiable.
GP15base, interview
There were also concerns that resources might not be available to meet any identified needs. If these were
not available, then the scope for PRISM to make a difference would be limited:
We have to have a system in place, where there is an alternative . . . if there’s no alternative, then all
of our GPs, all we’re gonna do is just say ‘admit, admit, admit’.
GP11base, interview
Respondents described how being unable to respond to identified needs would be likely to create
frustration among clinicians and disappointment among patients. There were also, among a minority of
respondents, anxieties about implications in terms of performance management, if practices were to
identify needs but then fail to respond to them:
So, if your patient has a certain level of risk, in the top 5% . . . and you haven’t [been able] to get
them lower . . . that’s my worry, because it’ll be like a stick to beat you.
GP12base, focus group C
Though the function of PRISM was generally identified as being individual case finding, a minority of
respondents recognised a potential role in service planning. They saw PRISM as an opportunity to
demonstrate how to improve community services by highlighting patients’ unmet needs:
If this helps us define and gives evidence to what we need, that’s where I see it coming from.
GP13base, focus group C
In interviews and focus groups, most respondents reflected on PRISM from an individual perspective, rather
than reporting any collective viewpoint in their practice. However, a minority of respondents did report on
discussions with colleagues about PRISM, with GPs saying that they had persuaded partners, and some
PMs that they had convinced GPs, to take the opportunity to try the technology and they described plans
for working together with other practice staff to bring PRISM into use:
We’ll involve the whole practice. We’ll involve the nurses – the clinical side, isn’t it? And we’ll have a
look at it in clinical meetings, which we have in any case, and we’ll go from there, I think.
GP01base, interview
It wouldn’t be everybody using it, but I think as long as we’ve got a doctor on-board . . . I’m there,
and then it’s the nurse – a small group . . . Sometimes if you get too many people involved, nothing
gets done.
PM07base, focus group A
However, more often there was a sense that there was no coherent interest in PRISM across the practice,
with some individuals being more inclined to use it than others. There was an acknowledgement that it
might not be easy to persuade colleagues to use PRISM, because it could be seen as bringing additional
work, in a context where clinicians already felt fully stretched:
We struggle at the moment anyway – everybody’s the same with time, with clinics, scripts, mail –
everything. After all of this there’s not much time to put in.
PM04base, focus group C
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As well as concerns about the work involved in implementing PRISM (learning how to use it, logging on,
running searches), there were some concerns about the additional work which might come from needing
to actively case manage any patients identified.
General practitioners and practice staff showed a willingness and open-mindedness about trying the PRISM
risk prediction tool as a way to move away from current practices that were seen as unsustainable, a case
of ‘trying to keep our head above water’ (GP18base, focus group B). However, there was consensus
among respondents that PRISM’s value was not as a tool in isolation, but as a way of identifying people
for referral to community services or resources.
Commitment and engagement with the Predictive RIsk Stratification Model by general
practice staff
In this section, we explore respondents’ initial reactions to PRISM, formed as they started to use the tool.
These relate to how context affected the process of introducing it in practices, the perceived relevance of
PRISM and the willingness of GP practice staff to use the tool. This links to the cognitive participation
component of the NPT framework (see Table 31). The data are drawn from the interviews and focus
groups conducted at the mid-point of the trial and the end of the trial period.
During the early period of the PRISMATIC trial, GPs were offered incentive payments through the QOF for
2013–14, which required them to identify 0.5% of patients at risk of emergency admissions and prepare
individual case management plans.31 This provided participating GPs with a particular structure and
purpose for using PRISM.
Perceived relevance and value of the Predictive RIsk Stratification Model to general practices
General practitioners said they understood the relevance of PRISM to delivering proactive care tailored to
reduce patients’ risks. As practices entered the QOF-reporting period, when they were required to review
patients at high risk of emergency admissions, the PRISM tool appeared to gain a new relevance related to
the QOF task. The wider potential of emergency admissions risk stratification tended to be overshadowed
as GPs and PMs focused on the immediate requirements of QOF and how PRISM helped to meet these:
I think that’s the main negative I would have for you, is that QOF has interfered, I would say, with the
study, because it made us use it for QOF and we’ve, essentially, not done anything with it otherwise.
GP03mid
In interviews at the end of the study, some respondents reflected that they realised the relevance of PRISM
to general practice because QOF had given them an opportunity to see the tool in action. Ideas for how to
use PRISM included reviewing different patient groups, such as those with lower-risk scores who could
improve self-management, or to identify patients who missed routine health checks. However, respondents
said that the annual rhythm of contractual requirements meant they had prioritised tasks that were linked
to financial payments and then moved onto ‘the next hoop they’re making you jump through’ (GP17end).
As a result of a changed context, they had not ‘capitalised’ (GP19end) on PRISM or used it within regular
practice since the QOF contract ended, for which several respondents apologised.
In general, respondents said that PRISM appeared to provide accurate data and, overall, GPs had
confidence in it. However, some respondents questioned its value as, they believed, it identified patients
whom they already knew to be high risk, based on their own clinical judgement, whereas others reported
that it could be some months out of date or appear to give illogical scores for some patients:
When we were doing the QOF stuff, we did use the tool and people felt it identified people that we
knew already, who were already had every input we could think of.
GP17end
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. . . there were some patients in those higher risk categories that weren’t obvious and were surprising.
But then when you look back at the actual data that generates the risk profile, you think: well that’s
spurious . . . and then it depends on the accuracy of the coding from the episode in hospital which,
obviously, isn’t accurate.
GP14mid
Though many high-risk patients were already known, most respondents also said the tool highlighted
some patients they would not normally consider high risk. These included people with addictions, homeless
people, housebound patients not regularly attended by practice staff, and children with life-threatening
illnesses, who could not easily be treated in primary care. They also agreed that PRISM could usefully
alert them to lower-risk patients who were not routinely seen and who were potentially amenable to
interventions to prevent their health deteriorating:
Those at high risk, they’d be known to us, those in the middle bracket were the kind of patients that
you were possibly able to help more.
PM02end
In this way, they said, it could add value to GPs’ clinical expertise by replacing some guesswork
with insight:
It gave you more of the structured and focused sort of target of what you could try to do to improve
things with some sort of feeling like there was evidence of that, it was an area that might be
beneficial rather than it being a bit more than guesswork.
GP13end
PRISM has shown that you can reasonably intelligently interpret and allocate points for ailments and
rank patients . . . I have never seen that done in anything else except the GP’s mind.
GP10end
Willingness to engage with the Predictive RIsk Stratification Model
The willingness and speed with which respondents used PRISM once it was introduced in the practice
varied according to their personal motivations and awareness of QOF. Proximity of the QOF deadline was
likely to prompt immediate use. Those practices that received PRISM early in the roll-out were not under
immediate pressure to fulfil the QOF requirements, and some respondents reported taking an exploratory
approach to their first use. In contrast, practices that gained access to PRISM nearer the deadline for
completing QOF tasks took a more focused and less exploratory approach to using PRISM:
. . . within the first couple of weeks of having it, and we all sat down and we went through the ones
who were on the top – sort of the top 30 so to speak, and just went through what we thought about
it and what interventions we thought might work. So it was more of a – without any plan, we just
discussed it.
GP06mid
We did it straight away, because the QOF timetable really meant that we had to have the reviews
done by the April, and ready for QOF . . . And so we thought: We’d better crack on and deal with it
. . . And that’s the main use we’ve had from [PRISM], actually, is identifying the people for the QOF
part of the risk profiling.
GP03mid
I think it’s kind of been hijacked really by the QOF requiring us to do certain things and so we’ve
tended to sort of focus on what the QOF requirements were, really, you know, for the first couple of
months, particularly, as it actually had to be done.
GP17mid
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Even those who had hoped to use the tool more broadly ended up taking a narrow approach as the QOF
requirements took priority over other practice activity:
What we hoped to do is not what actually happened. So, the idea was that we would do the review
and it would be with practice nurses right the way through to, possibly, even the district nurses . . .
what we did in the end was, me and the other three partners went through the patients and argued
the toss, basically, about it. We tried to discuss a few of them with the district nurses at the end of a
palliative care meeting . . . But it wasn’t within that original meeting, it was done over the new
few weeks.
GP06end
The winter months were described as being a particularly difficult time to implement a new system
because of workload.
Making the Predictive RIsk Stratification Model work: how general practice staff used
the Predictive RIsk Stratification Model
In this section, we explore how respondents used PRISM in every day practice. In terms of NPT, this section
considers the collective action required by participants to make PRISM function within general practice.
We draw on data from the interviews and focus groups conducted mid-trial and at the end.
Training staff to use the Predictive RIsk Stratification Model
Predictive RIsk Stratification Model was introduced to each practice in a training session for the GPs and
PMs who would be using the tool. Respondents reported that the training session had been useful. The
tool was straightforward to use and worked as they expected:
I suppose I’m fairly computer literate anyway, so I do pick up on the computer very- fairly easily,
and it’s . . . just a logical programme, if you ask me.
GP03mid
I mean at the end of the day, I think the website gives me what I was told to expect, really, was that it
would give me risk scores for people and stratify them and show them on pages, and that’s sort of
what it did.
GP15mid
The training focused on the practical aspects of accessing the PRISM data. Respondents said their ideas
about how to put risk score data to use came from the focus groups that some participants had attended
early in the study, from participants’ own aims or the QOF requirements:
. . . we only really wanted to know what we needed to know, to do the piece of work that we were
gonna get judged on.
GP32mid
Usability of the Predictive RIsk Stratification Model
Respondents said they had found the PRISM tool easy and intuitive to use. They said it was ‘straightforward’
(GP02end), ‘user-friendly’ (GP06end), ‘made sense’ (GP08end), ‘very organised, very matter of fact’
(GP10end) and the filtering options were ‘very good’ (GP02end). However, several GPs had experienced
technical problems with the system crashing or locking, or passwords not working; in some cases, slow local
broadband speeds and big practice lists prevented them quickly accessing and interrogating data. One GP’s
effort to access the technical help desk was ‘a nightmare’ (GP18end). With only small periods of available
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time to use PRISM between other responsibilities, respondents said that it was vital to have guaranteed
quick access. One GP explained his frustration when he tried to obtain some risk scores:
So here you are, flying out with the speed of light and thinking, well, okay, I’ll just get those . . . and
download it. Right, where’s my log-in number? And I found it and logged on and – it froze. And it
froze one time with [PM] as well so what she did was take a screen print . . . the truth is that cannot
happen. That is anathema to general practice. You have no time to breathe, so if it’s going to work,
this has got to be so robust.
GP05end
General practitioners who looked at data frequently reported that the system could be out of date. Many
were also frustrated that the risk scores and patient data were not interlinked with the clinical information
on practice information systems so they had to toggle between screens and programs or print data and
make manual comparisons.
How the Predictive RIsk Stratification Model affected the work of general practitioners
All respondents reported that they used PRISM to identify patients at high risk of emergency admissions in
order to fulfil the QOF requirements. They focused on the top PRISM tier using the tool to generate a list
of patients from which they selected a percentage for review:
It was fantastic because we were able to pick out the patients that the local health board had
highlighted, for the QOF thing.
GP11end
During the QOF work, we did use PRISM to help inform out meetings, to understand what happened
to the 52 patients that we looked at, used it as a base for discussions with other team members that
attended meetings. . . . and we did do these with care planning around those individuals, mostly by
house visits from the relevant GPs, so spread the work between us.
GP08end
We used it to pull off all the data that was necessary for the QOF.
GP18mid
In most cases, the lead GP or (less often) the PM looked at the PRISM data on screen, saved information in
an electronic spreadsheet or printed off lists, logging on very few times in order to acquire the information,
and did not filter patients in the top tier. However, others reported that they had used PRISM more
frequently and creatively. A small number who had more time before completing the QOF report, explained
how they explored patient data within the PRISM tool, to understand why some patients had high scores or
to review certain patient groups. One GP said that he had used PRISM on about 10 occasions during the
first 3 months to gather information to inform his practice:
I’ve gone back in to look at some of the patients . . . and why they’re risky. So, I sort of go back into
it, and sort of say, ‘well, I’ve got this patient to see,’ and I’ll sometime go back in and sort of look at
what PRISM’s identifying the risk to be so that when I go and do a review I can put that in context.
GP08mid
Another GP filtered high-risk patients to identify those with COPD in the top tier and COPD patients with
rising risk scores in the next tier down, plus elderly people likely to have social needs in those two tiers:
We changed tack a little bit. And we tried to focus in on specifics and we also tried to focus in on
those that were climbing. So, we identified anyone with an arrow meaning their risk had gone up
since last time and we tried to pin those down and do a chronic disease review on them.
GP06end
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Some GPs expressed disappointment at the information that PRISM provided and were uncertain about
how they could use it:
What I wanted, for instance was to download my 53 patients and download the information that
would allow me to work out why they’re on that list, in terms of what chronic diseases did they have,
and how many hospital admissions had they had, and how many drugs were they on, and so on . . .
And it really disappointed me that a lot of that I had to do manually.
GP15mid
Respondents reported that involvement with PRISM usually fell to a single individual within the practice,
who would then disseminate the information to others at practice or multidisciplinary meetings.
Respondents reported that they shared the PRISM information (patient lists with risk scores) within the
practice through routine practice meetings. Some respondents, particularly from practices that received
PRISM closer to the QOF deadline, said that they divided the list of high-risk patients among the partners
and worked individually:
We had another meeting then, to just discuss the patients who we were going to see. Some of us, I
think, well, sort of chose patients that perhaps we knew already, which perhaps wasn’t the ideal thing
to do, really, you know . . . it was more trying to meet the requirements of the QOF, rather than get a
meaningful outcome from it, I think.
GP17mid
I allocated people to different clinicians . . . I said ‘right you can have diabetes you can have COPD, you
can have asthma, or whatever’ and then I looked at the rest of them and there were something like
12 or 14, you know, who didn’t fit into any of these, who were odd ones really, and we just sort of
divvied these out . . . I mean, you can’t review 53 patients collectively.
GP15mid
In most practices, few staff other than those taking the lead on PRISM were reported as making direct use
of PRISM. Lack of interest, on top of demands on GPs’ time and difficulties incorporating the PRISM
information into practice routine, meant that respondents were not able to make widespread changes to
the way practices functioned. Several of the practices were short of GPs because of illness, retirement or
maternity leave. Some were planning to close or merge. Respondents were concerned that other practice
staff did not have the capacity or skills to take on more patients and also reported cuts in community
services and outpatient clinics. Many respondents reported in the end of study interviews that they had not
accessed the PRISM data after practices completed and submitted their QOF reports. A small number of
respondents said they had planned to keep using PRISM, but technical problems or lack of time meant
they were no longer using it. Only two practices reported that they were still using PRISM at the time of
the end-of-trial interviews.
How the Predictive RIsk Stratification Model affected the way general practitioners
responded to patient needs
General practitioners said that the QOF process encouraged them to intervene with identified high-risk
patients. They made an effort to respond with different or additional activities for the small percentage of
at-risk patients they selected from the top PRISM tier.
Respondents described types of actions that they took in response to a patient’s high-risk score. All
respondents reported carrying out an extra level of review and care to fine-tune the existing treatments
that these high-risk patients already received. They contacted many patients, paying a house call, inviting
them into surgery for a check-up or telephoning to see if anything was needed for ‘optimisation in their
treatment’ (GP31end), for example updating blood tests, bringing forward annual check-ups or making a
referral to outpatient clinics or nursing teams. However, they were concerned that teams did not have the
resources to respond to more activity and questioned whether or not patients were actually followed up:
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I think QOF work highlighted our lack of support in managing these individuals. So, although they did
have medical case review, that didn’t really generate much extra activity, particularly almost no
response from district nursing. So, consequently, the work had a fairly negative impact.
GP08end
In other instances, GPs felt that patients were already optimally managed and they used the contact to
provide reassurance:
Some of them we were doing everything we could and it was just telling them that we were as well.
GP03end
Some practices used the opportunity to inform patients about ways to better self-manage. Two practices
(10 and 11) identified frequent ED attenders and discussed, with patients and family members, other ways
of managing crises. Practice 19 asked the nurse to talk with patients about issues such as identifying
infections, weight management and spotting early warning signs:
We got these patients and tried to (take) more time in educating them . . . you teach them what to
do, how to identify a source of infection . . . with heart failure, exactly how to understand, keep
weighing themselves if they’re getting weight, more short of breath.
GP19end
Some GPs focused on non-medical needs which could reduce the chances of a patient deteriorating, by
referring patients to other care agencies and encouraging families to self-refer. However, they admitted
that it was difficult to engage other services, especially if the care was preventative rather than reactive:
. . . we would sit down, me, the PM, the district nurses, the midwives if necessary and the health
worker if necessary and we’d discuss the more difficult patients . . . highlight the problems that were
there or the potential problems . . . so that they were aware if we started running into problems and
we’d phone one of them.
GP11end
I’ve tried to involve social services or the CIIS [Community Integrated Intermediate Care Service] team
or packages of care and things to be put in place sooner rather than waiting for the crisis . . . start the
ball rolling earlier rather than leaving it 6 months down the line and them needing urgent respite
or something.
GP13end
Practice 3 changed arrangements to allow high-risk patients to always see the GP of their choice and
flagged this arrangement on their notes and for receptionists to see when arranging appointments, so
patients received continuity of care. Practice 6 made up emergency drug, steroid and antibiotic packs for
identified patients to use at weekends and bank holidays if they felt their health was deteriorating.
Practice 2 was able to modify a patient’s treatment following discussion at a multidisciplinary meeting:
It wasn’t until we discussed it with everybody in the room . . . so you had nurses saying ‘Oh yes, she’s
terrible, she doesn’t take any of her medications after 10 o’clock in the morning’. And the GPs went,
‘well, nobody’s told us’. So we can structure that and do it, so rather than twice daily medication, give
her once daily medication and solve the problem.
GP02mid
Just one GP, from practice 5, said that he did nothing above normal care and described the process as
‘an exercise in form filling’ (GP05end).
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Reflections on the Predictive RIsk Stratification Model by general practice staff
Respondents were invited to reflect on the PRISM tool and their experiences of using it, including how it
affected patients and their practices.
Perceived effects on emergency admissions and emergency department attendances
General practitioners thought it unlikely that using PRISM had any effect on emergency admissions and ED
attendances. There was a widespread feeling that admissions initiated by GPs were already low and could
therefore not be much reduced.
There are odd occasions where you were able to proactively help somebody or put a plan in place to
stop them being admitted to hospital. I think it’s a fallacy to think that you could reduce emergency
admissions from primary care because the primary care admissions are so small. The vast majority of
admissions to hospital go through A&E . . . as a practice, our admission rate is 0.8% . . . one case a
week, if that.
GP02end
I have seen cases where you try and get involved and actually you’re referring more, treating more and
more medication and then ending up using more resources, maybe appropriately, maybe not. But the
evidence isn’t there as yet, that I’ve seen, that doing a lot of things early on, whether that makes
much of a difference long term or not.
GP31end
Media coverage already made GPs very aware that they should not use emergency services inappropriately.
Although they acknowledged that primary care ‘was set up to be reactive’ (GP08end), they seemed very
concerned to use resources appropriately and carefully:
You think about it all the time, even if you’re in an out-of-hours setting and the budget isn’t yours,
and when you’re prescribing a drug, that the thing that’s at the back of the mind is the money, how
much of the resources are you using?
GP11end
However, some respondents could identify instances where an emergency admission may have been
avoided and the two GPs who each targeted a patient with frequent ED attendance reported that those
patients’ use of 999 services had fallen. Only one GP suggested that the PRISM reviewing may have been
associated with increased hospital admissions:
We did bring in a certain number of people and do care plans with them and then we ended up
admitting them because we’d seen them and they looked unwell.
GP31end
Effects on general practitioners and the way they worked
The majority of respondents described how PRISM changed their awareness of high-risk patients and
increased their contact with some of this group while they were undertaking QOF tasks in order to
reassure themselves that everything was being done to prevent a possible crisis:
It [a high risk score] does have an effect of making you sit up and think ‘bloomin’ heck, what’s he
doing up?
GP05end
We’d sit down and discuss the odd patient or so that were highlighted and see whether we could
improve things for them . . . see whether we could do something about it.
GP11end
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General practitioners reported that because the activity was tied to their contract, they were incentivised to
spend time on this work. They carried out a number of house calls, telephone contacts or extra appointments
themselves. They also coordinated care to involve other practitioners or clinicians:
Made some clinicians aware of them, initiated home visits, changes to medications, getting other
people involved in their care.
PM02end
Reviewing high-risk patients also resulted in additional work because the process meant they identified
unmet need that they then had to address:
You’re trying to be focused but actually what you’re actually doing is picking up people for
other reasons.
GP06end
You spent some time looking at their records, and it was then communicating to them what changes
if any were needed to be made and double checking then that everything was as we thought it was
and monitoring their blood pressure and things like that . . . I think it probably was more than we
needed to do.
GP03end
It did throw up quite a few surprises, some additional potential work that we weren’t addressing . . .
some of those are the people that would admit themselves and bypass us.
GP08end
They also understood that their actions, by giving patients extra attention, could increase a patient’s
risk score:
The very fact that we were seeing these patients . . . resulted in a flurry of referrals on their record that
put their risk higher . . . it will initially look like higher levels of risk by doing whatever interventions
we’ve done, put these patients at more risk really (is) how it would appear.
GP03end
Some respondents were more proactive with patients, and this raised their confidence and pride in their
work. The GP from practice 17 said that she encouraged her patients to engage with her and the available
services in order to prevent health crises:
More awareness of the benefits of getting people to engage with the chronic disease clinics and more
awareness of being proactive with managing people’s ongoing conditions in the consultation . . .
I think it makes me feel like I’m a better doctor for doing it.
GP17end
The GP from practice 6 said that using PRISM had broadened his perspective when treating patients and
described how he would review a patient whose risk score had risen:
You can’t do anything about an admission that’s already happened but it gives you an idea of where
your efforts are best suited . . . you can’t change that management with that patient. Everything
you’re doing is what you’re already doing, but you can see if somebody else has an intervention . . .
we might need to optimise their COPD care or their diabetic care, that’s what’s going to make the
difference with that patient.
GP06end
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Some GPs were concerned that they were focusing on a small number of patients, usually known to the
practice, when other patients may also need the same attention.
I thought I’d be using PRISM for the people who aren’t coming in, who have got those risks and
we’re not seeing them . . . so far we haven’t done that. Because, as I say, time meant we had to do
this particular 100 so we’ve not done anybody else yet.
GP03mid
Everyone knows their sickest patients, not everyone knows their third or fourth sickest patients and I
think that’s probably where it [PRISM] will become useful. I’ll be honest, we haven’t tackled that yet,
probably because it seems a bit complicated.
GPmid06
Most respondents agreed that it would be most useful to study and intervene with patients from lower-risk
tiers because it was possible to prevent health deterioration. However, the QOF requirements had not
included this and no respondents reported that they intervened with any of these patients. They also felt
that taking this approach would require too much time:
Those in the middle bracket were the kind of patients that you were possibly able to help more than
those . . . in the higher echelons that were already having all the input that was available. But it was
the ones in the next cohort down which might have been more useful because you can actually put in
things that will stop them from going up the pyramid.
GP02end
It’s the second tier down where we might be able to make a difference. The way that we were
required to do the QOF data meant that we had to use the highest risk group so I don’t think we got
the best out of it that we could’ve done because that top risk group we knew all the names . . . and
were already doing all we could for them. Unfortunately we haven’t had the time to look at the
people in the groups further down.
GP03end
Effects on general practitioner interaction with patients
General practitioners reflected on the effect that PRISM had on their interaction with patients, particularly
those in the highest risk group, even when no new interventions were available. Several respondents
thought that the increased GP–patient interaction could have been beneficial, regardless of the medical
interventions delivered:
I think the experience from the patient, when we actually popped in to see them, they actually liked
that, that we were actively going to see them . . . I can see there is a patient need around this. It’s just
whether it’s deliverable at the moment.
GP08end
Was it just that we were being particularly caring this year?
GP32end
Although GPs did not generally tell patients about PRISM or share the risk score, they used opportunities
to tailor self-management advice. However, they were careful not to alarm and precipitate self-referrals:
It [risk score] wasn’t directly volunteered. It was just a ‘we think that this would perhaps stop you
needing to go in this year, we’re hoping that this will stop you needing to go to hospital’ . . . they
don’t understand the difference between high risk of admission and high risk of being ill. They think
STAKEHOLDER VIEWS: THE PREDICTIVE RISK STRATIFICATION MODEL IMPLEMENTATION AND USE
NIHR Journals Library www.journalslibrary.nihr.ac.uk
90
that’s the same thing. So their use of the health service right the way from just telephone advice
through to rocking up at out-of-hours or A&E would go up.
GP06end
Several respondents questioned how far their actions did, or could, benefit patients when the process was
constrained by the QOF framework and limited by availability of resources:
There will have been people who were reviewed or assessed who otherwise wouldn’t have been, but
whether this translates into change in outcomes is a separate issue.
GP14end
Facilitators and barriers affecting use of the Predictive RIsk Stratification Model
Respondents said that lack of time was the single most important limitation on use of PRISM. Respondents
said they felt ‘overloaded . . . and burnt out’ (GP02end), ‘running so fast (we) can’t take a step off’
(GP32end) and ‘crisis-driven’ (GP18end):
We’re fire fighting and trying to get that switch, between fire fighting and more proactive care is
challenging because we’ve got too many fires to fight.
GP08end
They welcomed the principle of risk prediction using PRISM, but felt that it was unrealistic to work this way
without extra resources to support changed practice. They had been able to use PRISM through the QOF
system because it provided funding for more GP hours, which released them from the imperative of the
appointment schedule:
Having the money enabled us to spend the time that was needed to meet together and discuss
everything and go through the notes individually, contact the patients, do a management plan . . .
GP17end
However, this meant that most respondents could not see any way of using PRISM other than how it had
been used to complete the QOF tasks. Some recognised that potential benefits had not been properly
explored and considered and that ‘it was sad because it wasn’t done very well’ (GP05end). However,
all respondents came to the conclusion that continuing to use the PRISM risk prediction tool was not a
realistic way for them to practise:
You know, if it makes my day easier and its safer and improves patients’ health, then I’m happy to use
it. But I haven’t the time to go looking in depth without, you know, having some protected time.
GP10mid
In a perfect world, PRISM would be great. At the moment we are like a swan, frantically trying to
keep afloat.
GP02end
Many respondents also highlighted the very limited range of available treatment options to support
high-risk patients. They were disappointed that the intervention did not include additional services or
skilled staff to support care and enhance treatment for patients. Consequently, they felt deterred from
using the tool because it had little value unless they could access extra services to support identified
patients. GPs said that nurses were already working at capacity, and other community services provided
reactive not preventative care: all that GPs had currently was ‘access in a crisis’ (GP08end). They identified
that they needed a network of community health and social services to make the system work:
[PRISM] is a tool we’re going to use but there’s nothing that we can actually then do with what we
find out, other than us. So no other service linked to it. No add-on when things are so stretched
DOI: 10.3310/hsdr06010 HEALTH SERVICES AND DELIVERY RESEARCH 2018 VOL. 6 NO. 1
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snooks et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
91
already. And I can remember it taking me a little while to [understand] because I thought, I really
thought I was missing something.
GP13end
You think ‘right, OK, I need to get the CRT team into that one’, you ring them up and you get
‘I’m awfully sorry we’re booked up for 2 days’. And that’s an issue because (a) it’s a waste of my time
and that took a precious 10 minutes to get through, and to find the right person, and to have the
conversation, and then to be told it’s 2 days, is useless to me. So then I’ve got to ring the nursing home
back and say ‘they’ve got to go in’, because they’re not drinking now, you know. So the resource that
will prevent the admission, which is what I’m assuming PRISMATIC’s all about, is not there.
GP05mid
Several respondents stated that they were reluctant to invest much of their time in using PRISM while it
was still being trialled:
If there were examples where the amount of effort produced a magnified return, then I would be
quite interested to read that topic. And if you can prove that sitting down with your district nurses to
look at your top – say, let’s filter everybody over the age of 70, who are the top ten over 70, and that
proves, has got proof of reducing admissions, then why should I do that? Why should I spend my time
doing that it if it doesn’t stop me doing something else, if it doesn’t save my time, or if it doesn’t
earn income.
GP10mid
Suggestions for ways to improve the Predictive RIsk Stratification Model tool
Respondents proposed technical changes to enable integration of PRISM into their practice routines. They
wanted a single document with all of a patient’s data, to avoid needing to look at different sets of records
for clinical information, correspondence and PRISM, in order to properly interpret a patient’s risk score and
treatment history. The GP from practice 8 wished he could:
Jump backwards and forwards between patients . . . if it was all real-time as opposed to closer to real
time, I think you’d probably be more aware of what good you were doing and the impact it would
have. And things like secondary calls and sending messages and letters to coordinate care and things
would be much more easy if it was connected to the system, i.e. giving a print out of the reports to
the district nurses and things. It would be a lot easier if it was more seamless between the two.
GP08end
Integrating PRISM with the clinical software was cited as something that would not only make using the
tool easier, but might encourage GPs to use it more frequently:
It has to be that easily accessed, and that might just trigger: oh my goodness, you know, they’ve
fallen and I didn’t realise they had, or whatever other trigger they have on that list.
GP05mid
Views of a health service manager on the Predictive RIsk Stratification
Model risk tool: at the end point of the trial
At the end of the implementation period, we interviewed a senior manager in ABM UHB with a strategic
role for governance and operational issues for the professional side of primary care, who also had
oversight of the research and development projects. Although she had high-level responsibility for PRISM
within the health board, she had little capacity for engaging with practices to support its implementation,
but did have close contact with the research team, including the GP champions, and with clinical directors
working at local level.
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The manager reflected on the implementation and impact of PRISM during the PRISMATIC study. Her
perception was that PRISM had a limited impact on practice, though it had helped some GPs to identify
hitherto unknown people at risk, particularly younger people with alcohol problems. She saw the adoption
of PRISM into general practice as being inhibited by the fact that it was seen as additional work, and not
as something which would be of immediate help to them. She also believed that the tool had proved
‘clunky’ in use, with the disadvantage that:
. . . it wasn’t embedded in the GP system . . . so, if they were in the middle of a busy clinic, a surgery,
and a patient came in and they wanted to know what risks they were at . . . they would’ve had to
have closed down their current system and then opened PRISM . . . So, they weren’t gonna do that.
She also suggested that PRISM had not been used within ABM UHB to support service planning.
The manager identified a number of contextual issues which developed during the course of the study
period – some at local level, some at national level – which may have influenced implementation. At local
level, the old management structure of three localities was abolished and new clusters of practices were
set up, with GPs:
. . . being expected, within the contract, to look at their population health within their areas, and to
really try to re-design and influence it.
At the same time, there was a loss of GPs and practice nurses from primary care in the local area, many
leaving practice as they reached retirement age, with newly arriving clinicians less inclined to enter into
partnerships, and more likely to opt to be part-time employees. Smaller practices, in particular, were seen
to be struggling to be viable, and there were a number of practice closures. Combined with the increasing
pressures of demand from an ageing population and a health system stretched in both primary and
secondary care, this led to a situation described by the manager as:
. . . an absolute crisis out there. And it’s probably difficult for people who aren’t involved to know just
what a crisis point we’re at . . . we need solutions. So, I mean, this cannot go on as it is.
The Welsh Government set up an Intermediate Care Fund, which supported health boards to develop
community resource teams to provide multidisciplinary support for people at risk of admission. Three of
these teams were established in the ABM UHB area. Though they were seen by the manager as valuable,
the team’s focus was very much on providing interventions to those patients ‘at the tipping point’, that is,
at immediate risk of admission, rather than on working in a longer-term, proactive way.
The introduction and then disappearance of the QOF points associated with identifying high-risk patients
was seen by the manager as encouraging use of the PRISM tool, but only in a very limited way:
I think it did encourage and promote looking at the top 5%, because that’s all they would be paid for
. . . People will just do what they’re paid for . . . and they will not do the extra . . . the criticism of QOF
is that it’s become tick-box, and that GPs just do things to tick a box and to get points, and money,
and that that detracts from a more holistic approach.
The manager was very much aware of the challenges of trying to implement an intervention as part of a
research study, as a strong evidence base was not yet available to justify the intervention, and more
particularly the time needed to support and promote it and to educate people in its use.
I do think that’s partly because we didn’t . . . want to be promoting something we didn’t really – we
weren’t really sure worked . . . if people are expending a lot of energy on something, you want to be
sure it’s evidence-based . . . And it’s a bit of a catch 22.
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Summary of practice staff questionnaires
These findings summarise questionnaire data from general practice staff at intervention practices. Two
rounds of questionnaires were conducted: mid-trial (3–6 months post intervention) for a sample of invited
practices and at the end of the trial (18 months post intervention) for all practices in the study. Participation
in the first round was 9 out of 16 practices, and in the second round 25 out of 32 practices. In the summary
of results that follow, ‘3m’ refers to the mid-trial questionnaire point, and ‘18m’ to the end of the trial.
Text comments include the same numerical practice codes used elsewhere, and confirmation of whether
the comment was received at mid-trial or at the end. Questionnaires were completed by PRISMATIC GP
leads or their delegates (fellow GP or PM).
Training and induction
At the mid-trial point we asked respondents to indicate the usefulness of the training they received on
using PRISM. Seven out of eight respondents to this question found the training useful (six ‘very useful’
and one ‘moderately’). Two-thirds of respondents questioned at the mid-trial point first used PRISM within
1 week of their training.
Reported use of the Predictive RIsk Stratification Model
We asked respondents at the mid-trial point to estimate how many times they had logged into PRISM over
the preceding 3 months (Figure 7). The number of logins reported ranged from zero to 11+, with most
reporting between one and six logins. At the end of the trial we asked respondents to estimate how many
times they had logged into PRISM during the preceding 9 months; once again, most respondents reported
one to six logins (see Figure 7).
We asked respondents at the end of the trial to indicate when they last logged on to the PRISM website.
For over half of respondents, this was over 4 months previously, with 4 of the 14 respondents indicating
that they last used PRISM over 6 months previously. When asked at the end of the trial whether PRISM has
been used more or less over the past 6 months than in the first few months, 9 of 13 (69%) of respondents
reported less use.
The user-reported data are consistent with patterns of logins as recorded by NWIS (see Table 31 and
Figure 8). PRISM logins by registered users at PRISMATIC study practices (NWIS, 2016, personal
communication) below.
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9 months (9m, n= 25).
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Targeting patient groups
We asked respondents to indicate which groups of patients they had reviewed using PRISM (Figure 9). At
both the trial mid-point and at the end, patients in the highest risk groups (3 and 4) were reported as the
most frequent groups of patients reviewed; at the end of the trial, a wider range of patient groups was
reported as being reviewed.
When asked to indicate which one group was most frequently reviewed, respondents at mid-point were
most likely (5/9) to say it was those at level 3 (high risk); at end-point, however, the most commonly cited
group (5/13) was those patients at level 4 (the highest risk group).
Who uses the Predictive RIsk Stratification Model, and how?
We asked respondents at both time points to indicate who in their practice had been using PRISM, and
how (Table 39). Respondents indicated that use is largely by GPs (particularly those leading on PRISM) and
PMs. The most common way for clinicians and PMs to make use of PRISM data was by discussing these in
meetings, including MDT meetings within the practice.
Actions taken after using the Predictive RIsk Stratification Model
We asked respondents what actions were taken in terms of patient care after reviewing the PRISM data;
their responses are shown in Table 40.
At the mid-trial point, respondents reported that GP consultations (including face to face, telephone, home
visit) were the most frequent course of action. At the end of the trial, although GP contacts and referrals
to community providers were still widely reported, the single most frequently reported action for patients
identified through PRISM was the preparation of an active management plan:
What has been beneficial is the concept of the active management plan. I think this concept has come
partly from using the PRISM data and one that we still use. We are hoping to train a nurse to advance
nurse practitioner status to act as a chronic condition practitioner which would massively change the
way we would be able to respond and use PRISM.
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FIGURE 8 Predictive risk stratification model logins by registered users at PRISMATIC study practices (source: NWIS).
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TABLE 39 Who has been using PRISM in your practice and how have they used the information?
Practice staff
Logged in to see
PRISM on screen
Seen PRISM data
on a paper
print-out
Discussed in meetings
(including MDT)
Discussed in
informal meetings
3m 18m 3m 18m 3m 18m 3m 18m
GP leading on PRISM 5 7 4 6 9 12 4 3
Other GPs in your practice 0 3 1 5 8 12 1 2
Practice nurse 0 0 0 1 4 5 0 1
PM 5 6 3 6 9 14 2 4
Other – e.g. district nurse 0 1 0 0 7 6 0 3
Note
‘3m’ refers to the mid-trial questionnaire point and ‘18m’ refers to the end of the trial.
TABLE 40 What actions have you taken after reviewing patients using PRISM?
Action
Time point
3m
(n= 9)
18m
(n= 25)
GP consultation in person 6 14
GP consultation by telephone 5 13
GP consultation by home visit 4 12
Practice nurse appointment 2 8
Chronic conditions clinic in GP practice (e.g. diabetes mellitus, asthma) 3 12
Prepare active management plan 4 15
Communicate with or refer to the district nurse 3 7
Communicate with or refer to the health visitor 2 1
Refer to community nurse or case manager (e.g. respiratory, mental health, chronic conditions) 3 4
Communicate with or refer to mental health services 1 3
Refer to therapist (e.g. physiotherapist, occupational therapist, speech therapist, rehabilitation
therapist)
3 3
Refer to social services 3 4
Refer to an alternative medicine provider 0 2
Refer to voluntary sector (please identify who below) 2 3
Other (please identify who below) 3 2
Not used PRISM 1 Not asked
Have used PRISM, but not yet taken any actions 0 3
Note
‘3m’ refers to the mid-trial questionnaire point and ‘18m’ refers to the end of the trial.
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Two respondents provided particular detail on how PRISM supported care for patients with COPD who
were identified as high risk. The first described using PRISM as a way to initiative contact with specialists –
though challenges remained to finding ways to implement change:
Involved local consultant respiratory physician, as there was a pattern of patients with respiratory
problems appearing in patients on level 4. Sharing of information, plan to possibly meet again to
discuss patients . . . with COPD to try and develop a more collaborative approach to care. Useful
meeting but was not followed up on due to general busyness on both sides.
9, 3m
Patients did seem to value and appreciate the applications of PRISM, e.g. we targeted those with
COPD and implemented self-management plans which included having ‘just in case’ antibiotics
at home.
28, 18m
Issues affecting Predictive RIsk Stratification Model use
We asked respondents at both time points to describe what issues had affected their use of PRISM
(Table 41).
At the mid-trial point, the emphasis from respondents was on technological barriers, such as speed of the
PRISM website, and difficulties with logging in. Although these remained issues in the end-of-trial findings,
demands on time and lack of resources emerged as the most cited issues:
The issue is having dedicated time to analyse the PRISM data and implement the resulting workload.
At present it feels that as a GP we are running to stand still. PRISM may well be helpful, but when the
resources and time are available to implement it within this practice.
22, 18m
Among the ‘other’ issues identified was the technical one of PRISM not being integrated into existing
practice computer systems.
TABLE 41 Has anything affected your use of PRISM in the past (3/18 months)
Factor affecting PRISM use 3m (n= 9) 18m (n= 25)
Lack of clarity about PRISM 1 3
Speed of the website 3 8
Issues with logging in 4 7
Concerns about the accuracy of the PRISM data 0 2
Concerns about data sharing 0 0
Demands on time to access and understand the PRISM data 2 12
Demands on time to respond to the data 3 14
Anxieties about liability 0 0
Concerns that PRISM does not provide new information 0 4
Lack of resources to respond to identified needs 1 15
Staff trained to use PRISM had left practice Not asked 1
Other (please specify below) 3 3
Note
‘3m’ refers to the mid-trial questionnaire point and ‘18m’ refers to the end of the trial.
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The role of the 2012/13 General Medical Services contract
We asked respondents at the end of the trial to describe how, if at all, the 2012/13 GMS contract, which
included QPIs encouraging the use of a risk prediction tool, influenced the use of PRISM in their practice,
and 13 respondents gave free-text responses to this question. Most emphasised the importance of the
contract in encouraging the use of PRISM, with a small number going on to emphasise the value of PRISM
in supporting delivery of this QPI:
A very welcome helpful tool to identify in a systematic way the patients required for this QPI. I am not
sure how easy it would have been to do without the tool.
30, 18m
However, there was also an awareness among some that the contract had been the sole driver of
PRISM use:
I don’t think we would have used PRISM if it was not for the contract.
22, 18m
We used it almost exclusively because of QOF.
15, 18m
Opinions on the Predictive RIsk Stratification Model
We asked respondents at the mid-trial point to indicate how strongly they agreed with a number of
statements relating to how PRISM has changed the way they work (Figure 10).
Almost 90% agreed or strongly agreed that PRISM did a useful job at identifying patients at high risk of
emergency admission, and over 60% agreed that PRISM had enabled respondents to make a change to
the way they worked within the practice.
We asked the same questions at the end of the trial time point (Figure 11).
Agreement that PRISM did a useful job at identifying patients at risk was somewhat lower, at 72%. The
proportion of respondents agreeing or strongly agreeing that PRISM had enabled them to change they
worked had fallen to < 30%. Lack of time to use PRISM was an issue, and few practices agreed that they
were working together as a team to use it.
Future Predictive RIsk Stratification Model use
At the end of the trial, we asked respondents how they expected to use PRISM over the following 6 months;
13 out of 31 responded with free-text answers. There was a range of responses, from those who did not
expect to use it at all, to those who had definite plans:
We will continue to use PRISM to identify patients at risk and patients who should be included in our
palliative register.
23, 18m
We are planning on looking at the data with our chronic conditions nurse to identify patients that
need input.
25, 18m
There was a fairly consistent theme running through responses that future use of PRISM would depend on
time capacity within the practice, and, to a lesser extent, on being able to access resources or support
services to meet identified needs.
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FIGURE 10 Looking back over the past 3 months, what difference has PRISM made to the way you work? (3m, n= 9).
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FIGURE 11 Looking back over the past 9 months, what difference has PRISM made to the way you work? (18m, n= 13).
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Summary of stakeholder views on implementation and use of the
Predictive RIsk Stratification Model
The qualitative component of the study revealed some consistent themes in terms of attitudes to PRISM
across all stakeholder groups. All stakeholder groups seemed to be aware of a lack of certainty about the
intended role and function of PRISM, with its original purpose being identified as supporting service
planning, while later implementation focused on individual case-finding.
General practitioners and practice staff showed a willingness and open-mindedness about trying the PRISM
risk prediction tool as a way to move away from current reactive practice, which was seen as unsustainable.
However, there were concerns expressed – both before implementation and after – by all stakeholder
groups about its ability to support change in patient care without associated investment in new community
services or resources.
Almost all practices that responded to the end-of-trial survey reported that they made some use of PRISM,
although the total number of logins was not high and became less frequent during the course of the
intervention period, with only two practices reporting that they were still using it at the end.
The extent to which PRISM was used varied greatly across practices. A range of ways of using the
PRISM information was reported, with some practices printing off PRISM data (lists) for later discussion.
Generally, patients were discussed in practice meetings (often initiated by QOF requirements), some of
which were attended by staff from other disciplines and organisations. Respondents reported four types
of interventions taken in response to a patient’s high-risk score: (1) fine-tuning existing treatment,
(2) improving self-management skills, (3) trying to address non-medical needs and (4) making changes to
the way that treatment and care was provided.
The introduction of PRISM to general practices coincided with contractual requirements (QOF) to select
0.5% of their practice patients at high risk of emergency hospital admission and prepare case
management plans. The QOF requirement appears to have been a major driver of PRISM use, and also to
have shaped the exact way in which practices used the tool – focusing on those patients in the highest risk
group. After the QOF reporting period ended, use of PRISM appears to have fallen away.
General practitioners cited as barriers to using PRISM: the lack of time to work prospectively; inadequate
referral services; limited internet access; out-of-date data; and the PRISM data not being integrated with
practice records. They said that they needed financial incentives alongside additional community-based
services for identified patients in order to regularly use the tool.
Reflecting on PRISM, GPs reported that they were unsure whether or not using it had any effect on
emergency admissions and ED attendances, but two GPs who each targeted a patient with frequent ED
attendance reported that those patients’ use of 999 services had fallen. Respondents felt that PRISM
changed their awareness of patients and focused them on targeting at-risk patients to reassure themselves
all steps were taken to prevent a possible crisis. All had concentrated on high-risk patients, despite feeling
these were least suitable for proactive management, yet they believed that they had provided more
attention and treatment, which was reassuring to patients.
Strengths and limitations of qualitative strand of study
Strengths
The multiple data collection methods (interviews, focus groups, survey, login information) allowed us to
triangulate findings, which helped interpretation of quantitative findings. Collection of data at different
time points allowed us to track how attitudes to and use of PRISM changed over time.
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Using the NPT framework to interpret interview data enabled us to fully consider the stages and actions
associated with implementing an intervention in a health-care setting to increase our understanding of the
ways they responded in this study.
Limitations
Interviews with policy and health board staff about the story of PRISM took place some years after PRISM
was developed, potentially affecting their memory of events because of the time period and role changes.
In most cases, we talked to only one respondent from participating general practices. This was usually the
GP responsible for leading use of PRISM, and their knowledge and use of PRISM was not always shared by
other staff. In a minority of practices, the PRISM lead GP changed between the three data collection
points, because they retired or moved practice.
We were unable to gather the views of community health staff after the tool was implemented, as most
staff declined to attend a follow-up focus group because their roles had changed. Only one health services
manager agreed to be interviewed at the end of the study.
General practitioners taking part in the PRISMATIC trial volunteered for the study. In interviews, several
identified themselves as interested in, or supportive of, research and wanted to contribute to knowledge
generation by participating. They were therefore likely to be atypical of many GPs and their response to
PRISM may not be that of other members of their profession.
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Chapter 7 Service user involvement
In line with good practice, service user involvement in the PRISMATIC trial was intended from the outsetand throughout. A summary of service user involvement can be found in Table 42.
TABLE 42 Summary of service user involvement in the PRISMATIC trial
Type of
involvement
activity Role Process Comments
Supporting
service user
involvement
Service users were actively
involved across all activities
associated with delivering
the PRISMATIC trial
Information, guidance, honoraria,
expenses and briefing sessions
were provided to facilitate active
involvement
Named individual (BAE) supported
the trial manager (MRK) to ensure
active involvement. In addition,
provided single contact for service
users
Service users recruited through the
SUCCESS group: membership of this
group gave access to mutual support
and a wider service user perspective
Mid-study meeting held to review
involvement and further support
needed
Long time scales enabled strong
relationships across all research
partners
RMG
meetings
Two service users were
invited to be members of
the RMG, and contributed
to all decisions about
managing and undertaking
the study
24 meetings scheduled (2010–16)
Two service users were at almost
all meetings; just one meeting
took place without a service user
member present
One individual remained involved
throughout the study; the second
place was taken by four different
individuals
Individuals received induction before
starting role and were offered
pre-meeting briefings
Service user perspectives were
sought at all stages, especially when
developing patient consent process,
preparing patient information and
questionnaires, holding a prize draw
for questionnaire respondents,
interpreting final results
TSC meetings Two service users were
invited to be members of
the six-person TSC, and
provided independent
study scrutiny and
oversight
Five meetings held (2013–15)
Three out of the five meetings
attended by at least one service
user
Service users received training before
joining the TSC which covered the
role of a TSC and provided
background about the PRISMATIC
trial
Opportunity provided for briefing
before each TSC meeting
Qualitative
analysis and
write-up of
results
One service user was
invited to the qualitative
subcommittee to develop
coding framework and
review drafts of qualitative
results
Two meetings held (2013–14)
Both meetings were attended by
one service user and three
researchers. All contributed to
e-mail discussions following
meetings and reviewed drafts of
the results
continued
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TABLE 42 Summary of service user involvement in the PRISMATIC trial (continued )
Type of
involvement
activity Role Process Comments
Writing events To contribute service user
perspective to all
discussions about
communications and
dissemination
Six meetings held (2012–15)
Two service users were invited to
each meeting: at least one
attended each meeting
Workshop sessions held at two
meetings to consider potential study
outputs for service user audience
Discussions held about how to
describe the PRISMATIC trial service
user involvement in final report
Service users contributed to all
discussions as equal team members
and agreed publications plan
Publicity and
dissemination
Service users contributed to
publicity and dissemination
materials about PRISMATIC
Service users reviewed and
contributed to seven PRISMATIC
newsletters, aimed at participating
GP practices and health services
managers
One service user contributed to
edition 6, writing about her
experience of being involved in
research
One service user contributed to
edition 7, explaining how risk
prediction tools can help patients,
especially those with early-stage
chronic illness who can expect their
condition to deteriorate
Two newsletters contained articles
by GP champions linked to the
research team
The SUCCESS group members
advised on, and reviewed, the
patient information pages of the
PRISMATIC trial website
Service users involved in
publicising PRISMATIC to patients
Service users suggested production
and distribution of a poster about
the PRISMATIC trial, for display in GP
practices, to inform patients about
the study
One service user and one GP
champion were interviewed by a TV
crew about the study. The package
was screened on the BBC Wales
evening news
Service users were co-authors on
all study outputs
Service users co-authored conference
presentations
Service users co-authored journal
publication reporting baseline
qualitative findings (Porter et al.)84
Further bid
development
Service users collaborated
in developing further
research about risk
prediction
Service users contributed through
research development groups and
reviewing draft applications
Seven service users attended a
research discussion group to
consider risk prediction research
priorities: outcome informed future
bid development
At least one service user was named
as a co-applicant on all large-scale
research proposals linked to use of
risk prediction tools and proactive
care
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Recruiting and supporting service users to be involved in the
PRISMATIC trial
We recruited two service users to the RMG. As people changed, five individuals were involved over 5 years.
They were all members of the SUCCESS group. All were diagnosed with chronic conditions and some also
cared for family members. One of these individuals was actively involved throughout the whole period of
the PRISMATIC trial. Poor health meant three other individuals had to give up their role. To reduce the
burden on individuals, we recruited a reserve service user so there were potentially three to attend meetings
and less need for anyone with family responsibilities or feeling unwell. Despite receiving briefings and
project information, the reserve person reported that it was difficult to retain continuity when not regularly
involved and there were long periods between meetings. When his health limited his ability to drive, the
study team agreed not to recruit another person and resumed working with two service users.
Halfway through the trial (December 2013), we held a meeting for service users and core research staff
(BAE, MRK and HH) to review their experience and identify ways to enable them to sustain and increase
their involvement.
Study meetings
At least one, often two, service users attended almost all RMG meetings (23/24). We recruited two
different service users to the TSC; they attended three of five meetings.
We also involved service users in task-related meetings such as writing days, meetings to undertake
qualitative analysis and research development groups discussing further research linked to the topic of
risk prediction.
Research activities
Throughout the period of the PRISMATIC trial, service users were involved in a range of research
activities including:
l RMG meetings – all aspects in an equal role with other RMG members
l reviewing research information
¢ format of patient questionnaires
¢ patient letters and information sheets
¢ interview schedules
¢ abstracts and posters presented at conferences
l qualitative data analysis
l commenting on strategies to increase questionnaire response rates (prize draw)
l deciding to have a patient page on the PRISMATIC trial website (RMG decision)
l developing and reviewing the patient page of the PRISMATIC trial website (at SUCCESS group meetings)
l commenting on consent issues relating to the use of anonymised data
l publicity (British Broadcasting Corporation, newsletters); focus of British Broadcasting Corporation
publicity was on one of the service users
l TSC – two members
l developing and piloting service user terms of reference (at SUCCESS group meetings and RMG)
l informal dissemination about the PRISMATIC trial to patient networks
l co-applicant on further research bids, including a systematic review of risk prediction models and
developing an intervention to communicate risk scores with patients.
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Reflections from one service user member of the PRISMATIC study
I considered the PRISMATIC research to be advantageous to service users and I was pleased to be part
of its development. I was able to pose questions and ask for explanations as part of the PRISMATIC
team but felt there were some aspects of the research which could have taken a wider view.
As a service user with chronic conditions I am aware of the problems with access to health services
especially primary services, for example, GP surgeries. The research did not address the initial
presentation at a GP surgery. GP receptionists were not able to identify the patients on the top of the
PRISM pyramid (this was a problem when these patients were requesting an appointment). The remit
for PRISMATIC did not include this and was considered to be the responsibility of the surgeries and
I accept this.
I do not have any issues to raise about involving service users as it has got to be beneficial in a
research study. Service users, to be an asset to research and researchers, need to have some training
and understanding of working within this environment. They must also understand the remit but
never be afraid to put forward issues that they consider will benefit patients. That should be why we
are taking part in research and we must not lose sight of this.
I do think it was good enough involvement. What could be done better is explaining the remit more.
There have been times when I could not see how a particular research project can work without some
other basic changes made to make the research work in practice. When I have posed these questions
I can tell the information is not compatible with the research criteria.
Being part of a research project like PRISMATIC works for me. But what really worked for me was
when I asked [name] to explain in plain English where we were at a particular time and the newsletter
he produced after the event.
My reflections on the results and report are ’didn’t we do well’.
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Chapter 8 Discussion and conclusions
Summary of key findings
Systematic review
l We found that previous research related to implementation of PRISMs for the management of
emergency admissions to hospital has shown minimal effects overall, but has been largely observational
in nature, suffered from operational issues in implementation, tended to focus on processes of care
rather than health outcomes, and that studies were heterogeneous in terms of intervention,
populations and study design.
Primary outcome
l The rate, and proportion, of people with emergency admissions increased overall in the intervention
phase of the trial, effects that were consistent across predicted risk levels.
Secondary outcomes
l Attendances at the ED were higher in the intervention phase than in the control phase; GP event-days
were slightly lower; there were no clear effects on outpatient visits; bed-days overall were higher;
mental health quality-of-life scores were similar between phases, but physical health scores were higher
in the intervention phase; satisfaction scores were slightly lower in the intervention phase.
l Mortality was similar across intervention and control periods.
l Technical performance of the tool was good. Evidence of underprediction of risk was apparent at
higher-risk levels, balanced by overprediction of risk at the lowest risk level.
Costs
l The implementation cost of PRISM in the first year was estimated to be £822 per practice, £0.12
per patient.
l Total health-care costs after the implementation of the PRISM scoring tool in primary care practices
were £76 per patient higher than in the control phase.
l Considering the increased number of emergency admissions in the intervention phase, the PRISM tool
can be considered dominated by the control (routine practice).
Processes of change associated with the Predictive RIsk Stratification Model
Usage of PRISM appeared to be low and declined over time. Usage was strongly driven by the QOF
requirements in the GP contract, focusing on a small proportion (0.5%) identified as being at the highest
risk of emergency admission to hospital. GPs were generally open to trying PRISM, but extreme pressures
on their role limited their time and capacity for using it to its full potential. All stakeholders were aware of
the limited potential of PRISM to support improvements to patient care without additional resources being
put into community-based care services. GPs reported that PRISM changed their awareness of patients and
focused them on targeting the highest-risk patients, though these may have been least suitable for
proactive management. They agreed that PRISM was potentially very useful to manage patients from
lower-risk tiers.
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Strengths and limitations of study
Our stepped-wedge study design, with randomised allocation of clusters of GP practices to receive the
PRISM tool over a 1-year period and using linked data follow-up, allowed us to carry out a rigorous
evaluation of this population-level intervention that included primary outcomes for > 250,000 people. We
were able to anonymously link self-reported questionnaires for a sample of patients to our routine data
outcomes, giving us a picture of effects on health service use as well as quality of life and satisfaction.
Using linked data allowed us to include almost the whole population for those general practices that
participated in the study. Inclusion of outcomes for such a high number of participants means that even
small differences are detected and are statistically significant. In this case, effects were small but consistent,
and across such high numbers of participants, resulted in large cost differences between phases.
Our mixed-methods approach allowed us to explore implementation and reported usage as well as
perceived challenges and benefits. The incorporation of qualitative methods, health economic analyses, as
well as the investigation of technical performance, has ensured that a comprehensive evaluation has been
undertaken to inform health-care decision-making of the value (from clinical, service, patient and economic
outcomes) of PRISM.
This is the first evaluation of the effects of the introduction of a PRISM in a real-life setting, although the
tools have now been widely introduced across the UK as part of a comprehensive policy for the care of
people with chronic conditions, with higher rates of management of patients outside hospital, through
primary- or community-based services or self-care. However, within the constraints of a funded evaluation,
we were only able to include outcomes up to 18 months from implementation of PRISM at the first
practices. We do not know what the longer-term effects would be.
Self-reported health-related quality-of-life and satisfaction findings are based on a sample which was
weighted to favour patients at higher levels of risk. These scores therefore need further analysis to account
for non-responders and for this weighting, so that findings are representative of the whole population.
There were a number of practical and analytical challenges associated with using anonymised linked
routine data for the assessment of cost-effectiveness. With respect to the cost-effectiveness analyses,
there is little literature available on the conduct of health economic analyses alongside trial designs of this
nature. We demonstrated that appropriate methods can be applied; a particular strength of our analyses is
that we undertook cost, cost-effectiveness, cost–consequences and cost–utility analyses, and trial-based
budget impact to provide as full a picture as possible of the economic impact of PRISM. However, several
challenges were unexpected. The economic analysis (other than the implementation costs associated with
PRISM) could not be done until the SAIL data were made available for final analysis; and logistical aspects
such as accessing the data proved problematic throughout the analysis period. Another essential lesson
learnt was the need to work closely with the statistical analysis (e.g. a fully integrated statistical and
economic analysis plan should be produced) to ensure standardisation and harmonisation of outcomes
given their relative importance to reporting both clinical effectiveness and cost-effectiveness.
Further limitations relate to the dynamic context, with changing policy and practice environment before,
during and after recruitment. We believe our study design is well suited to this context, frequently
encountered by evaluative studies in health care. Against this background, beyond the PRISM tool it was
challenging to define the wider intervention that was designed to reduce emergency admissions, and we
were unable to disentangle effects of PRISM from the introduction of QOF targets for the care of those at
the highest level of risk of emergency admissions to hospital.
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Implications for policy and practice
This research addresses a major policy concern for the NHS – how best to manage patients in the community
to avoid unnecessary, disruptive and costly emergency admissions. In 2012–13 there were 5.3 million
emergency admissions to hospitals costing approximately £12.5B.3 Over 2 million unplanned admissions per
year are for those aged ≥ 65 years – accounting for 68% of hospital bed-days – and the use of more than
51,000 acute beds at any one time.85 In 2009/10 the average length of stay was approximately 3 days for
patients aged < 65 years, but 9 days for patients aged ≥ 65 years.7 Approximately half of all bed-days are
attributable to just 5% of the population – typically older people with multimorbidity.3,86 An emergency
admission to hospital is a disruptive and unsettling experience which can have a negative impact on a
patient’s life as they are exposed to clinical and psychological risks and likely to have increased their
dependency on discharge.7 It is widely recognised that there are opportunities to improve management of
care for older patients with multimorbidity in primary and community settings – and that doing so is necessary
to reduce avoidable emergency admissions.3
The use of EARP tools is widely advocated16 to support the identification of vulnerable patients for proactive
targeted care aimed at preventing emergency hospitalisation – a ‘triple fail’ event that is harmful, costly
and results in poor patient satisfaction.6 ‘It is now well recognised in the NHS that predictive risk tools
are essential to use if high quality care is to be offered’ (Jennifer Dixon, Chief Executive of the Health
Foundation).87 EARP tools can support the allocation of scarce resources through the identification of
patients in need who can be proactively targeted with support appropriate to their needs. The use of EARP
tools is widely advocated in academic, policy and clinical literature and is, for example, a core component of
both the English and Welsh chronic/long-term conditions models.5,14
Provisional indications from a UK-wide survey led by one of the co-applicants are that > 70% of UK
practices now have access to an EARP tool. The development and validity of the tools has been widely
researched,26 but little research has been undertaken into their effectiveness.15,26 The 2015 NHS England
paper Next Steps for Risk Stratification in the NHS notes a ‘pressing need for further research’ about the
effectiveness of hospital-avoidance interventions.15
There is some debate about how best to use EARP tools – and whether or not focus should be on those at
the highest level of risk. Lewis,15 for instance, suggests that at this level there is little scope for improvement,
whereas Wallace et al. suggest that numbers at this level are so small that overall impact is limited when
following this approach.88 However, UK health policy is clearly focused on the management of patients at
the highest level of risk. GP contracts have incentivised EARP use for case management of patients at high
risk of hospitalisation, with over £480M allocated for the Avoiding Unplanned Admissions Enhanced Service
in England between 2014 and 2017.18 Participation in the Enhanced Services (ES) is widespread with around
7500 practices taking part in the ES – over 95% of all practices (NHS Digital, 2015, personal communication).
Their responsibilities are to use a risk prediction model or alternative to identify vulnerable older people,
high-risk patients and patients needing end-of-life care who are at risk of unplanned admission, and create a
register of at least 2% of patients aged > 18 years.18
For those patients on the register, the practice is expected to offer care co-ordination and active care
planning and review, involving patients as partners in the management of their health. The ES is aligned
with NHS policy guidance for patient-centred care and supporting self-management, with GPs encouraged
to involve patients in their care planning through shared decision-making.18,89 The King’s Fund’s 2013 list
of priorities for sustainable health services begins with active support for self-management and primary
prevention, including the targeting of high-risk groups.85
The reach and scale of ES and the potential impact on patients and health and care resources is considerable,
with over 800,000 patients across the whole of England on the case management register in each of the
intervention years (2014/15 and 2015/16).
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Incentivisation of the targeting of those at the very highest levels of risk has become routine practice in
Wales through QOF measures and in England through the funding of an enhanced service, although
originally predictive risk stratification tools were seen as a way of managing care across the spectrum of
risk. In 2013, Geraint Lewis, Chief Data Officer, NHS England, drew attention to this:
It is important to remember that patients at very high-predicted risk of hospitalisation only account for a
modest proportion of all unplanned admissions. Therefore, to have a meaningful impact on admission
rates at the population level, it will be important to consider less-intensive, lower-cost interventions for
patients at moderately high-predicted risk. Indeed, there is a danger that by focusing exclusively on the
integration of care for very high-risk patients, virtual wards may be diverting attention away from the
integration of care for lower risk patients.
Lewis et al.90 This work is licensed under a Creative Commons Attribution
3.0 Unported Licence (http://creativecommons.org/licenses/by/3.0)
There has been an assumption that, if EARP tools predict those at high risk of emergency admission to
hospital with reasonable accuracy, patients will benefit from targeted care to improve their health and
reduce unplanned episodes of care. However, this is based on assumptions – with little empirical evidence
to date – about how risk prediction tools and incentivisation of care work in practice. Our findings have
shown effects that are opposite to those intended. Although GPs reported that the use of the PRISM tool
overall was low, they also reported carrying out reviews of the PRISM-generated lists of people predicted
to be at the highest level of risk of emergency admission to hospital. They reported that they felt very
stretched without additional resources to allocate specifically to the care of these patients. We have found
an increase in emergency admissions and ED attendances at all risk levels, associated with introduction
of the PRISM tool, and once we had adjusted for all significant covariates, including age, season and
trend over time. This is challenging to explain, and is an effect that would not have been detected in a
traditional evaluation that focused on relatively small numbers of those at the highest level of risk. Our use
of anonymised linked routine data has allowed us to detect effects across the whole population. We
refer to recently published results showing a similar unexpected effect on emergency episodes related to
introduction of an air pollution alert system.91 We can hypothesise that PRISM, alongside QOF targets to
target care at those at highest risk of emergency hospital admission, both sensitised GPs and practice staff
to need at this level, while shifting the focus from others at lower risk, thereby missing opportunities to
avoid emergency admission to hospital in those seen as less frail.
Conclusions
We have carried out the first large study of what happens when you introduce EARP in the real world.
Use of anonymised data linkage has allowed us to carry out an experimental study with a randomised
design at population level, with a very high rate of inclusion of primary and secondary routine outcomes,
as well as self-reported outcomes for a sample of patients and health economic analysis.
Our results are surprising and alarming – increases in activity and costs across the board. We do not fully
understand how or why this is happening; possible reasons include sensitisation of GPs and identification
of unmet need; lack of resources to respond to need apart from hospitalisation; and concentration on
those at highest predicted risk may mean that attention slips from those with lower predicted risk scores.
Despite low reported use of PRISM, we found clinically and operationally important effects of the
introduction of the new risk stratification tool alongside contractual (QOF) incentives to target those at the
highest risk of emergency admission to hospital. These effects were unexpected and in the opposite
direction to those intended. We are unable to disentangle the effects of the introduction of the PRISM
tool from those of the QOF targets, but this reflects practice across the UK, where emergency admission
predictive risk stratification tools have been introduced alongside an incentivised enhanced service.
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We see no reason to expect that findings would be different from those found across this mixed urban
and semi-urban population in south Wales.
Recommendations for research in order of priority
1. Evaluation of targeting of different services to different levels of risk, rather than the strong current focus
on the very highest level of risk (QOF and enhanced service). In the PRISMATIC trial our evaluation of
PRISM became an evaluation of PRISM alongside incentivisation of targeted care for those at highest risk
through QOF targets. The PRISM tool itself can only be part of a wider intervention. PRISM was not
designed to be used with such a focus on the highest level of risk, but UK health policy has focused on
these patients and PRISM was used to identify patients to meet these targets. We do not know what
effects would be found if efforts – and resources – were to be targeted at those at a slightly lower-risk
level, and whether or not the generation of a risk score per se can have the effects that we found. We
recommend further exploration of this aspect, as risk tools are not going away – we cannot ‘unknow’
what we know – and we need to understand mechanisms and effects much better if they are to be used
to improve care and outcomes for patients. This will require a new study based on an experimental
design – preferably a randomised trial clustered by practice to exclude biases caused by changing policy
and practice within the study time frame. This study must be underpinned by theory and a logic model,
and include a strong process evaluation to understand mechanisms of change. We recommend also
that this study should be carried out in sites across England and Wales and that longer-term outcomes
are included.
2. Investigation of effects on vulnerable populations, health inequalities and by health condition type; in
the PRISMATIC trial we have detected effects at aggregate and risk group levels, but have not delved
into differential effects within the general practice population. This could partially be achieved by
secondary analysis of the PRISMATIC trial data set, but some new investigation would also be required.
3. Acceptability of predictive risk stratification and communication of scores to patients and practitioners
is an important topic to explore, but it is more important at this stage to establish effects, costs and
mechanisms of change.
DOI: 10.3310/hsdr06010 HEALTH SERVICES AND DELIVERY RESEARCH 2018 VOL. 6 NO. 1
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snooks et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
111

Acknowledgements
This study was only possible thanks to the expertise and commitment of a wide range of people andorganisations. Although we specifically acknowledge the following parties, we would like to extend our
thanks to all of those who supported this work.
l All the participating general practices and their staff.
l All patients and stakeholders who participated in the trial.
l NWIS, which developed the PRISM tool, and provided considerable support and expertise throughout
the trial. We would particularly like to thank the following staff members: Ken Leake, Dave Price,
Mick Kelly, Cecilia Jones, David Leach, Tracey Taylor, Claire John and Simon Scourfield.
l The research support staff at the National Institute for Social Care and Health Research (now rebranded
Health and Care Research Wales). In particular, for their support with practice engagement and
research tasks, we thank Kathy Malinovszky, Carol Thomas, Zoe Abbott and Rachel McGrath.
l Our GP champions: Deborah Burge-Jones, Sarah Smallcombe and Kerry Bailey-Jones.
l NIHR HSDR (previously the Service Delivery and Organisation programme) for funding and then
supporting this research throughout, and especially in light of the changes from the original
funded proposal.
l Geraint Lewis for specialist advisory support.
l Sherry Jenkins, Anne Surman, Claire Evans, Moira Morgan, Rhiannon Griffiths, Kayleigh Nelson and
Ashra Khanom for administrative support.
l Clare Boucher (Swansea University Medical School subject librarian).
l Members of our TSC and DMEC: Sarah Purdy, Gareth Davies, Adrian Edwards, Ben Carter and
Chris Jones.
l Our service user representatives: Jan Davies, Shirley Whitman, Jackie McCarthy and Rosita Wilkins.
l Christine Foley for transcription services, and Opinion Research Services for assisting with the
processing of anonymous questionnaires.
l The SAIL DATABANK team at Swansea University for their help with our data linkage. In particular,
we would like to thank Cynthia McNerney, Caroline Brooks, Dan Thayer and Ronan Lyons and
members of the Information Governance Review Panel.
Contributions of authors
Helen Snooks (Professor of Health Services Research), chief investigator, led the development of the
research question, study design, and was responsible for trial delivery and conduct.
Kerry Bailey-Jones (GP) and Deborah Burge-Jones (GP) acted as study GP champions, offering general
practice insight and experience throughout.
Jeremy Dale (Professor of Primary Care), co-applicant, provided expertise in primary and emergency
care research.
Jan Davies (Service User Representative), RMG member and service user advisor.
Bridie Evans (Research Officer), service user involvement lead and qualitative support.
Angela Farr (Researcher in Swansea Centre for Health Economics) helped prepare implementation
costs section.
Deborah Fitzsimmons (Professor of Health Outcomes Research) supported the management of the
health economic analysis and contributed to the draft of the cost-effectiveness chapter.
DOI: 10.3310/hsdr06010 HEALTH SERVICES AND DELIVERY RESEARCH 2018 VOL. 6 NO. 1
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snooks et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
113
Jane Harrison (Public Health Wales, previously ABM UHB Assistant Medical Director for Primary Care) led
the introduction of PRISM in ABM UHB.
Martin Heaven (Senior analyst at FARR Institute @ CIPHER) provided expertise and support for data linkage.
Helen Howson (Welsh Government) advised on policy concerning chronic conditions management
throughout the study.
Hayley Hutchings (Professor of Health Services Research and Deputy Director of STU), research manager,
supervised staff, and led the writing of the study protocol and methods chapter.
Gareth John (Information Manager at NWIS) supported implementation of PRISM, advised and facilitated
data linkage, and was key liaison for NWIS throughout the study.
Mark Kingston (Research Officer), project and data manager, co-ordinated the day-to-day delivery of the
trial, including site liaison, and wrote first drafts of the introduction and systematic review.
Leo Lewis (Senior Fellow, International Foundation for Integrated Care) advised on predictive risk
stratification implementation throughout the study.
Ceri Phillips (Professor of Health Economics), co-applicant, helped develop the original study and support
health economics components.
Alison Porter (Associate Professor), qualitative lead.
Bernadette Sewell (Health Economist) wrote the analysis plan for the health economic evaluation,
analysed health economics data and led draft of cost-effectiveness chapter.
Daniel Warm (Service Transformation Programme Manager, Hywel Dda UHB) provided advice on
information systems management.
Alan Watkins (Associate Professor), senior statistician, developed analysis plan and analysed data.
Led draft of clinical effectiveness chapter.
Shirley Whitman (Service User Representative), RMG member and service user advisor.
Victoria Williams (Research Officer) supported the qualitative data analysis and chapter draft.
Ian T Russell (Emeritus Professor of Clinical Trials), co-applicant, provided methodological support,
including statistical expertise.
All authors contributed to the writing of the report and approved the final version.
Publications
Hutchings HA, Evans BA, Fitzsimmons D, Harrison J, Heaven M, Huxley P, et al. Predictive risk stratification
model: a progressive cluster-randomised trial in chronic conditions management (PRISMATIC) research
protocol. Trials 2013;14:301.
Kingston MR, Evans BA, Nelson K, Hutchings HA, Russell IT, Snooks HA. Costs, effects and implementation
of emergency admission risk prediction models in primary care for patients with, or at risk of, chronic
conditions: a systematic review protocol. BMJ Open 2016;6:e009653.
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
114
Porter A, Kingston MR, Evans BA, Hutchings H, Whitman S, Snooks H. It could be a ‘Golden Goose’:
a qualitative study of views in primary care on an emergency admission risk prediction tool prior to
implementation. BMC Fam Pract 2016;17:14.
Data sharing statement
Data are stored within the SAIL databank at the Health Information Research Unit at Swansea University.
All proposals to use SAIL data sets must comply with Health Information Research Unit’s information
governance policy.
DOI: 10.3310/hsdr06010 HEALTH SERVICES AND DELIVERY RESEARCH 2018 VOL. 6 NO. 1
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snooks et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
115

References
1. World Health Organization. Noncommunicable Diseases Country Profiles 2011. Geneva: World
Health Organization; 2011.
2. Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K. The burden and costs of chronic
diseases in low-income and middle-income countries. Lancet 2007;370:1929–38.
3. National Audit Office. Emergency Admissions to Hospital: Managing the Demand. London:
National Audit Office; 2013.
4. Department of Health. Improving Quality of Life for People with Long Term Conditions. London:
Department of Health; 2013. URL: www.gov.uk/government/policies/improving-quality-of-life-for-
people-with-long-term-conditions (accessed 20 November 2014).
5. Department of Health. The National Service Framework for Long-term Conditions. London:
Department of Health; 2005.
6. Lewis G, Kirkham H, Duncan I, Vaithianathan R. How health systems could avert ‘triple fail’ events
that are harmful, are costly, and result in poor patient satisfaction. Health Aff 2013;32:669–76.
https://doi.org/10.1377/hlthaff.2012.1350
7. The King’s Fund. Older People and Emergency Bed Use: Exploring Variation. London: The King’s
Fund; 2012.
8. Freund T, Wensing M, Mahler C, Gensichen J, Erler A, Beyer M, et al. Development of a primary
care-based complex care management intervention for chronically ill patients at high risk for
hospitalization: a study protocol. Implement Sci 2010;5:70. https://doi.org/10.1186/
1748–5908–5-70
9. Department of Health. Integrated Care and Support: Our Shared Commitment. London:
Department of Health; 2013.
10. The Health Foundation and Nuffield Trust. Focus on Preventable Admissions: Trends in Emergency
Admissions for Ambulatory Care Sensitive Conditions, 2001 to 2013. London: The Health
Foundation and Nuffield Trust; 2013.
11. Purdy S. Avoiding Hospital Admissions. What Does the Research Evidence Say? London: The King’s
Fund; 2010. URL: www.kingsfund.org.uk/sites/files/kf/Avoiding-Hospital-Admissions-Sarah-Purdy-
December2010_0.pdf (accessed 18 August 2015).
12. Sanderson C, Dixon J. Conditions for which onset or hospital admission is potentially preventable
by timely and effective ambulatory care. J Health Serv Res Policy 2000;5:222–30.
13. Tian Y, Dixon A, Gao H. Data Briefing: Emergency Hospital Admissions for Ambulatory
Care-Sensitive Conditions. London: The King’s Fund; 2012.
14. Welsh Assembly Government. Designed to Improve the Health and Management of Chronic
Conditions in Wales. An Integrated Model and Framework. Cardiff: Welsh Assembly
Government; 2007.
15. Lewis G. Next Steps for Risk Stratification in the NHS. London: NHS England; 2015.
16. Nuffield Trust. Choosing a Predictive Risk Model: A Guide for Commissioners in England. London:
Nuffield Trust; 2011.
17. Stokes J, Checkland K, Kristensen SR. Integrated care: theory to practice. J Health Serv Res Policy
2016;21:282–5. https://doi.org/10.1177/1355819616660581
DOI: 10.3310/hsdr06010 HEALTH SERVICES AND DELIVERY RESEARCH 2018 VOL. 6 NO. 1
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snooks et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
117
18. NHS England. Enhanced Service Specification. Avoiding Unplanned Admissions: Proactive Case
Finding and Patient Review for Vulnerable People. London: NHS England; 2014.
19. Allaudeen N, Schnipper JL, Orav EJ, Wachter RM, Vidyarthi AR. Inability of providers to
predict unplanned readmissions. J Gen Intern Med 2011;26:771–6. https://doi.org/10.1007/
s11606–011–1663–3
20. The King’s Fund. Evercare Needs Evaluation of Cost Effectiveness Before it is Rolled Out Further,
Says The King’s Fund. 2005. URL: www.kingsfund.org.uk/press/press-releases/evercare-needs-
evaluation-cost-effectiveness-it-rolled-out-further-says-kings (accessed 16 September 2015).
21. Donnan PT, Dorward DT, Mutch B, Morris AD. Development and validation of a model for
predicting emergency admissions over the next year (PEONY): a UK historical cohort study.
Arch Intern Med 2008;168:1416–22. http://dx.doi.org/10.1001/archinte.168.13.1416
22. Ross P, Curry C, Goodwin N. Case Management. What it is and How it Can Best be Implemented?
London: The King’s Fund; 2011.
23. Moons KG, Royston P, Vergouwe Y, Grobbee DE, Altman DG. Prognosis and prognostic research:
what, why, and how? BMJ 2009;338:b375.
24. Meehl P. Part III: Diagnosis and Prediction. Waller NG, Yonce LJ, Grove WM, Faust D, Lezenweger MF,
editors. A Paul Meehl Reader: Essays on the Practice of Scientific Psychology. Mahwah, NJ: Lawrence
Erlbaum Associates; 2006. pp. 207–91.
25. Kivimäki M, Batty GD, Singh-Manoux A, Ferrie JE, Tabak AG, Jokela M, et al. Validating the
Framingham Hypertension Risk Score: results from the Whitehall II study. Hypertension
2009;54:496–501. https://doi.org/10.1161/HYPERTENSIONAHA.109.132373
26. Wallace E, Stuart E, Vaughan N, Bennett K, Fahey T, Smith SM. Risk prediction models to predict
emergency hospital admission in community-dwelling adults: a systematic review. Med Care
2014;52:751–65. http://dx.doi.org/10.1097/mlr.0000000000000171
27. Freund T, Wensing M, Geissler S, Peters-Klimm F, Mahler C, Boyd CM, et al. Primary care
physicians’ experiences with case finding for practice-based care management. Am J Manag Care
2012;18:e155–61.
28. Haas LR, Takahashi PY, Shah ND, Stroebel RJ, Bernard ME, Finnie DM, et al. Risk-stratification
methods for identifying patients for care coordination. Am J Manag Care 2013;19:725–32.
29. European Commission. European Innovation Partnership on Active and Healthy Ageing. A
compilation of Good Practices: Replicating and Tutoring Integrated Care for Chronic Diseases,
Including Remote Monitoring at Regional Level. Brussels: European Commission; 2013.
30. Stokes J, Panagioti M, Alam R, Checkland K, Cheraghi-Sohi S, Bower P. Effectiveness of case
management for ‘at risk’ patients in primary care: a systematic review and meta-analysis.
PLOS ONE 2015;10:e0132340. https://doi.org/10.1371/journal.pone.0132340
31. Welsh Assembly Government. Quality and Outcomes Framework Guidance for the GMS Contract
Wales 2013/14. Cardiff: BMA Cymru Wales; 2013.
32. Wennberg D, Siegel M, Darin B, Filipova N, Russell R, Kenney L, et al. Combined Predictive Model
Final Report. 2006. URL: www.kingsfund.org.uk/sites/files/kf/field/field_document/PARR-combined-
predictive-model-final-report-dec06.pdf (accessed 27 May 2015).
33. Kingston MR. Initial Uses of the PRISM Risk Stratification Tool in CCM Demonstrator Sites: a
Qualitative Study. Llantrisant: National Leadership and Innovation Agency for Healthcare; 2010.
34. Hutchings HA, Evans BA, Fitzsimmons D, Harrison J, Heaven M, Huxley P, et al. Predictive risk
stratification model: a progressive cluster-randomised trial in chronic conditions management
(PRISMATIC) research protocol. Trials 2013;14:301. http://dx.doi.org/10.1186/1745-6215-14-301
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
118
35. Kingston MR, Evans BA, Nelson K, Hutchings H, Russell I, Snooks H. Costs, effects and
implementation of routine data emergency admission risk prediction models in primary care
for patients with, or at risk of, chronic conditions: a systematic review protocol. BMJ Open
2016;6:e009653. http://dx.doi.org/10.1136/bmjopen-2015-009653
36. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Reprint – preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. Phys Ther 2009;89:873–80.
37. Department of Health. The NHS Improvement Plan: Putting People at the Heart of Public Services.
London: HMSO; 2004.
38. Kocher RP, Adashi EY. Hospital readmissions and the Affordable Care Act: paying for coordinated
quality care. JAMA 2011;306:1794–5. https://doi.org/10.1001/jama.2011.1561
39. Centre for Reviews and Dissemination. Systematic Reviews: CRD’s Guidance for Undertaking
Reviews in Health Care. York: Centre for Reviews and Dissemination, University of York; 2009.
40. Thomas BH, Ciliska D, Dobbins M, Micucci S. A process for systematically reviewing the literature:
providing the research evidence for public health nursing interventions. Worldviews Evid Based
Nurs 2004;1:176–84. http://dx.doi.org/10.1111/j.1524–475X.2004.04006.x
41. Walsh D, Downe S. Appraising the quality of qualitative research. Midwifery 2006;22:108–19.
42. Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version
5.1.0 [Updated March 2011]. The Cochrane Collaboration; 2011. URL: http://handbook.cochrane.org
43. Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al. Guidance on the Conduct of
Narrative Synthesis in Systematic Reviews. Lancaster: Institute of Health Research; 2006.
44. Baker A, Leak P, Ritchie LD, Lee AJ, Fielding S. Anticipatory care planning and integration:
a primary care pilot study aimed at reducing unplanned hospitalisation. Br J Gen Pract
2012;62:e113–20. https://doi.org/10.3399/bjgp12X625175
45. Dhalla IA, O’Brien T, Morra D, Thorpe KE, Wong BM, Mehta R, et al. Effect of a postdischarge
virtual ward on readmission or death for high-risk patients: a randomized clinical trial. JAMA
2014;312:1305–12. https://doi.org/10.1001/jama.2014.11492
46. Freund T, Mahler C, Erler A, Gensichen J, Ose D, Szecsenyi J, et al. Identification of patients likely
to benefit from care management programs. Am J Manag Care 2011;17:345–52.
47. Levine S, Steinman BA, Attaway K, Jung T, Enguidanos S. Home care program for patients at high
risk of hospitalization. Am J Manag Care 2012;18:e269–76.
48. Reilly S, Abell J, Brand C, Hughes J, Berzins K, Challis D. Case management for people with
long-term conditions: impact upon emergency admissions and associated length of stay. Prim
Health Care Res Dev 2011;12:223–36. http://dx.doi.org/10.1017/s1463423611000028
49. Roland M, Lewis R, Steventon A, Abel G, Adams J, Bardsley M, et al. Case management for at-risk
elderly patients in the English integrated care pilots: observational study of staff and patient
experience and secondary care utilisation. Int J Integ Care 2012;12:e130.
50. Takahashi PY, Pecina JL, Upatising B, Chaudhry R, Shah ND, Van Houten H, et al. A randomized
controlled trial of telemonitoring in older adults with multiple health issues to prevent hospitalizations
and emergency department visits. Arch Intern Med 2012;172:773–9. http://dx.doi.org/10.1001/
archinternmed.2012.256
51. Upatising B, Hanson GJ, Kim YL, Cha SS, Yih Y, Takahashi PY. Effects of home telemonitoring on
transitions between frailty states and death for older adults: a randomized controlled trial. Int J Gen
Med 2013;6:145–51. http://dx.doi.org/10.2147/IJGM.S40576
DOI: 10.3310/hsdr06010 HEALTH SERVICES AND DELIVERY RESEARCH 2018 VOL. 6 NO. 1
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snooks et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
119
52. Abell J, Hughes J, Reilly S, Berzins K, Challis D. Case management for long-term conditions:
developing targeting processes. Care Manag J 2010;11:11–18.
53. Sauto Arce R, De Ormijana AS, Orueta JF, Gagnon MP, Nuño-Solinís R. A qualitative study on
clinicians’ perceptions about the implementation of a population risk stratification tool in primary
care practice of the Basque health service. BMC Fam Pract 2014;15:150. https://doi.org/10.1186/
1471-2296-15-150
54. Hall S, Kulendran M, Sadek A, Green S, de Lusignan S. Variability in selecting patients to manage
in the community: a service evaluation of community matron’s case-finding strategies. Fam Pract
2011;28:414–21. http://dx.doi.org/10.1093/fampra/cmq095
55. McEvoy P, Escott D, Bee P. Case management for high-intensity service users: towards a relational
approach to care co-ordination. Health Soc Care Community 2011;19:60–9. https://doi.org/
10.1111/j.1365–2524.2010.00949.x
56. Roland M, Abel G. Reducing emergency admissions: are we on the right track? BMJ
2012;345:e6017. https://doi.org/10.1136/bmj.e6017
57. Billings J, Dixon J, Mijanovich T, Wennberg D. Case finding for patients at risk of readmission to
hospital: development of algorithm to identify high risk patients. BMJ 2006;333:327.
58. van Walraven C, Dhalla IA, Bell C, Etchells E, Stiell IG, Zarnke K, et al. Derivation and validation of
an index to predict early death or unplanned readmission after discharge from hospital to the
community. CMAJ 2010;182:551–7. http://dx.doi.org/10.1503/cmaj.091117
59. Crane SJ, Tung EE, Hanson GJ, Cha S, Chaudhry R, Takahashi PY. Use of an electronic
administrative database to identify older community dwelling adults at high-risk for hospitalization
or emergency department visits: the elders risk assessment index. BMC Health Serv Res
2010;10:1–7. http://dx.doi.org/10.1186/1472-6963-10–338
60. Department of Health. Supporting People with Long Term Conditions: Commissioning Personalised
Care Planning a Guide for Commissioners. London: HMSO; 2009.
61. Bojke C, Philips Z, Sculpher M, Campion P, Chrystyn H, Coulton S, et al. Cost-effectiveness of shared
pharmaceutical care for older patients: RESPECT Trial findings. Br J Gen Pract 2010;60:e20–7.
http://dx.doi.org/10.3399/bjgp09X482312
62. Richmond S, Morton V, Chi Kei Wong I, Russell I, Philips Z, Miles J, et al. Effectiveness of shared
pharmaceutical care for older patients: RESPECT trial findings. Br J Gen Pract 2010;59:14–20.
63. Brown CA, Lilford RJ. The stepped wedge trial design: a systematic review. BMC Med Res Methodol
2006;6:54.
64. Ford DV, Jones KH, Verplancke JP, Lyons RA, John G, Brown G, et al. The SAIL Databank: building
a national architecture for e-health research and evaluation. BMC Health Serv Res 2009;9:157.
https://doi.org/10.1186/1472-6963-9-157
65. Chisholm D, Knapp MR, Knudsen HC, Amaddeo F, Gaite L, van Wijngaarden B. Client
socio-demographic and service receipt inventory – European version: development of an instrument
for international research. EPSILON Study 5. European Psychiatric Services: Inputs Linked to
Outcome Domains and Needs. Br J Psychiatry Suppl 2000:s28–33.
66. Carey RG, Seibert JH. A patient survey system to measure quality improvement: questionnaire
reliability and validity. Med Care 1993;31:834–45.
67. SF-36.org. The SF-12®. An Even Shorter Health Survey. URL: www.sf-36.org/tools/sf12.shtml
(accessed 16 January 2013).
68. Department of Health. NHS Reference Costs 2014/15. London: Department of Health; 2015.
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
120
69. NHS Careers. Pay for NHS Health Informatics Staff. 2014. URL: www.nhscareers.nhs.uk/working-in-
the-nhs/pay-and-benefits/agenda-for-change-pay-rates/ (accessed 5 October 2015).
70. Curtis L. Unit Costs of Health and Social Care. Canterbury: Personal Social Services Research Unit,
University of Kent; 2010.
71. The NHS Information Centre for Health and Social Care. Trends in Consultation Rates in General
Practice 1995/96 to 2008/09: Analysis of the QResearch® Database. Nottingham: University of
Nottingham; 2009.
72. Bryman A. Social Research Methods. Oxford: Oxford University Press; 2012.
73. Marshall C, Rossman GB. Designing Qualitative Research. 5th edn. Los Angeles, CA: Sage; 2011.
74. Ziebland S, McPherson A. Making sense of qualitative data analysis: an introduction with
illustrations from DIPEx (personal experiences of health and illness). Med Educ 2006;40:405–14.
75. Miles MB, Huberman AM. Qualitative Data Analysis: An Expanded Sourcebook. London:
Sage; 1994.
76. May C, Finch T, Mair F, Ballini L, Dowrick C, Eccles M, et al. Understanding the implementation of
complex interventions in health care: the normalization process model. BMC Health Serv Res
2007;7:148.
77. Murray E, Treweek S, Pope C, MacFarlane A, Ballini L, Dowrick C, et al. Normalisation process
theory: a framework for developing, evaluating and implementing complex interventions.
BMC Med 2010;8:63. https://doi.org/10.1186/1741-7015-8-63
78. McEvoy R, Ballini L, Maltoni S, O’Donnell CA, Mair FS, MacFarlane A. A qualitative systematic
review of studies using the normalization process theory to research implementation processes.
Implement Sci 2014;9:2. http://dx.doi.org/10.1186/1748-5908-9-2
79. Evans BA, Bedson E, Bell P, Hutchings H, Lowes L, Rea D, et al. Involving service users in trials:
developing a standard operating procedure. Trials 2013;14:219. https://doi.org/10.1186/
1745–6215–14–219
80. Walter I, Davies H, Nutley S. Increasing research impact through partnerships: evidence from
outside health care. J Health Serv Res Policy 2003;8(Suppl. 2):58–61. https://doi.org/10.1258/
135581903322405180
81. National Institute for Health Research. INVOLVE Briefing Notes for Researchers: Involving the Public
in NHS, Public Health and Social Care Research. Eastleigh: INVOLVE; 2012. URL: www.invo.org.uk/
resource-centre/resource-forresearchers (accessed 20 November 2015).
82. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting
parallel group randomised trials. BMC Med 2010;8:18.
83. Curtis L. Unit Costs of Health and Social Care 2014. Canterbury: Personal Social Services Research
Unit, University of Kent; 2014.
84. Porter A, Kingston MR, Evans BA, Hutchings H, Whitman S, Snooks H. It could be a ‘Golden
Goose’: a qualitative study of views in primary care on an emergency admission risk prediction tool
prior to implementation. BMC Fam Pract 2016;17:14.
85. The King’s Fund. Transforming our Health Care System: Ten Priorities for Commissioners. London:
The King’s Fund; 2013.
86. Department of Health. Raising the Profile of Long Term Conditions Care: A Compendium of
Information. London: Department of Health; 2008.
87. Nuffield Trust. The Future of Predictive Risk Tools for the NHS. 2011. URL: www.nuffieldtrust.org.
uk/media-centre/press-releases/future-predictive-risk-tools-nhs (accessed 23 March 2015).
DOI: 10.3310/hsdr06010 HEALTH SERVICES AND DELIVERY RESEARCH 2018 VOL. 6 NO. 1
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snooks et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
121
88. Wallace E, Smith SM, Fahey T, Roland M. Reducing emergency admissions through community
based interventions. BMJ 2016;352:h6817. https://doi.org/10.1136/bmj.h6817
89. NHS. Liberating the NHS: No Decision Without Me, About Me. London: NHS; 2012.
90. Lewis G, Vaithianathan R, Wright L, Brice MR, Lovell P, Rankin S, Bardsley M. Integrating care for
high-risk patients in England using the virtual ward model: lessons in the process of care
integration from three case sites. Int J Integr Care 2013;13:e046.
91. Lyons RA, Rodgers SE, Thomas S, Bailey R, Brunt H, Thayer D, et al. Effects of an air pollution personal
alert system on health service usage in a high-risk general population: a quasi-experimental study
using linked data. J Epidemiol Community Health 2016;70:1184–90. http://dx.doi.org/10.1136/
jech-2016–207222
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
122
Appendix 1 Baseline focus group guide for
general practice staff
l What knowledge did you previously have of predictive risk stratification tools?
¢ What risk tools have you used?
¢ Generic versus disease specific.
¢ Views of risk stratification in general?
l Does your practice seek to identify people at high risk of hospitalisation at present?
¢ How does it do this?
¢ How do you use that information?
¢ Do not identify high-risk patients?
l How does your practice currently deal with people considered at high risk of hospitalisation?
¢ Proactively, responsively, not at all, other?
¢ How does your practice know which patients are in hospital or have been discharged, at any
one time?
l How does your practice feel about using PRISM?
¢ Do you have a clear understanding of what the tool is for?
¢ Who will use it/some more than others?
¢ What motivated your practice to sign up for PRISM?
¢ Who/what influenced your practice in the decision?
¢ When did you/your practice first become aware of PRISM?
¢ What did you know of the origin and developments of PRISM?
l Do you have any concerns about PRISM or how it will be implemented?
¢ Concerns about what it’s for/overall purpose?
¢ Practical/technical difficulties with using it?
¢ Concerns about accuracy – frequency of update, measures feeding into it?
¢ Concerns about data handling and sharing?
¢ Demands on time to input/update?
¢ Use as performance monitoring tool – compliance, liability?
l How do you expect to use PRISM?
¢ Do not expect to use.
¢ Focus for discussion.
¢ New approach to dealing with patients?
¢ Expected strengths/weaknesses?
DOI: 10.3310/hsdr06010 HEALTH SERVICES AND DELIVERY RESEARCH 2018 VOL. 6 NO. 1
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snooks et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
123
l Do you expect PRISM to change the way you work?
¢ Which staff do you expect to use PRISM?
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Appendix 2 Baseline focus group guide for
community/health staff
l Can you briefly describe your role? (Ask all these prompts for everyone.)
¢ Job title.
¢ What it involves (clinical/non-clinical, managerial)?
¢ Where you are based?
¢ What geographic area are you responsible for?
¢ What input do you have into the design of health and social services in your locality/
network/community?
l What knowledge did you have of predictive risk tools before the PRISMATIC study?
¢ Generic (i.e. emergency admissions) versus disease specific.
¢ Have you used any predictive risk tools?
¢ Do you currently use any predictive risk tools?
¢ How do you use them/what do you do with the information?
¢ Views of risk tools in general?
l Do you currently seek to identify people at high risk of hospitalisation?
¢ How do you do this?
¢ How do you use that information?
¢ Proactively, reactively, not at all, other.
¢ Any variation between localities?
l Do you/your organisation know which patients are in hospital or have been recently discharged at any time?
l What do you see as advantages of identifying people at high risk of hospitalisation?
¢ At practice level.
¢ At locality level.
¢ At health board level.
l When did you first become aware of PRISM?
¢ What did you know of the origin and developments of PRISM?
(Present PRISM summary including summary of origin and purpose of tool. Explain justification for predicting
EAs. Explain regression to the mean.)
l How do you feel about PRISM?
¢ Do you have a clear understanding of what the tool is for?
¢ How do you think it could be used/will be used?
¢ Neath Port Talbot/Bridgend/Swansea variation?
¢ What will influence GPs’ use of PRISM?
¢ Why do you think some GP practices have declined PRISM/the PRISMATIC study?
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l How do you expect PRISM will influence your work?
¢ No influence.
¢ Focus for discussion.
¢ New approach to delivering care.
¢ Expected strengths/weaknesses.
¢ Individual changes or organisational changes?
¢ Neath Port Talbot/Bridgend/Swansea variation?
¢ What scope do you have in your role to respond to PRISM?
l Do you expect PRISM to change the way that people with chronic conditions are managed in Abertawe
Bro Morgannwg?
¢ How?
¢ Which staff do you expect to be affected?
¢ Individual or organisational changes?
¢ Neath Port Talbot/Bridgend/Swansea variation?
l Do you have any concerns about PRISM?
¢ Implementation?
¢ Concerns about what it’s for/overall purpose?
¢ Concerns about feasibility to respond?
¢ Demands on time to respond?
¢ Practical/technical difficulties with GP practices using it?
¢ Concerns about accuracy – frequency of update, measures feeding into it?
¢ Concerns about data handling and sharing?
¢ Use as performance monitoring tool – compliance, liability?
l Bearing everything in mind that we have talked about today, what impact overall do you think PRISM
will have in Abertawe Bro Morgannwg?
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Appendix 3 Interview guide for chronic
conditions management leads across Wales
P lease describe your role in this health board and how it relates to PRISM.
1. Other than PRISM, what risk prediction tools are you aware of?
¢ What risk tools are being used in your health board?
¢ Generic versus disease specific.
¢ Any tools stratifying whole population?
2. What are your views on risk prediction/stratification tools in general?
(Probe: individual views vs. colleagues/organisation.)
3. When was PRISM first considered as a tool for use in your health board?
¢ When (timing/policy–political context)?
¢ Who proposed it (Welsh Assembly Government/local health board)?
¢ Why was it proposed (i.e. what was PRISM aiming to achieve)?
¢ What was the role of the chronic conditions management demonstrator in testing PRISM?
¢ Extent of support (from you, from health board colleagues, from GPs, from other
health practitioners).
¢ Extent of knowledge and understanding (from you, from health board colleagues, from GPs, from
other health practitioners).
4. How was PRISM expected to be used?
¢ By whom? (Official view vs. your view.)
¢ To do what? (Official view vs. your view.)
¢ Anticipated effect on planning and managing chronic conditions care?
¢ Anticipated effect on individuals delivering chronic conditions care?
¢ Vision for PRISM? (Official view vs. your view.)
¢ How was PRISM to be funded/supported/made to happen? (Official view vs. your view?)
¢ Strengths/weaknesses of PRISM? (Official view vs. your view?)
5. To what extent has PRISM been implemented in your health board?
¢ What has helped in the process of implementing PRISM?
¢ Political/financial context.
¢ Organisational restructuring (health boards, National Leadership and Innovation Agency for
Healthcare/Informing Healthcare).
¢ Views of GPs and health professionals.
¢ Health boards/managers.
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¢ What has hindered the process of implementing PRISM?
¢ Political/financial context.
¢ Organisational restructuring (health boards, National Leadership and Innovation Agency for
Healthcare/Informing Healthcare).
¢ Views of professional bodies: BMA/General Practitioners Committee Wales.
¢ Views of GPs and health professionals.
¢ Health boards/managers.
6. How much of your role was it to communicate information about PRISM to your colleagues?
¢ How did you do this?
¢ How did people respond?
¢ Did you have to change your method or your message?
7. How do you predict the story of PRISM will unfold from now?
¢ What is needed to implement PRISM?
¢ Will that happen?
¢ Are you considering using another risk stratification tool instead of PRISM?
8. The latest QOF contract is likely to include the use of risk stratification tools to help target patients at
risk of hospitalisation. What impact will that have on your health board?
9. If a chronic conditions management demonstrator site, how has being a demonstrator site, and testing
PRISM, affected views about PRISM?
¢ Your views.
¢ Other managers/commissioners.
¢ GPs’ views.
¢ Other health practitioners.
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Appendix 4 Interview guide for policy leads
across Wales
When was risk stratification first considered as a tool to help provide health services in Wales?
l Who proposed it (individual/department)?
l When (timing/policy–political context)?
l Why?
l Extent of support?
Why was PRISM developed rather than use an existing risk stratification tool?
l Who made the decision?
l Vision for PRISM? (Official view vs. your view.)
l Extent of support?
l Strengths/weaknesses of PRISM?
How was PRISM expected to be used?
l By whom? (Official view vs. your view.)
l To do what? (Official view vs. your view.)
¢ Anticipated effect on organisations planning and managing chronic conditions care?
¢ Anticipated effect on individuals delivering CC care?
l How was PRISM to be funded/supported/made to happen? (Official view vs. your view.)
Can you describe how far you think Wales has got with implementing PRISM?
l How much variation has there been across Wales?
¢ Demonstrator versus non-demonstrator site.
l What has helped in the process of implementing PRISM?
¢ Political/financial context.
¢ Organisational restructuring (health boards, National Leadership and Innovation Agency for
Healthcare/Informing Healthcare).
¢ Views of GPs and health professionals.
¢ Health boards/managers.
l What has hindered the process of implementing PRISM?
¢ Political/financial context.
¢ Organisational restructuring (health boards, National Leadership and Innovation Agency for
Healthcare/Informing Healthcare).
¢ Views of GPs and health professionals.
¢ Health boards/managers.
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How do you predict the story of PRISM will unfold from now?
l What is needed to implement PRISM?
l Do you feel that will that happen?
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Appendix 5 Interview guide for general practice
staff: mid-trial
1. Your practice received training to use PRISM about 3 months ago. What happened next?
¢ Used immediately/delayed start.
¢ What decisions were made with colleagues – at PRISM training or after?
¢ Who used it initially?
¢ Not used.
¢ How easy/how difficult was it to start using PRISM?
2. What influence did the training have on your planning for and use of PRISM?
¢ Views on training session.
¢ Views on handbook.
3. Over the past 3 months, how has your practice been using PRISM?
¢ How frequently?
¢ How long do you usually spend each time you review PRISM data?
¢ Who has been involved?
¢ Single user.
¢ Routine practice meetings.
¢ Special meetings to discuss PRISM.
¢ Who with: MDT, GPs, community network staff?
¢ Informal meetings.
¢ Clarify how long other people spend reviewing PRISM data.
¢ How do you use the information provided by PRISM?
¢ Do you review individual or grouped data?
¢ Do you inform the patient that you are using PRISM?
4. Please think back to the most recent occasion you used PRISM. Can you talk me through what
you did?
¢ Used at screen/reviewed printed lists?
¢ Alone/in meetings?
¢ Which groups of patients (risk levels, conditions, other categories)?
¢ What actions have you taken as a result of the information provided by PRISM?
¢ GP consultation in person.
¢ GP consultation by telephone.
¢ GP consultation by home visit.
¢ Practice nurse appointment.
¢ Clinic in GP practice (e.g. diabetes mellitus, asthma).
¢ Prepare active management plan.
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¢ Communication with/refer to Community Resource Team.
¢ Communication with/refer to district nurse.
¢ Communication with/refer to health visitor.
¢ Refer to community nurse/case manager (e.g. respiratory, mental health, chronic conditions).
¢ Communication with/refer to mental health services (identify which).
¢ Communication with/refer to therapist (e.g. physiotherapist, occupational therapist, speech
therapist, rehabilitation) – identify which.
¢ Communication with/refer to social services.
¢ Refer to alternative medicine provider.
¢ Refer to voluntary sector service (say what).
¢ Other (please give details).
¢ Have you needed to identify additional resources when taking action as a result of information
provided by PRISM? Probe what.
5. How has the way you use PRISM changed during the past 3 months?
¢ Used by different people.
¢ Started then stopped using PRISM.
¢ Only recently started using PRISM.
¢ Change in patients being reviewed through PRISM.
¢ Changed frequency of use – how?
6. Is there anything that has limited your use of PRISM?
¢ Concerns about what it’s for/overall purpose.
¢ Practical/technical difficulties with using it.
¢ Issues with web access/password logins.
¢ Concerns about accuracy – frequency of update, measures feeding into it.
¢ Concerns about data handling and sharing.
¢ Demands on time to access and understand.
¢ Use as performance monitoring tool – compliance, liability.
¢ Does not provide new information.
¢ Unable to respond to identified needs.
7. How do you feel about using PRISM at the moment?
¢ Do you have a clear understanding of what the tool is for?
¢ Does it give you new/useful information?
¢ Value for money?
¢ What has influenced your/your colleagues’ use of PRISM?
¢ How does your experience match your expectations?
¢ Impact of QOF in deciding how you use PRISM.
8. What difference has PRISM made to the way you work and patient care in the past 3 months?
¢ Why?
¢ Individual changes or organisational changes?
¢ Extent of your role in communicating/using PRISM in the practice.
¢ Do you think this is making a difference to emergency admissions?
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9. How do you expect to use PRISM over the next 6 months?
¢ Do not expect to use.
¢ Expect to use differently from first 3 months.
¢ Focus for discussion.
¢ New approach to dealing with patients.
¢ Expected strengths/weaknesses.
¢ Extent of your role in communicating/using PRISM in the practice.
¢ Impact of QOF.
10. Thank you for telling me what you think about PRISM. If I talked to your colleagues, would they share
your views or do they feel differently?
¢ Their experience of using it.
¢ Their experience of impact on their work.
¢ Their expectations for next 6 months.
¢ Other GPs, practice nurse, PM, etc.
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Appendix 6 Interview guide for general practice
staff: end trial
I f interviewing a different person from the 3 month respondent . . .
Last time we visited your practice, we talked to Dr . . . Could you explain why this interview is taking place
with you?
l Change of staff (doctors left and arrived).
l Change of person leading PRISM in the practice and why.
l When did this change take place?
l Any other staff changes in past 6 months?
1. Last time we talked to you/your practice, you said you mainly used PRISM for . . . (check back to
3-month interview content).
Over the past 6 months, how has your practice been using PRISM?
¢ How frequently?
¢ How long do you usually spend each time you review PRISM data?
¢ Who has been involved?
¢ Single user.
¢ Routine practice meetings.
¢ Special meetings to discuss PRISM.
¢ Who with – MDT, GPs, community network staff?
¢ Informal meetings.
¢ Clarify how long other people spend reviewing PRISM data.
¢ How do you use the information provided by PRISM?
¢ Do you review individual or grouped data?
¢ Do you inform the patient that you are using PRISM?
¢ Have you discussed individual emergency admissions risk scores with patients?
2. What has influenced the use of PRISM in your practice in the past 6 months?
¢ Received guidance from:
¢ ABM UHB
¢ locality teams
¢ Deb Burge-Jones.
¢ Change of QOF/QPI requirements to identify high-risk patients.
¢ Identifying what works best in this practice.
¢ Anything which has supported your use of PRISM?
¢ Time of year (winter vs. summer).
¢ Other influences on how you use PRISM?
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3. How has the way you use PRISM changed during the past 6 months?
¢ Used by different people.
¢ Started then stopped using PRISM.
¢ Only recently started using PRISM.
¢ Change in patients being reviewed through PRISM.
¢ Changed frequency of use – how?
4. Please think back to the most recent occasion you used PRISM. Can you talk me through what you did?
¢ Used at screen/reviewed printed lists?
¢ Alone/in meetings?
¢ Which groups of patients (risk levels, conditions, other categories)?
¢ Used in individual patient consultation?
¢ What actions have you taken as a result of the information provided by PRISM?
¢ GP consultation in person.
¢ GP consultation by telephone.
¢ GP consultation by home visit.
¢ Practice nurse appointment.
¢ Clinic in GP practice (e.g. diabetes mellitus, asthma).
¢ Prepare active management plan.
¢ Communication with/refer to Community Resource Team.
¢ Communication with/refer to district nurse.
¢ Communication with/refer to health visitor.
¢ Refer to community nurse/case manager (e.g. respiratory, mental health, chronic conditions).
¢ Refer to secondary care.
¢ Communication with/refer to mental health services (identify which).
¢ Communication with/refer to therapist (e.g. physiotherapist, occupational therapist, speech
therapist, rehabilitation) – identify which.
¢ Communication with/refer to social services.
¢ Refer to alternative medicine provider.
¢ Refer to voluntary sector service (say what).
¢ Other (please give details).
¢ Have you needed to identify additional resources when taking action as a result of information
provided by PRISM? Probe what.
¢ Is this action typical of your normal use – what else have you done?
5. Is there anything that has limited your use of PRISM?
¢ Concerns about what it’s for/overall purpose.
¢ Practical/technical difficulties with using it.
¢ Issues with web access/password logins.
¢ Lack of integration with practice systems.
¢ Concerns about accuracy – frequency of update, measures feeding into it.
¢ Concerns about data handling and sharing.
¢ Demands on time to access and understand.
¢ Use as performance monitoring tool – compliance, liability.
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¢ Does not provide new information.
¢ Unable to respond to identified needs.
Last time we talked to you, you said . . . limited your use of PRISM. How has that changed?
6. How do you feel about using PRISM at the moment?
¢ Do you have a clear understanding of what the tool is for?
¢ Does it give you new/useful information?
¢ Value for money?
¢ What has influenced your/your colleagues’ use of PRISM?
¢ How does your experience match your expectations?
¢ Impact of QOF in deciding how you use PRISM? (To be reworded when we know whether the
2014/15 QOF requirements are relevant.)
7. What difference has PRISM made to the way you work and patient care in the past 6 months?
¢ Compared with 3 months before?
¢ Compared with pre PRISM?
¢ Why?
¢ Individual changes or organisational changes?
¢ Extent of your role in communicating/using PRISM in the practice?
¢ Do you think this is making a difference to emergency admissions?
¢ Do you think this is making a difference to any other outcomes?
When we talked to you 6 months ago, you said PRISM made . . . difference. Why do you think this
has changed? (If there is a change.)
8. How do you expect to use PRISM over the next 6 months?
¢ Do not expect to use.
¢ Expect to use differently from past 6 months.
¢ Focus for discussion.
¢ New approach to dealing with patients.
¢ Expected strengths/weaknesses.
¢ Extent of your role in communicating/using PRISM in the practice.
¢ Impact of QOF (depending on 2014/15 QOF requirements).
¢ Becoming a routine part of practice?
9. Thank you for telling me again what you think about PRISM. If I talked to your colleagues, would they
share your views or do they feel differently?
¢ Their experience of using it.
¢ Their experience of impact on their work.
¢ Their expectations for next 6 months.
¢ Other GPs, practice nurse, PM, etc.
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Appendix 7 Predictive risk stratification model
use questionnaire for practices post intervention
i) Name of practice: _______________________ 
 
 
ii) Date of completion: _____________ 
 
1. Who uses PRISM in this practice? 
 
2. Please estimate how many times you have logged on to the PRISM website 
in the past nine months.  
Never  
1-3 times  
4-6 times  
7-10 times  
11-19 times  
20 or more times  
 
 
3. How frequently do you/your practice use data generated by PRISM, such as 
risk scores and risk profiles?  
Weekly  
Fortnightly  
Monthly  
Quarterly  
No regular pattern  
Not used  
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4. Please estimate how long you usually spend each time you review PRISM 
data.  
Up to 15 minutes  
Up to 30 minutes  
Up to 45 minutes  
Approximately 1 hour  
1-2 hours  
More than 2 hours  
No regular pattern  
Not used  
Tried but failed to review PRISM data  
5. What actions have you taken for patients identified through PRISM? Please 
select all that apply.  
Refer to therapist (e.g. physio, OT, speect, rehab)   
 Communicate with or refer to health visitor  
 Practice nurse appointment  
 Have used PRISM but not yet taken any actions  
 GP consultation in person  
 GP consultation by home visit  
 Refer to community nurse or case manager   
 Refer to alternative medicine provider  
 Chronic conditions clinic in GP practice (e.g. diabetes, asthma)  
 GP consultation by telephone  
 Not used PRISM  
 Prepare Active Management Plan  
 Refer to Social Services  
 Communicate with or refer to mental health services  
 Communicate with or refer to the district nurse  
 Refer to Voluntary Sector (please identify who below)  
Please detail other actions you have taken or give further information 
about options listed above 
 
 
6. Has anything affected your use of PRISM in the past nine months? Please 
select all options that apply to your practice.  
Lack of clarity about PRISM  
Demands on time to respond to the data  
Demands on time to access and understand PRISM data  
Issues with logging in  
Other (please specify below)  
Concerns about data sharing  
Anxieties about liability  
Concerns about the accuracy of PRISM data  
Lack of resources to respond to identified needs  
Website issues - i.e. low speed, error messages  
Concerns that PRISM does not provide new information  
 
6b) Please tell us more about any issues which have affected your use of PRISM over the 
past nine months 
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Appendix 8 Patient questionnaire pack
 
 
The PRISMATIC study. Predicting people’s risk of 
needing emergency hospital treatment  
December 2012  
Information sheet version 5 
This information sheet is about a study being carried out by Swansea 
University.  It explains: 
• why the study is being conducted 
• the nature of your contribution 
• the benefits/consequences of your participation 
• why you have been invited to take part. 
If there is anything which is not clear, please ask and we will be happy to 
discuss it with you. Our contact details are provided overleaf. It is entirely your 
choice whether or not you take part in the study. If you decide to take part we 
will ask you to complete a questionnaire which will be sent to you up to three 
times over the next two years. 
If you are willing to help, please sign the enclosed consent form and return 
this with the completed questionnaire in the envelope provided. 
Background 
Our population contains increasing numbers of older people and people who 
have one or more long term conditions. This places greater demands on 
health and social care services. It is recognised that patients with long term 
conditions are not always managed and treated effectively. Too many are 
admitted to hospital as emergencies. Also, community services are not always 
available or don’t work well together.  
To help improve services, GPs in Wales are starting to use a scoring system 
to predict people’s risk of having an emergency hospital admission in the 
coming year. The system will provide GPs with risk scores for all patients in 
their practice, with scores ranging from 1 to 100 (very low to very high risk). 
Why is this study being undertaken? 
We don’t know how a scoring system which predicts people’s risk of needing 
emergency treatment will be used in Wales – and if it will help patient care. 
This study aims to find out whether GPs and other health professionals use it 
and how it affects the way people are cared for. 
This information may help improve the way scoring systems are used in the 
future to benefit patients. 
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The study has a number of different parts, including discussion groups with 
health professionals and collecting information about the cost of using the 
system.  
Who is conducting the research?  
The research is being undertaken by a team from the College of Medicine, 
Swansea University. It is funded by the Department of Health. 
This information sheet has been sent to you from your GP practice. Your 
name will not be passed to the researchers unless you consent to take part by 
completing the enclosed form.  
Why have I been asked to take part in this study? 
Within the Abertawe Bro Morgannwg NHS Health Board area, patients from 
GP practices who will receive the scoring system are being contacted. Your 
practice is taking part in the study, and will receive the scoring system within 
the next 18 months. Your name has been selected at random from your 
practice’s patient list. The researchers want to find out patients’ experience of 
health and care services over the next two years. This will allow us to see if 
anything changes once practices start using the scoring system. Patients with 
long term conditions and those without any diagnosis are being included, so 
we can gather information about different experiences. 
What we are asking you to do? 
If you choose to take part, you will be sent a questionnaire to complete on up 
to three different occasions. The first questionnaire is enclosed with this 
information sheet. Subsequent questionnaires may be sent in 9 and 18 
months time. If you need help reading anything or filling in the questionnaire it 
will be perfectly acceptable for you to get help from a friend, family member or 
carer. 
Do I have to take part? 
No, it is your choice whether or not you take part. If you decide to take part 
you may withdraw at any time without the need to give an explanation.  
Who will see the information and results about this study? 
The information collected will be securely stored and analysed on computers 
based at Swansea University. Your name will not be used in the study or 
disclosed to anyone by the research team. There will be a report and other 
publications following from this study but they will not identify you personally. 
Questionnaire data will be stored securely for five years after the study before 
being destroyed. 
As part of the study, Swansea University will link the information from your 
questionnaires with your routinely collected health data (e.g. information about 
hospital visits). This will help us recognise any changes in the use of services 
over time. The University will remove identifiable information to ensure that no 
one will be able to identify you from the file.  
What if there is a problem? 
We do not believe there will be any problems arising from your taking part in 
this study. However, if there is anything you are not happy with please contact 
the study team (details below) who will do their best to answer your questions. 
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If you remain unhappy and wish to complain formally, the research team can 
provide details of the ABMU Health Board complaints procedure. 
[contact details for research team were supplied here]
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Predicting people’s risk of needing  
emergency hospital treatment.  
 
Consent form for people taking part in the study 
 
 
 
 
 
Please initial each box: 
 
I confirm that I have read the information sheet version 5, understand it and  
have had an opportunity to ask questions. 
 
The information sheet has explained why the study is being undertaken and  
how it is being undertaken. 
 
I understand that my participation is voluntary and that I may withdraw at  
any time without giving reason and this will not affect the future care I 
receive. 
 
I agree to take part in the study and that the research team will send me  
questionnaires to complete over the next two years 
 
 
 
 
 
…………………………………………….     ……………………………………..     
…………………. 
Name                            Signature                               Date                  
 
initial
initial
initial
initial
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February 2013 
 
Dear Patient, 
 
I am writing to ask for your help with a study about health services in Wales.  
A team from the College of Medicine, Swansea University is studying the effect of a new 
scoring system (Prism) which is being introduced in GP practices in Wales. The system 
provides GPs with a score which predicts people’s risk of needing emergency hospital 
treatment in the following year. The study aims to find out whether GPs and other health 
professionals use the system and how it affects the way people are treated and cared for. 
Our practice is taking part in the study known as PRISMATIC. Your name has been selected 
at random from our patient list. As part of the study we would like to send you up to three 
questionnaires for this study. We hope the findings will help improve health services. 
An information sheet is enclosed with more information. Please read this and if you are willing 
to take part, please complete the consent form and questionnaire and return them to the 
research team at Swansea University in the FREEPOST envelope provided.  
This letter has come from your GP practice. Your details have not been seen by the 
research team and they will not be given your name unless you agree to take part. If 
you would like further information please visit the study website [website details] or contact 
the research team at Swansea University on [number provided] 
Thank you very much for your help, and we hope you will support this research.  
Yours sincerely, 
[lead GP] 
 
Encl:  Information Sheet 
 Consent form 
 Pre paid envelope 
 Questionnaire  
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For this section exploring health-related quality of life we used version 2 of the 
Short Form questionnaire-12 items (SF-12). 
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For this section exploring health-related quality of life we used version 2 of the 
Short Form questionnaire-12 items (SF-12). 
DOI: 10.3310/hsdr06010 HEALTH SERVICES AND DELIVERY RESEARCH 2018 VOL. 6 NO. 1
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snooks et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
149
APPENDIX 8
NIHR Journals Library www.journalslibrary.nihr.ac.uk
150
DOI: 10.3310/hsdr06010 HEALTH SERVICES AND DELIVERY RESEARCH 2018 VOL. 6 NO. 1
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snooks et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
151
APPENDIX 8
NIHR Journals Library www.journalslibrary.nihr.ac.uk
152
DOI: 10.3310/hsdr06010 HEALTH SERVICES AND DELIVERY RESEARCH 2018 VOL. 6 NO. 1
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Snooks et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
153
APPENDIX 8
NIHR Journals Library www.journalslibrary.nihr.ac.uk
154
Appendix 9 Predictive risk stratification model
training plan
Delivered by PRISMATIC GP champion and member of research team 
As agreed with practice. Typically lead PRISMATIC GP and practice manager, and 
any other practice staff able and wishing to attend. A registered PRISM user from the 
practice must be in attendance in order to access the tool. 
1. Ensure training takes place with access to an internet accessible pc 
2. Ensure practice has log on details available in training session with registered 
PRISM user and Caldicott guardian attending if possible 
3. Ensure practice site pack is available for training session, and PRISM 
handbook ready for use in training. 
Background/Data Protection 10 minutes 
Accessing tool   5 -10 minutes 
Tour of tool    10 minutes 
Discussion on use   15 minutes 
Wrap up    5 minutes 
Training log (trainer only) 10 minutes 
Welsh Government commissioned tool in 2006 alongside Chronic Conditions 
Management policy and framework. Tool released in 2008 with update 2010. 
Purpose - to provide a tool to help identify people at risk of hospitalisation so 
they can be proactively targeted prior to deterioration, prior to admission. 
Welsh Risk Prediction Service (WRPS) created to manage PRISM. Run by 
NWIS. 
Site pack 4a - 
Study flyer 
 
Why undertaking research – need for rigorous research in this field – little 
quality research on risk stratification use.  
BMA/GPC Wales involved in discussions over research design. 
Study aim - To describe the processes of introducing a predictive risk 
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Site pack 4b – 
Project 
Description 
 
stratification model (PRISM) and to estimate its effects on the delivery of 
care, resources used and patient outcomes. 
Findings to inform policy and practice.  
Further details in site pack 4b, 4c. 
 
Site pack 8 – 
Schedule 
First practices starting March 2013, with random roll out over a year. 
Study period lasts 18 months. – i.e. to summer 2014. 
Analysis and reporting will follow.  
Latest schedule of practices receiving PRISM will be emailed each month by 
prismatic team. Also available at www.trustresearch.org.uk/prismatic. 
Routine GP and hospital data via SAIL databank, PRISM risk scores. 
Questionnaires at 3 points, user interviews (a crucial part of understanding 
how PRISM is used, any issues etc) 
  
Site pack – 
contents 
Summarise contents – note section 2 is to be completed alongside 
questionnaires. Rest is for information. As new documents are received from 
study team, they should be added to the site pack to keep it up to date. 
Site pack 2b – 
Questionnaire 
practice log 
Importance of questionnaire log for audit purposes and ensuring patient 
confidentiality 
Site pack 10 - 
notes 
Notes page at end for any thoughts/issues/concerns/ improvements if they 
wish to write them down 
 
PRISM 
handbook – 
user 
registration 
Role of Caldicott guardian and ISAs – only the practice CG able to authorise 
or remove users. They need to apply as users too though to access the full 
tool (tbc – so sign up CG as user). 
 
The Caldicott Principles (for sharing patient identifiable data) 
i. Justify the purpose.  
ii. Don’t use patient identifiable information unless it is absolutely necessary.  
iii. Use the minimum necessary patient identifiable information.  
iv. Access to patient identifiable information should be on a strict need to know 
basis.  
v. Everyone should be aware of their responsibilities.  
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vi. Understand and comply with the law. 
 
If the discussions are about care for a patient, then you can discuss appropriate 
personal information in the interests of the patient - but again use the minimum 
necessary - as per a 'normal' discussion with a fellow NHS employee when seeking a 
referral or consultant opinion for example.  
Access cannot be granted to non NHS staff. 
 
  
PRISM web 
pages  
Remind of web address.(https://kryten.hsw.nhs.wales.uk/PRISM) 
Add as desktop shortcut and bookmark (favourite) the web page – do this in 
session. 
Point out link to PRISMATIC website www.trustresearch.org.uk/prismatic 
PRISM contact 
page 
Confirm where to find technical support number (link at bottom of screen) – 
in contacts at bottom of PRISM web page 
 - Site 
pack – how to 
add PRISM 
users  
PRISM sign up 
page 
Confirm instructions for sign up in site pack  
Sign up a user during session if someone in room wishes to and sufficient 
time. 
Show practice staff location of sign up link on webpage 
 -
PRISM log in 
page 
Password advice – important to type correctly. Flag up the password reset 
option. Identify support if lost password.  
Ask Caldicott Guardian to log in 
Caldicott Guardian approves the user request. 
PRISM 
pyramid page 
Explain pyramid – whole practice population stratified – i.e. put into different 
levels – according to risk of emergency admission in next 12 months. 
Uses anonymised data – 37 variables from GP practices and secondary 
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care, and WIMD.  
Confirm that default presents absolute risk in the practice 
Risk models based on CCM model and framework – i.e. different types of 
intervention for different risk levels. E.g. 
 Lvl 4 - individual case management,  
 Lvl 3 - disease management,  
 Lvl 2 - supported self-care  
 Lvl 1 - prevention of illness and promotion of health and wellbeing 
Read out the risk score ranges being used..e.g. Lvl 4 = 50% risk or above. 
 
PRISM risk 
level 2 page 
Explain hyperlinks – can click on them to explore further. Ask user to click on 
level 2 patients and explain that these are the patients who are not in the 
very highest level of risk.  
Explain that risk scores are presented in descending order, but it would be 
wrong to think that there is much difference in risk between people of very 
similar risk scores. 
Note people can move between levels over time – and they could move 
even if their risk stays the same (if relative risk) 
PRISM 
individual 
patient page 
Ask user to click on a random patient and ask them to open some of the tabs 
– e.g. secondary care indicators. 
Explain that risk scores are updated monthly automatically by NHS Wales  
Informatics Service 
Data lags – there will be a delay in an incident, from when it happens, to 
when data entered, and to when uploaded to NWIS and then to PRISM.  
  
PRISM 
pyramid page 
Ask user to go back to pyramid page. Show them the filters and apply one or 
more, then press ‘apply filter’ to change population being looked at. 
 
PRISM 
pyramid page 
Illustrate NHS number search facility 
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PRISM risk 
threshold page 
Illustrate ability to amend relative or absolute risk thresholds. 
 
If appropriate, discuss views so far and see if practice staff have ideas on 
how they might use PRISM to support patient care 
PRISM 
Handbook- 
section c 
Go through how to use guide  
Explain nature of the guide – not prescriptive, flexible for practices to decide 
how best to use PRISM. Needs commitment of practices to give it a go – in 
order for value of research to be realised, as per signed agreements. 
One page 
guide 
Discuss potential practice use –  
who might use, services to link with, etc. 
 Note follow up phone call from GP champion in one month to provide further 
guidance/support. Agree who best to contact and trainer should record this 
on the training log. 
 
 
PRISM 
Handbook 
Appendix B 
Remind practice staff of contacts page in handbook and online – technical 
tool queries to NWIS, research queries to SU and queries to GP champs – 
via prismatic@swansea.ac.uk 
 
Who was present for training – name and role 
Questions raised 
Concerns/issues 
User added in training yes/no 
Initial thoughts on usage in practice 
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Follow up contact from GP champion – who to contact at practice and their 
contact number. 
Trainer completes and returns training log to prismatic@swansea.ac.uk 
Follow up phone call by GP champion trainer 1 month post training. 
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Using PRISM  - Summary 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
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Appendix 10 Profile of practice staff participation
in qualitative data collection
Practice
Role Years in role FT/PT Age (years) Gender
Data collection method
ID Size Baseline Mid-study End of study
1 M GP 13 FT 45–54 Female I Q Q
1 PM 5 FT 35–44 Female I – –
1 PN NS NS NS Female FG – –
2 L GP 12 FT 35–34 Male FG I I
2 PM 9 FT 35–44 Male FG I I
3 L GP 10 FT 35–44 Female TI I I
4 M GP 6 FT 35–44 Male FG Q Q
4 PM 4 FT 25–34 Female FG – –
5 M GP 28 FT 55–64 Female FG I I
6 M GP 9 FT 25–34 Male FG I I
7 L GP 6 FT 35–44 Male FG Q Q
7 PM 16 FT 45–54 Male FG – –
8 M GP 18 FT 45–54 Male FG I I
9 M GP 33 FT 55–64 Male TI Q Q
10 S GP 23 FT 45–54 Male FG I I
10 PM 6 FT 35–44 Female FG – –
11 S GP 25 FT 55–64 Male TI I I
12 L GP 19 FT 45–54 Male FG Q Q
13 M GP 20 FT 45–54 Female FG – –
13 GP 15 FT 35–44 Female – I I
14 S GP 20 FT 45–54 Male TI I I
14 PM 20 FT 45–54 Female – I –
15 L GP 25 FT 45–54 Male I I I
16 M GP 13 PT 35–44 Female TI Q Q
17 L GP 14 FT 45–54 Female FG I I
18 L GP 25 FT 45–54 Male – I –
18 GP 16 FT 35–44 Female FG I I
18 PM 10 PT 55–64 Female FG – –
19 S GP 10 FT 35–44 Female FG I I
19 PM 9 FT 55–64 Female FG – –
20 M GP 10 FT 35–44 Male FG Q Q
21 M GP 18 FT 45–54 Male FG – –
21 GP 28 FT 45–54 Male – I I
22 S GP 10 FT 25–34 Male – Q Q
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Practice
Role Years in role FT/PT Age (years) Gender
Data collection method
ID Size Baseline Mid-study End of study
22 PM 7 FT 35–44 Female FG – –
22 PM 2.5 FT 35–44 Female FG – –
23 S GP 20 FT 55–64 Female TI Q Q
24 S GP 6 FT 35–44 Male FG Q Q
24 PM 13 FT 55–64 Female FG Q Q
25 M GP 8 FT 45–54 Male FG Q Q
26 M GP 28 FT 45–54 Male I Q Q
27 M GP 11 FT 35–44 Female TI I I
28 M GP 15 FT 35–44 Male FG Q Q
28 PM NS NS NS Female FG – –
29 NS PM 7 FT 35–44 Female FG – –
30 M GP 10 FT 35–44 Female FG Q Q
31 S GP 3 FT 25–34 Male – I I
31 PM 19 FT 45–54 Female FG – –
31 PN 7 FT 35–44 Female FG – –
32 L GP 17 FT 45–54 Male FG I I
32 PM NS NS NS Male – I –
–, did not take part at this stage; FG, focus group; FT, full time; I, face-to-face interview; L, large (≥ 10,000 population);
M, medium (5000–10,000 population); NS, data not supplied; PN, practice nurse; PT, part time; Q, questionnaire; S, small
(≤ 5000 population); TI, telephone interview.
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